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Chapter 1
Hematopoiesis
Hematopoietic stem cells (HSCs) give rise to all lineages of blood cells, which include 
thrombocytes (required for blood clotting), red blood cells (responsible for oxygen 
transport), and leukocytes (responsible for defense against pathogens). Importantly, HSCs 
also have the capacity of self-renewal and thereby the process of hematopoiesis is a 
lifelong process. After birth, hematopoiesis occurs mainly in the bone marrow. However, 
during fetal development HSCs reside in different niches, including the yolk sac, liver, and 
spleen.1,2 HSCs give rise to lymphoid and myeloid progenitor cells, which further maturate 
(differentiate) into all blood cell types (Figure 1). During the process of differentiation, 
blood cells gain more functionality at the expense of their proliferative potency. These 
features keep the process of hematopoiesis in balance. Proliferation and differentiation 
are tightly controlled by different factors, including transcription factors (e.g. IKZF1) and 
micro-environmental factors (e.g. cytokines and growth factors). 
Leukemia
In leukemia the process of normal hematopoiesis is disturbed. Proliferation, differentiation 
and cell death of the different blood cells types are no longer in balance. Disturbance 
of these processes result in the expansion of malignant leukocytes, also called blasts, at 
the expense of healthy blood cells. Leukemia can be classified based on the origin of 
progenitor cell, i.e. myeloid or lymphoid. Furthermore, classification is based on the onset 
of the disease: acute or chronic. Acute leukemia displays a fast rise and is characterized by 
an uncontrolled high proliferation of blasts with an immature phenotype. Chronic leukemia 
on the other hand has a mature phenotype. Therefore these blasts can also perform of their 
‘normal’ functions, resulting in a more slow onset.
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Figure 1. Schematic overview of hematopoiesis. Adapted from Larsson et al.3
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Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. In the 
Netherlands approximately 125 children are diagnosed with the disease every year. 
Survival rates show an remarkable improve during the last decades: in the early 1960 
cure rate was approximately 10% whereas nowadays approximately 90% of the patients 
can be cured (Figure 2). Despite this dramatic increase in outcome, this still means that one 
out of the ten children diagnosed with ALL cannot be cured. Pediatric ALL is heterogeneous 
disease, caused by the malignant transformation of either T-cell (T-ALL,~15% of the cases) 
or B-cell progenitors (BCP-ALL, ~85% of the cases). The scope this thesis is on pediatric 
BCP-ALL.
Figure 2. Survival of 2852 children with newly diagnosed ALL between 1962 and 2007.4
B-cell development and the bone marrow microenvironment
The bone marrow microenvironment plays a crucial role in the development and differentiation 
of HSCs. This niche consists of hematopoietic and non-hematopoietic cells. Mesenchymal 
stromal cells (MSCs), non-hematopoietic cells, play an important role in the regulation of 
HSC differentiation, through both cytokine secretion and direct cell-to-cell communication.5-7 
In addition, the process of maturation is regulated intracellular by transcription factors. These 
transcription factor create a regulatory network in which activation of the B-cell development 
genes is ensured and genes involved in the commitment to other lineages are silenced. Key 
regulators of normal B-cell development include ERG, IKZF1, EBF1, and PAX5, as shown in 
Figure 3.8 
HSCs generally remain in a quiescent, dormant, state, close to the endosteal (inner) 
surface of the bone. Thereby they preserve self-renewing capacity and prevent stem cell 
exhaustion. During maturation progenitor cells migrate from the endosteal niche to the 
vascular niche (close to the blood vessels).7,9 B cell maturation can be subdivided in several 
stages, characterized by rearrangement status of the immunoglobulin heavy and light 
chains. This recombination process gives rise to an extensive (unique) receptor repertoire. 
Additionally, migration of progenitors cells through the bone marrow microenvironment, 
enables interaction of these cells with different niches.
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Leukemic cells also reside in the bone marrow microenvironment. During progression of 
leukemia, blasts spread at the expense of healthy progenitor cells. Thereby they might take 
advantages of niche specific signaling or manipulate their microenvironment to promote 
survival.10 The importance of the bone marrow microenvironment for leukemic cells is 
demonstrated by the protection the niche provides against chemotherapeutic agents.11,12 
In in vitro assays, MSCs mimic this support of the bone marrow microenvironment.13-17 
Understanding the leukemic cells-niche interaction is important for targeting this process 
in the treatment of leukemia. 
MSC
Sinusoid
Endothelial
cell
IKZF1 EBF1 PAX5
ERG
Bone
Osteoclast
Mature
B cell
IgM IgD
Stem cell Large pre-
B cell
Small pre-
B cell
Immature
B cell
Early pro-
B cell
Late pro-
B cell
Pre-BCR IgM
Figure 3. Schematic overview of maturation of B cells and the bone marrow microenvironment.
Pathobiology of B-cell Precursor Acute Lymphoblastic Leukemia
BCP-ALL is thought to originate from various genetic hits in progenitor B-cells, resulting 
in their malignant transformation. These lesions include aberrations in genes involved in 
B-cell development, proliferation, or survival of cells. Aberrations can be defined as point 
mutations, chromosomal translocations, or alterations in copy numbers affecting specific 
genes or even whole chromosome(s).18
A common mechanism underlying the pathobiology of BCP-ALL cases includes 
chromosomal translocations. Two segments from different chromosomes are rearranged, 
resulting in novel (altered) chromosomes. Consequently, genes that are located on the 
translocated part of the chromosomes are placed in a new environment. This can result in 
the fusion of two different genes, forming one new fusion gene. The t(12;21) rearrangement, 
a translocation between chromosome 12 and 21, is an example of a genetic aberration 
present in ~28% of BCP-ALL cases. The resulting ETV6‑RUNX1 fusion gene contains a 
part of the ETV6 gene, a nuclear phosphoprotein that is a member of the ETS family of 
transcription factors, fused to RUNX1, a transcription factor involved in lymphoid and 
myeloid differentiation. Other chromosomal translocations include t(9;22) and t(1;19), 
resulting in BCR‑ABL1 and TCF3‑PBX1 translocations, respectively. Both aberrations 
are detected in a minority of the BCP-ALL cases (3% and 8%, respectively). In addition, 
approximately 3% of the BCP-ALL cases harbors rearrangements involving the KMT2A 
gene. KMT2A, located on chromosome 11, can translocate to different chromosomes (e.g. 
chromosome 4 and 9), resulting in different fusion genes (e.g. KMT2A‑AF4, KMT2A‑AF9). 
Although this subtype is detected in a minority of BCP-ALL cases, it is a hallmark of infant 
ALL (age of patients below 366 days).
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Chromosomal translocations predominantly contain genes involved in (regulation) of 
transcription. In this perspective, the BCR‑ABL1 fusion gene is an exception: the tyrosine 
kinase ABL1 is placed under the control of BCR promoter, resulting in a constitutively 
active protein tyrosine kinase. Protein tyrosine kinases are enzymes that facilitate the 
activation of specific proteins via the phosphorylation of select tyrosine residues in these 
proteins. The BCR‑ABL1 tyrosine kinase activates multiple signaling pathways, involved 
in proliferation and survival of cells. Unlike transcription factors, tyrosine kinases can be 
inhibited by precision medicines.19 Therefore, inhibition of the BCR‑ABL1 fusion protein by 
specific tyrosine kinase inhibitors (e.g. imatinib) offers an attractive treatment strategy in 
these cases. 
Besides chromosomal rearrangements, approximately 28% of the pediatric BCP-ALL cases 
is characterized by an increase in chromosomal copy numbers. Presence of more than 50 
chromosome is a characteristic of high hyperdiploidy. The remaining group of BCP-ALL 
patients (~30%) involves genetically unclassified cases (B-other). Recent studies showed 
that a subgroup of these genetically unclassified cases have a gene expression profile that 
resembles the profile of BCR‑ABL1-positive cases, although the BCR‑ABL1 translocation is 
absent. Therefore these cases are classified as BCR‑ABL1-like cases.20,21 Kinase activating 
lesions (other than BCR‑ABL1) were identified in a subgroup of these BCR‑ABL1‑like 
patients.22,23 For remaining BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases, the 
underlying pathogenesis remains poorly understood. BCR‑ABL1-like is present in 19% 
of pediatric BCP-ALL cases, whereas non-BCR‑ABL1-like B-other BCP-ALL is detected in 
~11% of the pediatric cases.
Different subtypes of BCP-ALL are associated with different treatment outcomes. ETV6‑
RUNX1-positive, high hyperdiploid, and TCF3‑PBX1-positive cases have a favorable 
prognosis. non-BCR‑ABL1‑like B-other BCP-ALL is associated with an intermediate 
outcome. KMT2A-rearranged, BCR‑ABL1-positive, and BCR‑ABL1-like are poor 
prognostic subtypes (Figure 4).
Although pediatric BCP-ALL is often characterized chromosomal abnormalities, additional 
lesions need be present to induce overt leukemia.18 The high frequency of ETV6‑RUNX1 
translocation in cord blood samples of healthy neonates compared to the low incidence of 
Figure 4. Genetic subtype of pediatric BCP-ALL.
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pediatric ETV6‑RUNX1-positive BCP-ALL indicates the requirement of additional genomic 
aberrations for the development of leukemia.24 Copy number alterations (CNAs) in B-cell 
development genes (e.g. IKZF1, EBF1, PAX5) are an example of additional, cooperating 
lesions.20,25 These aberrations affect differentiation and proliferation processes of B-cells 
and thereby predispose cells for malignant transformation.26 The BCR‑ABL1 fusion 
gene also requires additional lesions to develop BCP-ALL, as indicated by a study in a 
monozygous twin. Identical BCR‑ABL1 genomic translocations were detected in neonatal 
blood spots of both children. However, only the twin harboring an IKZF1 deletion 
developed leukemia.27 
Taken together, pediatric BCP-ALL can be subdivided in different subtypes, which are 
associated with different treatment responses and long-term clinical outcome. These subtypes 
are often characterized by chromosomal translocations. Besides these chromosomal 
translocations, cooperating lesions (e.g. CNAs) are required to induce an overt leukemia.
Treatment of pediatric ALL
Chemotherapeutic agents that are currently used for the treatment of ALL are already in 
clinic for decades. These drugs are relative aspecific and cause adverse side-effects. The 
remarkable improve in outcome of BCP-ALL patients was mainly achieved by improved 
risk stratification and intensification of chemotherapy with these old drug. However, 
further intensification is not possible due to severe side effects.4,28 Therefore, new treatment 
approaches are warranted. 
During recent years, evidence increased that the BCR‑ABL1 fusion protein has kinase 
activity. Specific inhibition of this kinase offered an attractive treatment strategy and 
therefore led to the development of the selective ABL tyrosine kinase inhibitor imatinib 
mesylate.29-31 Introduction of imatinib, combined with intensive chemotherapy, significantly 
improved prognosis of BCR‑ABL1-positive patients.32
The treatment of newly diagnosed ALL can be divided in several phases (i.e. induction, central 
nervous system (CNS) prophylaxis, consolidation, intensification, and maintenance).28 
Induction therapy aims to achieve cytomorphological complete remission, meaning 
that <5% leukemic cells (blasts) can be detected in microscopic slide of the patient’s 
bone marrow sample. A combination of chemotherapeutic agents is used to induce 
complete remission, in which glucocorticoids, asparaginase, vincristine, and sometimes 
anthracyclines, have an important role. After this induction therapy, patients receive 
consolidation therapy containing 6-mercaptopurine, cyclophosphamide, cytarabine, 
and methotrexate. Subsequently, patients are stratified in risk groups mainly by minimal 
residual disease (MRD) levels.28,33,34 During the following intensification and maintenance 
phase, therapy will be reduced for patients with favorable stratification parameters 
(standard risk), intensified  in patients with medium risk parameters, and strongly intensified 
in patients at high risk. A combination of chemotherapeutic agents is used to consolidate 
remission and prevent spread of leukemic cells to the CNS. The intensification phase 
contains the same drugs as the induction therapy. Finally, maintenance therapy is given for 
a prolonged period to avoid regrowth of residual leukemic cell, which contains thiopurines 
and methotrexate complemented dexamethasone and vincristine for medium and high risk 
patients. Moreover, high risk patients often receive a stem cell transplantation.
In conclusion, the treatment protocol of pediatric BCP-ALL can be subdivided in different 
phases, which aim to achieve complete remission.
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Outline of the thesis
To improve the treatment of BCP-ALL, new targeted approaches are warranted. Therefore, 
more insight is required in the pathobiology of pediatric BCP-ALL. This thesis aimed to gain 
insight the pathobiology of genetically unclassified BCP-ALL cases (i.e. BCR‑ABL1-like 
and non-BCR‑ABL1‑like B-other) and thereby identify new targets for precision medicines. 
BCR‑ABL1-like as well as non-BCR‑ABL1-like-B-other are large heterogeneous subtypes. 
The BCR‑ABL1-like subtype is characterized by enrichment of CNAs in genes involved in 
B-cell development (e.g. IKZF1), intrachromosomal amplification of chromosome 21, and 
dicentric chromosome (9;20).20,35 In addition, chromosomal translocations involving ABL 
(ABL1, ABL2, PDGFRB, CFS1R) or JAK (JAK2, CRLF2, EPOR) class kinases are present in 
a subgroup of patients.22,23,36 Like BCR-ABL1, these fusion proteins might offer an attractive 
target for precision medicines. In Chapter 2 and 3 we focused on this group of patients. 
The frequency of ABL or JAK class chromosomal translocations was studied in BCR‑ABL1-
like and non-BCR‑ABL1-like B-other patients. Moreover, the clinical characteristics of 
these fusion gene positive patients were studied. Although ABL class inhibitors are already 
applied in the treatment of BCP-ALL for BCR‑ABL1-positive cases, the effect of JAK 
inhibitors in BCP-ALL is less well known. In Chapter 3, we therefore analyzed the potency 
of JAK2 kinase inhibition in patients harboring JAK2 aberrations (translocations and point 
mutations). Unfortunately, in only a minority (18%) of the BCR‑ABL1‑like cases tyrosine 
kinase translocations are detected. For the remaining group of BCR‑ABL1-like and non-
BCR‑ABL1-like B-other patients, no druggable targets have yet been identified. To gain 
insights in the pathobiology of these cases, gene expression profiles were analyzed of a 
large cohort of BCP-ALL cases. These analyses revealed STAP1 to be highly expressed in 
a subgroup of BCR‑ABL1-like and non-BCR‑ABL1-like B-other patients. Previous reports 
hint that STAP1 is involved in the B-cell receptor (BCR) signaling cascade. Indeed pathway 
analysis showed an association between high expression levels of STAP1 and precursor 
BCR (pre-BCR) signaling genes.37,38 In Chapter 4, we studied the role of STAP1 in BCP-ALL 
cell survival, as well as the association between STAP1 and the pre-BCR signaling 
cascade. In Chapter 5, we studied the frequency and patterns of CNAs in genes involved 
in lymphoid differentiation, proliferation, cell cycle, and transcription. In this chapter 
we aimed to gain insight in associations between CNAs, cellular drug resistance, and 
clinical outcome parameters. In the final research chapter of this thesis we focused on the 
interaction between leukemic cells and the bone marrow micro-environment (Chapter 6). 
MSCs are key components of the process of hematopoiesis through both cytokine secretion 
and direct cell-to-cell communication.5,6 In addition, MSCs protect BCP-ALL cells against 
chemotherapeutic agents.13-17 Unraveling this mechanism of protection may provide novel 
options for therapeutic intervention.
The work presented in this thesis demonstrates the potency of precision medicines in 
pediatric BCP-ALL, but also shows its limitations. The findings of this thesis and its future 
directions are discussed in Chapter 7 and summarized in Chapter 8 (in English and Dutch).
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ABSTRACT
Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) 
is characterized by gene expression similar to that of BCR‑ABL1-positive disease and 
unfavorable prognosis. This BCR‑ABL1-like subtype shows a high frequency of B-cell 
development gene aberrations and tyrosine kinase-activating lesions. To evaluate the 
clinical significance of tyrosine kinase gene fusions in children with BCP-ALL, we studied 
the frequency of recently identified tyrosine kinase fusions, associated genetic features, 
and prognosis in a representative Dutch/German cohort. We identified 14 tyrosine kinase 
fusions among 77 BCR‑ABL1-like cases (18%) and none among 76 non-BCR‑ABL1-like 
B-other cases. Novel exon fusions were identified for RCSD1‑ABL2 and TERF2‑JAK2. JAK2 
mutation was mutually exclusive with tyrosine kinase fusions and only occurred in cases with 
high CRLF2 expression. The non/late response rate and levels of minimal residual disease 
in the fusion-positive BCR‑ABL1-like group were higher than in the non-BCR‑ABL1-like 
B-others (p<0.01), and also higher, albeit not statistically significant, compared with the 
fusion-negative BCR‑ABL1-like group. The 8-year cumulative incidence of relapse in 
the fusion-positive BCR‑ABL1-like group (35%) was comparable with that in the fusion-
negative BCR‑ABL1-like group (35%), and worse than in the non-BCR‑ABL1-like B-other 
group (17%, p=0.07). IKZF1 deletions, predominantly other than the dominant-negative 
isoform and full deletion, co-occurred with tyrosine kinase fusions. This study shows that 
tyrosine kinase fusion-positive cases are a high-risk subtype of BCP-ALL, which warrants 
further studies with specific kinase inhibitors to improve outcome. 
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INTRODUCTION
Children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with the BCR‑ABL1 
fusion gene form a small patient group with a poor prognosis, which has been substantially 
improved in recent treatment protocols with the addition of imatinib and other tyrosine 
kinase inhibitors.1,2 Approximately 15% of cases of BCP-ALL are characterized by a gene 
expression signature similar to that of BCR‑ABL1-positive disease and an unfavorable 
prognosis.3,4 This BCR‑ABL1-like subtype is found in approximately 50% of so-called 
B-other cases, which are BCP-ALL cases negative for the sentinel cytogenetic lesions 
BCR‑ABL1, ETV6‑RUNX1, TCF3‑PBX1, rearrangement of MLL, or high hyperdiploidy 
(51-65 chromosomes). BCR‑ABL1-like BCP-ALL shows a high frequency of B-cell 
development gene aberrations, especially IKZF1 deletions,3-5 and tyrosine kinase 
activating lesions.6,7
Tyrosine kinase activating lesions are diverse and include tyrosine kinase fusion proteins, 
cytokine receptor overexpression, or activating point mutations in genes encoding kinases, 
cytokine receptors, or signaling molecules (recently reviewed in 8). In our study, we 
focus on tyrosine kinase fusion genes because they are most similar to the well-known 
BCR‑ABL1 fusion gene and expected to be clonal leukemia drivers. Detection of tyrosine 
kinase fusions could guide targeted treatment with tyrosine kinase inhibitors and improve 
outcome in a similar way as currently for BCR‑ABL1-positive patients. 
Tyrosine kinases known to be involved in fusions include the ABL class kinases ABL1, ABL2, 
PDGFRB and CSF1R as well as the JAK class kinase JAK2. Each of these kinases has 
been detected in in-frame fusions with multiple 5’ partner genes resulting in the expression 
of a constitutively active, oncogenic kinase. The number of patients without sentinel 
chromosomal abnormalities and the diversity of novel tyrosine kinase fusions poses a 
challenge to routine fusion gene detection. Previous studies have described the discovery 
and oncogenic potential of ABL and JAK class fusion genes and the sensitivity of patients' 
cells or in vitro cell models to tyrosine kinase inhibition.6,7 Selection of patients for fusion 
detection in these studies was based on gene expression profiling indicating Philadelphia-
like ALL.6,7 A large Japanese study screened all B-other cases by transcriptome analysis 
or multiplexed RT-PCR for 15 fusions and found both methods similarly sensitive.9 Other 
studies describe systematic screens in B-other cases by FISH or RT-PCR to detect specific 
tyrosine kinase fusions.10,11
We aimed at the detection of recently identified tyrosine kinase fusion genes in 153 B-other 
cases of a population-based cohort of 574 Dutch/German pediatric BCP-ALL patients at 
initial diagnosis to address the frequency of tyrosine kinase fusions, their clinical response 
characteristics, and associated genetic lesions in B-cell development genes.
RESULTS
Tyrosine kinase fusions are restricted to BCR-ABL1-like subtype
We identified 14 ABL/JAK class tyrosine kinase activating fusion genes among 77 
BCR‑ABL1-like cases (18%), and none among 76 non-BCR‑ABL1-like B-other cases (Table 
1; Supplemental Figure S1). We found nine tyrosine kinase fusions predictive for activated 
ABL signaling: 4 EBF1‑PDGFRB, 2 SSBP1‑CSF1R, and one each of ZMIZ1‑ABL1, FOXP1‑
ABL1, RCSD1‑ABL2. Five tyrosine kinase fusions are predictive for activated JAK signaling: 
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three PAX5‑JAK2, one each of BCR‑JAK2 and TERF2‑JAK2. The exons included in the fusion 
transcripts were the same as described previously,6,12,13 except for RCSD1 exon 3-ABL2 
exon 5 (Supplemental Figure S2), and TERF2 exon 10-JAK2 exon 19 with a deletion of the 
last 11 coding nucleotides of TERF2 exon 10 (Supplemental Figure S3). All detected fusion 
transcripts encode in-frame fusion proteins as evaluated using ProteinPaint.14
Table 2 summarizes the genomic analyses of the tyrosine kinase fusion cases. All PDGFRB, 
CSF1R and ABL1 fusions showed aberrant FISH patterns with the appropriate break apart 
FISH probes (Table 2, Supplemental Figure S4). In addition, both ABL1 fusions showed 
add(9)(q34) in their karyotypes (ABL1 is located on 9q34), together with add(10)(q21) 
in the ZMIZ1‑ABL1 case (ZMIZ1 is located on 10q22), and with del(3)(p13) in the 
FOXP1‑ABL1 case (FOXP1 is located on 3p13). Two EBF1‑PDGFRB cases showed an 
interstitial 5q deletion on array-CGH, one case arose by balanced t(5;5) translocation, 
and one case showed a more complex copy number alteration, with loss of EBF1 exon 
16 and gain of a genomic region encompassing EBF1 exons 7-9 (Table 2; Supplemental 
Figure S5A-B). EBF1 exon 16 deletion was confirmed by MLPA in the two interstitial 5q 
deletion cases and the complex case (Table 2). Genomic breaks were also detected in 
SSBP2‑CSF1R, BCR‑JAK2 and TERF2‑JAK2 fusions (Table 2, Supplemental Figure S5C-F). 
Interestingly, one SSBP2‑CSF1R fusion probably arose by chromothripsis of chromosome 
5 (Supplemental Figure S5D). Finally, when we ordered the gene expression levels of the 
involved tyrosine kinases for the 153 B-other BCP-ALL cases, the expression in the fusion 
cases ranked in the top (median percentile 2.6%, range 0.7-14%; Table 2). 
CRLF2 high expression and PAR1 deletions are common in both BCR-ABL1-like and 
B-other cases
High gene expression levels of the cytokine receptor CRLF2 were found in 16% of 
BCR‑ABL1-like cases, none of which overlapped with ABL/JAK class tyrosine kinase fusion 
cases, and also in 16% of non-BCR‑ABL1-like B-other cases. About 50% of CRLF2-high 
cases carried a JAK2 mutation.15 The frequency of CRFL2 high expression cases with a 
PAR1 deletion, JAK2 mutation or both was similarly high in BCR‑ABL1-like (9/12 cases) 
BCR-ABL1-like (n=77) Remaining B-other (n=76)
ABL1/ABL2 fusion 3.9% 0%
ZMIZ1-ABL1 1
FOXP1-ABL1 1
RSD1-ABL2 1
PDGFRB fusions 5.2% 0%
EBF1-PDGFRB 4
JAK2 fusions 6.5% 0%
PAX5-JAK2 3
BCR-JAK2 1
TERF2-JAK2 1
CRLF2 expression* 15.6% 15.8%
PAR1 deletion** 10.5% 10.7%
Table 1. Frequency of identified tyroxine kinase fusion genes 
*Expression of Affymetrix U133 Plus 2.0 probe set 208303_s_at above the 90th percentile of the total BCPALL group, as described 
previously5. **Deletion of IL3RA and CSF2RA and retention of CRLF2 as determined by MLPA.
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 2Case Tyrosine kinase 
fusion
Simplified 
karyotype Array-CGH
a
EBF1 
exon 
16b
FISHc
Expr 
rankd
Exons 
fused
Vali-
dation
R32 EBF1‑PDGFRB ND
deletion chr5: 149,494,702-
158,058,047 0.64
PDGFRB 
split 1% e15-e11 RT-PCR
A288 EBF1‑PDGFRB
46,XY,t(2;12)
(q23~24;q12)
[20]/46,XY[14]
diploid ND PDGFRB split 5% e14-e11 RT-PCR
A472 EBF1‑PDGFRB 46,XY[20]
deletion chr5: 149,494,702-
158,030,723; gain chr5: 
158,049,831-158,428,865
0.62 PDGFRB split 4% e15-e11 RT-PCR
A428 EBF1‑PDGFRB
46,XY[20].ish 
7(cep7,D7S522)
x1,i(7) (q10)
(D7S522+,cep7+, 
D7S522+)[13/25]
gain chr5: 158,222,469-
158,428,865 0.54
PDGFRB 
split 6% e15-e11 RT-PCR
A123 SSBP2‑CSF1R ND
small deletions typical of 
chromothripsis 1.0
PDGFRB 
split 1% e16-e12 RT-PCR
A526 SSBP2‑CSF1R 46,XY[10]
gain chr5: 80,740,416-
149,403,322 1.1
PDGFRB 
split 3% e16-e12 RT-PCR
A91 ZMIZ1‑ABL1
47,XY,add(9)
(q34), add(10)
(q21),mar[9]
diploid 1.1 ABL1 split 2% e18-e2 RT-PCR
A26 FOXP1‑ABL1
46,XY,del(3)(p13), 
add(9)(q34),i(22)
(q10), inc[6]
diploid 1.0 ABL1 split 14% e27-e4 TLA; PCR
A530 RCSD1‑ABL2
46,XY[4]/ 
42~46,XY,inc[3] ND 0.71 ND 1% e3-e5
RT-PCR; 
TLA
A31 PAX5‑JAK2
46,XX,del(1)
(q3?2q4?4), 
inc[2]/46,XX[18]
diploid 0.94 ND 1% e5-e19 RT-PCR
A286 PAX5‑JAK2 46,XX[17] diploid 0.81 ND 6% e5-e19 RT-PCR
A204 PAX5‑JAK2 ND diploid 0.96 ND 3% e5-e19 RT-PCR
A214 TERF2‑JAK2 46,XY[20]
gain chr16: 67,958,182-
88,690,630; deletion chr9: 
593,494-5,068,342
0.95 ND 3% e10-e19 RT-PCR; TLA
A216 BCR‑JAK2 ND
deletion chr9: 194,193-
5,068,342; gain chr9: 
5,080,443-5,647,733; 
gain chr22: 14,513,474-
21,885,107; deletion chr22: 
21,898,315-22,667,667
0.91 ND 1% e1-e17 RT-PCR; TLA
Table 2. Molecular characteristics of identified tyrosine kinase fusion genes
a Genome positions in build hg18, copy number changes shown for the genes involved in the fusion; see also Supplemental Figure 
S5. b EBF1 exon 16 copy number ratio determined by MLPA. A value below 0.75 is called as a deletion.
c FISH break apart probes from Cytocell were used. The centromeric PDGFRB probe overlaps with CSF1R and can be used to detect 
breakpoints in CSF1R as well as in PDGFRB. d Expr rank indicates the percentile in rank of the tyrosine kinase gene expression among 
153 B-other BCP-ALL cases on Affymetrix U133 Plus 2 arrays. ND: not determined
and B-other cases (11/12 cases (Figure 1). CRLF2 expression had no prognostic value in 
this Dutch/German BCP-ALL cohort as described previously.5
Tyrosine kinase fusion cases are enriched for IKZF1 deletion variants 
Next, we compared the frequency of B-cell development gene lesions between the tyrosine 
kinase fusion-positive BCR‑ABL1-like cases, the fusion-negative BCR‑ABL1-like cases, 
and the non-BCR‑ABL1-like B-other cases. While IKZF1 deletions were common both in 
fusion-positive and fusion-negative BCR‑ABL1-like cases (64% vs. 40%; p=0.14), IKZF1 
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deletions other than exon 4-7 or full deletion, including deletion of exons 1, 1-2, 1-3, 
2-3, 2-7, 2-8, 4-8, 5 and 7-8, occurred more frequently in the fusion-positive compared 
with the fusion-negative BCR‑ABL1-like cases (43% vs. 15%; p=0.03; Table 3). Except for 
deletions in EBF1, enriched in EBF1‑PDGFRB fusion cases due to interstitial 5q deletion, 
none of the other genes detected by P335 MLPA (PAX5, ETV6, RB1, BTG1, CDKN2A/B, 
PAR1) showed an aberrant deletion frequency in tyrosine kinase fusion cases compared 
with non-BCR‑ABL1-like B-other cases (Table 2). In the fusion-positive cases, CDKN2A/B 
deletion was less frequent than in the fusion-negative BCR‑ABL1-like cases (14% vs. 
63%, p=0.002; Table 3). Two large genomic lesions previously described to occur in 
BCR‑ABL1-like BCP-ALL, dic(9;20) and intrachromosomal amplification of chromosome 
21, 3, 16 were mutually exclusive with the identified tyrosine kinase fusions (Table 3).
Tyrosine kinase fusion cases show poor treatment response to induction therapy and 
high minimal residual disease levels 
Finally, we evaluated clinical response characteristics. Of 12 tyrosine kinase fusion-positive 
cases with evaluable data, 5 patients did not achieve complete morphological remission at 
the end induction therapy; 4 of them were late responders, and one was a non-responder 
resulting in early death (Figure 2A). This non/late response rate at the end of induction 
therapy was higher in the fusion-positive cases compared with non-BCR‑ABL1-like B-other 
Figure 1. Distribution of tyrosine kinase fusions and CRLF2 high expression cases
Pie diagrams showing the percentages of tyrosine kinase (TK) fusion cases and CRLF2 high expression 
among (A) 77 BCR‑ABL1-like B-other cases, and (B) 76 non-BCR‑ABL1‑like B-other cases. Within the 
CRLF2 high expression cases, a sub-distribution of cases with JAK2 mutation and/or PAR1 deletion 
is shown. In the non-BCR‑ABL1-like B-other cases, two PAR1-deleted cases were not tested for JAK2 
mutations. 
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Table 3. Clinical and molecular features of ABL/JAK class tyrosine kinase fusions
(42% vs. 7%, p=0.004) and also higher, albeit not statistically significant, compared with 
fusion-negative BCR‑ABL1-like cases (42% vs. 17%, p=0.11; Table 3). Furthermore, fusion-
positive cases were characterized by higher levels of minimal residual disease (MRD) 
compared with non-BCR‑ABL1-like B-other cases at end of induction therapy (p=0.001) 
and before consolidation (p=0.002) and also, although less significant, compared with 
fusion-negative BCR‑ABL1-like cases (p=0.09, p=0.04, respectively; Table 3). The 8-year 
cumulative incidence of relapse (CIR) in the BCR‑ABL1-like group with tyrosine kinase 
a NCI-Rome high risk is defined by white blood cell count (WBC) ≥_50x109/L and/or age ≥ 10 years. b Minimal residual disease 
PCR high (≥10-3), intermediate (≥10-4 and <10-3), low (<10-4); TP1, after the first induction course of chemotherapy, DCOG ALL-
10 protocol day 33, ALL-9 protocol day 42, COALL day 28; TP2, before consolidation, day 79. c Prednisone response on day 8 
≥1.0x109 blasts/L (DCOG ALL-8/10 protocols). d Complete remission (CR) after induction (day 33 in DCOG ALL-9/10, day 42 
in ALL-8) is defined on morphological grounds by the presence of <5% leukemic blasts and regenerating hematopoiesis. e Common 
IKZF1 deletions are defined as full deletion (exons 1-8) and deletion of exons 4-7. f Other IKZF1 deletions included deletion of exons 
1, 1-2, 1-3, 2-3, 2-7, 2-8, 4-8, 5 and 7-8.
TK fusion-
positive BCR-
ABL1-like
TK fusion-
negative 
BCR-ABL1-
like
Fisher P TK fusion-
positive vs. TK 
fusion-negative 
BCR-ABL1-like
Non-BCR-
ABL1-like 
B-other
Fisher P TK 
fusion-positive vs. 
non-BCR-ABL1-
like B-other
CliniCal features
Male 11/14 (79%) 28/63 (44%) 0.036 44/76 (58%) 0.23
age  ≥ 10 years 7/14 (50%) 18/63 (29%) 0.2 25/76 (33%) 0.24
WBC  ≥ 50x109/L 6/14 (43%) 32/63 (51%) 0.77 23/76 (30%) 0.37
NCI high riska 11/14 (79%) 43/63 (68%) 0.53 42/76 (55%) 0.14
MRD TP1a                         High
Intermediate
Low
7/11 (64%)
3/11 (27%)
1/11 (9%)
17/36 (47%)
4/36 (11%)
15/36 (42%))
0.093
10/45 (22%)
5/45 (11%)
30/45 (67%
0.001
MRD TP2b                            High
Intermediate
Low
4/7 (57%)
0/7 (0%)
3/7 (43%)
4/30 (13%)
3/30 (10%)
23/30 (77%))
0.037
1/34 (3%)
1/34 (3%)
32/34 (94%)
0.002
Risk arm MR or HR 12/14 (86%) 15/36 (42%) 1 47/74 (64%) 0.13
Prednisone poor responsec 2/7 (29%) 3/31 (10%) 0.22 3/31 (10%) 0.22
No CR after inductiond 5/12 (42%) 10/58 (17%) 0.11 5/73 (7%) 0.004
MoleCular features
IKZF1 deletion                 Total
Commone
Otherf
9/14 (64%))
3/14 (21%)
6/14 (43%)
25/62 (40% )
16/62 (26%)
9/62 (15%)
0.14
1
0.026
13/73 (18%)
5/73 (7%)
8/73 (11%)
0.0009
0.11
0.009
EBF1 deletion 4/14 (29%) 9/62 (15%) 0.24 3/73 (4%) 0.012
EBF1 single exon 16 del 4/14 (29%) 0/62 (0%) 0.0008 0/73 (0%) 0.0005
PAX5 deletion/amp 3/14 (21%) 32/62 (52%) 0.072 26/73 (36%) 0.37
ETV6 deletion 2/14 (14%) 9/62 (15%) 1 18/75 (24%) 0.73
BTG1 deletion 2/14 (14%) 1/62 (2%) 0.085 6/74 (8%) 0.61
CDKN2A/B deletion 2/14 (14%) 39/62 (63%) 0.002 29/75 (39%) 0.13
RB1 deletion 1/14 (7%) 6/62 (10%) 1 5/74 (7%) 1
CRLF2 high expression 0/14 (0%) 12/63 (19%) 0.11 12/76 (16%) 0.2
PAR1 deletion 0/14 (0%) 8/62 (13%) 0.34 8/75 (11%) 0.35
dic(9;20) 0/14 (0%) 15/57 (26%) 0.031 2/74 (3%) 1
iAMP21 0/14 (0%) 10/57 (18%) 0.19 2/74 (3%) 1
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fusions (35% ± 16%) was comparable with the remaining BCR‑ABL1-like group (35% ± 
6%), and worse than the non-BCR‑ABL1-like B-other group (17% ± 5%; Gray p-value 
0.066; Figure 2B). Of the three relapsed fusion-positive cases, one died of relapse and 
two were alive at end of follow-up (6-12 months). Remarkably, the percentage of males 
was higher in fusion-positive than fusion-negative BCR‑ABL1-like cases (79% vs. 44%, 
p=0.04; Table 3). 
Figure 2. BCR-ABL1-like tyrosine kinase fusion cases
(A) Clinical characteristics and follow-up for the tyrosine kinase fusion cases. Barplot representing years 
from diagnosis to event or censoring. Treatment protocol and arm, prednison window response (Pred), 
morphological response after induction therapy (Resp), minimal residual disease (MRD), and deletion 
status of IKZF1 are shown.  MRD monitoring by PCR was performed for research purposes in ALL-9 
and COALL03 and for MRD-guided risk stratification in ALL-10. WT indicates no IKZF1 deletion. For 
definition of Pred, Resp, and MRD see footnotes Table 3. Response ‘unkn’ indicates patients with low 
cellularity bone marrow which could not be evaluated. * Indicates patients who received bone marrow 
transplant, for which HR-treated cases were eligible. (B) Cumulative incidence of relapse and non-
response curves for tyrosine kinase fusion positive BCR‑ABL1-like cases, fusion-negative BCR‑ABL1-like 
cases, and non-BCR‑ABL1-like B-other cases. Relapse and non-response were considered as events, 
death as competing event. Cumulative incidence probabilities were estimated using a competing risk 
model, equality was tested with the Gray test.
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R32 M ALL8-HR* poor LR nd nd WT EBF1-PDGFRB
A288 M ALL10-HR* poor LR high high DEL4-7 EBF1-PDGFRB
A472 M ALL10-HR* good CR high high WT EBF1-PDGFRB
A428 M ALL10-MR good unkn high low DEL1-8 EBF1-PDGFRB
A123 F COALL03-HR nd CR int nd DEL1-8 SSPB2-CSF1R
A526 M ALL10-HR* good CR high high DEL2-7 SSBP2-CSF1R
A91 M ALL9-SR nd LR nd nd WT ZM1Z1-ABL1
A26 M ALL9-HR nd NR nd nd DEL2-8 FOXP1-ABL1
A530 M ALL10-HR* good unkn high high DEL2-3 RCSD1-ABL2
A31 F ALL9-HR nd CR int low DEL1 PAX5-JAK2
A286 F ALL10-SR good CR low low WT PAX5-JAK2
A204 M COALL03-HR nd CR high nd DEL2-7 PAX5-JAK2
A214 M COALL03-HR* nd LR high nd WT TERF2-JAK2
A216 M COALL03-HR* nd CR int nd DEL2-3 BCR-JAK2
A
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DISCUSSION
We identified ABL/JAK class tyrosine kinase fusion genes in 14/153 (9%) of DCOG/
COALL B-other cases and these fusions were restricted to the BCR‑ABL1-like B-other 
subgroup. Given that these 153 cases were derived from a population-based selection 
of BCP-ALL5 and that these fusions do not co-occur with other driver leukemic fusions 
(BCR‑ABL1, rearranged MLL, TCF3‑PBX1, ETV6‑RUNX1), ABL/JAK class tyrosine kinase 
fusions cases are estimated to represent approximately 2.5% of pediatric BCP-ALL, 
making this heterogeneous subgroup similar in size to the BCR‑ABL1-positive cytogenetic 
subtype. Although the number of cases evaluated in our study is modest, the frequency of 
tyrosine kinase fusion cases is similar to those reported in other cohorts: 3% ABL/JAK class 
fusions in a high-risk pediatric US cohort6 and 5% ABL/JAK class fusions among Japanese 
pediatric B-other cases.9
The most comprehensive detection of novel tyrosine kinase fusion genes requires 
transcriptome or whole genome sequencing. These costly methods have not been applied 
to complete cohorts but rather to subsets of cases, for example cases selected based 
on Philadelphia-like gene expression or absence of sentinel chromosomal abnormalities, 
mostly in retrospective studies.6,9 More targeted approaches to detect recently identified 
tyrosine kinase fusions include RT-PCR 9, capture-targeted sequencing17 or targeted locus 
amplification (TLA) and sequencing.18 We combined genomic information from copy 
number, gene expression, targeted RT-PCR, FISH, and TLA to detect tyrosine kinase fusion 
genes in a representative cohort of 153 BCP-ALL cases without sentinel chromosomal 
aberrations that were taken from a population-based cohort of 574 cases at initial 
diagnosis of BCP-ALL. We found tyrosine kinase fusions exclusively in the BCR‑ABL1-like 
B-other group, and found them non-overlapping with two chromosomal abnormalities 
that were described earlier to occur in BCR‑ABL1-like cases, iAMP21 and dic(9;20).3 
Moreover, while CRLF2 high expression cases are present both in BCR‑ABL1-like and non-
BCR‑ABL1-like B-others, we found that tyrosine kinase fusions and high CRLF2 expression 
were mutually exclusive. The current study did not aim at discovering novel tyrosine kinase 
fusions, therefore there is a small probability that a sample with a novel tyrosine kinase 
gene is included in the tyrosine kinase fusion negative group. 
Our finding that tyrosine kinase fusions are only found in patients with BCR‑ABL1-like 
features, and our earlier finding that tyrosine kinase fusion cases are identified by both 
the St. Jude and Erasmus MC BCR‑ABL1-like expression signatures,16 means that a pre-
screening method based on gene expression, such as the US-developed low density 
array, is suitable to narrow down the patient population to be screened for tyrosine kinase 
fusions. An alternative approach screens patients selected by poor early clinical response 
for tyrosine kinase fusions.10
We found that ABL/JAK kinase fusion cases were characterized by poor initial response 
to induction treatment, high MRD levels, and a higher relapse rate compared with non-
BCR‑ABL1-like B-other ALL cases but a comparable relapse rate as BCR‑ABL1-like ALL 
without tyrosine kinase fusions. In correspondence, a recent Japanese study showed that 
the event-free survival of tyrosine kinase-activating fusion cases (albeit including CRLF2 
rearrangements) was unfavorable compared with fusion-negative BCP-ALL 9, Schwab 
et al. described that EBF1‑PDGFRB-positive patients were MRD positive at the end of 
induction10, and Roberts et al. described MRD positivity and inferior survival in the total 
group of Philadelphia-like cases. Recent protocols using MRD-based risk-directed therapy 
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suggest that initial poor treatment response in tyrosine kinase fusion-positive cases or the 
total group of Philadelphia-like cases can be overcome with intensive chemotherapy, 
leading to durable remission.10,19 Ex vivo leukemic patients’ cells with JAK and ABL class 
fusions were shown to be sensitive to tyrosine kinase inhibitors.6,7,15 Promising early 
clinical results suggests that ABL class tyrosine kinase fusion patients respond well to ABL 
class inhibitors imatinib or dasatinib.6,10,20,21 Together with our data, these reports stress 
the importance of prospective detection of tyrosine kinase fusions and incorporation of 
tyrosine kinase inhibitors in ALL treatment protocols to improve outcome.
METHODS
Patient samples
This study comprised 574 children with newly diagnosed BCP-ALL enrolled in consecutive 
Dutch Childhood Oncology Group trials (DCOG ALL-8, ALL-9 and ALL-10)5,22 and 
German Cooperative ALL trials (COALL 06-97 and 07-03)23,24. These patient cohorts were 
described and analyzed together previously.3,5 Written informed consent was obtained 
from parents or guardians and institutional review boards approved the use of excess of 
diagnostic material for research purposes. These studies were conducted in accordance 
with the Declaration of Helsinki. Mononuclear cells were collected using Lymphoprep 
sucrose gradient centrifugation (Nycomed Pharma, Oslo, Norway) from bone marrow 
aspirates and peripheral blood samples obtained prior to treatment. Where needed, 
mononuclear cells were enriched to >90% leukemic cells by depleting normal cells using 
anti-CD marker coated magnetic beads (Dynal, Oslo, Norway) as described previously.25 
DNA and total RNA were isolated using TRIzol (Invitrogen Life Technologies, Breda, the 
Netherlands) and quantified using a Nanodrop ND1000 (Nanodrop, Wilmington, DE). 
From this cohort, we focused on B-other patients, defined as patients without the sentinel 
chromosomal abnormalities BCR‑ABL1, MLL rearrangements, ETV6‑RUNX1, TCF3‑PBX1, 
and high hyperdiploidy. Among the B-other cases, BCR‑ABL1-like cases identified by 
hierarchical clustering of gene expression data were described previously in our cohort.5 
For 153 out of 204 B-other/BCR‑ABL1-like cases in the cohort, tyrosine kinase fusion 
testing was performed (see flow chart in Supplemental Figure S1).
Tyrosine kinase fusion detection
Detection of tyrosine kinase fusion genes was performed by RT-PCR followed by 
Sanger sequencing for six fusion transcripts EBF1‑PDGFRB, PAX5‑JAK2, NUP214‑ABL1, 
RANBP2‑ABL1, ETV6‑ABL1, RCSD1‑ABL1 and STRN3‑JAK2 described by Roberts 
et al.7 In addition, we performed a more extensive RT-PCR panel6 enabling detection 
of 30-39 fusion genes (depending on availability of material). For RT-PCR primers see 
Supplemental Table S1. We used targeted locus amplification for 21 cases to detect fusion 
genes involving ABL1, PDGFRB, CSF1R, ABL2, TYK2, and JAK2 (TLA, Cergentis, Utrecht, 
the Netherlands).18,26 We used break apart FISH with PDGFRB/CSF1R and ABL1 probes 
(Cytocell) to confirm fusions. The methods applied to each case depended on the type 
and amount of available patient material and is indicated in Supplemental Figure S1. For 
the comparison of tyrosine kinase fusion positive versus negative patients, we included 
153 samples that were tested at least by the 7-fusion RT-PCR panel. For expression rank 
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analysis (Table 2), the Affymetrix microarray gene expression values for each tyrosine 
kinase gene were ranked from high to low for the 153 samples. Then the percentile rank of 
the fusion-positive case among the 153 samples was calculated.
Genome-wide DNA copy number arrays (array-CGH)
Copy number analysis was performed using Agilent SurePrint G3 Hmn 4x180K arrays 
(Agilent Technologies, Amstelveen, the Netherlands) co-hybridized with 1 µg patient DNA 
labeled with ULS-Cy5  and 1 µg reference genomic DNA male pool (G147A, Promega, 
Leiden, the  Netherlands) labeled with ULS-Cy3 (Agilent Genomic DNA ULS Labeling Kit). 
Copy number microarray data were normalized using median log ratio in the CGHcall27 
version 2.14.0, centralized using CGHnormaliter28 version 1.8.0, and segmented and 
called using CGHcall default settings (-1 for loss, 0 for diploid, 1 for gain and 2 for 
amplification) in R version 2.14.1. 
Multiplex ligation-dependent probe amplification
The SALSA P335 ALL-IKZF1 (a3) and the SALSA P202 Multiplex Ligation-dependent 
Probe Amplification (MLPA) assays (MRC-Holland) were used to identify or confirm 
genomic lesions on the following genes: IKZF1, CDKN2A, CDKN2B, ETV6, PAX5, 
RB1, BTG1 and EBF1 as described previously.5,29 In short, 125 ng of genomic DNA was 
used to generate DNA fragments with incorporated FAM nucleotides according to the 
manufacturer's protocol. The amplified fragments were quantified using an ABI-3130 
genetic analyzer (Applied Biosystems, Carlsbad, CA). Peak intensities were normalized to 
the manufacturer's control probes and to a synthetic control reference generated from five 
normal DNA samples in the same MLPA run. A peak ratio lower than 0.75 was considered 
a deletion, a ratio between 0.75 and 1.3 was considered normal copy number, a ratio 
higher than 1.3 was considered a gain in copy number.
Targeted locus amplification
Targeted Locus Amplification (TLA) combined with deep-sequencing was used to detect 
fusion genes and sequence mutations in regions up to 100 kb around a pre-selected primer 
pair by crosslinking of physically proximal genomic sequences as described before.16 
Briefly, DNA and protein in 10-15 million viable leukemic blast cells were crosslinked in a 
2% formaldehyde solution. Cells were lysed and DNA was digested with NlaIII, followed 
by ligation, de-crosslinking and DNA purification. DNA molecules were trimmed with 
NspI and ligated at a concentration of 5 ng/µl to promote intramolecular ligation to DNA 
fragments of approximately 2 kb. These chimeric fragments were PCR amplified, sonicated 
and adaptor-ligated for paired-end high-throughput Illumina sequencing. A total of 31 
primer sets targeting 19 recurrently affected genes were designed and multiplexed, 
including the genes involved in the classical cytogenetic subtypes MLL, RUNX1, TCF3, 
and IKZF1, the tyrosine kinase genes ABL1, ABL2, PDGFRB, CSF1R, JAK1, JAK2, JAK3, 
FLT3, and TYK2, and the cytokine signaling genes CRLF2, EPOR, IL7R, TSLP, SH2B3, and 
IL2RB.17
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Fluorescent in-situ hybridization (FISH)
FISH was performed on interface nuclei using break apart probes (Cytocell, Cambridge, 
UK) for PDGFRB and ABL1. The FISH probes for PDGFRB overlap with the neighboring 
CSF1R locus. At least 100 interphase nuclei were evaluated. 
Reverse transcriptase PCR (RT-PCR)
cDNA was synthesized from 1 µg total or copy RNA using M-MLV reverse transcriptase 
and combined oligo-dT and pdN6 priming in 20 µl (Promega, Madison, WI). PCR was 
performed on 2.5 µl cDNA using Taq polymerase, MgCl2 and buffer from Applied 
Biosystems (Bleiswijk, Netherlands). For primer sequences see Supplemental Table S1.
Association with clinical outcome
Cumulative incidence of relapse (CIR) was estimated using a competing risks model. We 
considered relapse as event, and death as competing event. To test for equality of CIRs, 
Gray's test has been applied. The CIR probability (pCIR) with standard error was reported. 
Outcome analyses were performed in R 3.0.1, using the packages cmprsk version 2.2-6 0, 
mstate version 0.2.631, and survival version 2.37-432.
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 Gene fusion Forward  Primer ID Forward sequence 5' to 3'
Reverse  
Primer ID Reverse sequence 5' to 3'
ETV6-ABL1 ETV6 exon5 ggagaataatcactgcccagcgtcct ABL1 exon 4 gccaccgtcaggctgtatttcttcc
NUP214-ABL1 NUP241 exon 20 cagtggccttggaggaaaacccagt ABL1 exon 4 gccaccgtcaggctgtatttcttcc
RANBP2-ABL1 RANBP2 exon 16 tggttctttgcgaaatgcagattca ABL1 exon 4 gccaccgtcaggctgtatttcttcc
RCSD1-ABL1 RCSD1 exon 3 cagccagtaaaccaacccgaaggaa ABL1 exon 4 gccaccgtcaggctgtatttcttcc
SNX2-ABL1 SNX2 exon 3 cggaaccttctcctgcagtcacacc ABL1 exon 4 gccaccgtcaggctgtatttcttcc
ZMIZ1-ABL1 ZMIZ1 exon 17 gaccggcagatgaaca ABL1 exon 3 cattccccattgtgattatag
PAG1-ABL2 PAG1 exon 7 ccttcaggagaaggaagggggagagg ABL2 exon6 gtcgtggatgggggacacaccatag
RCSD1-ABL2 RCSD1 exon 3 cagccagtaaaccaacccgaaggaa ABL2 exon6 gtcgtggatgggggacacaccatag
ZC3HAV1-ABL2 ZC3HAV1 exon 11 tgtcagagatccatcacctacatcca ABL2 exon6 gtcgtggatgggggacacaccatag
SSBP2-CSF1R SSBP2 exon 12 tcatgcctagtccagcagattcaacca CSF1R exon 14 tggctcatgatcttcagctcggaca
MYH9-CSF1R MYH9 exon 1 gcgggaaggcggcgaggag CSF1R exon 14 tggctcatgatcttcagctcggaca
MEF2D-CSF1R MEF2D exon 7 cctgcgagtcatcacttc CSF1R exon 14 tggctcatgatcttcagctcggaca
EBF1-CSF1R EBF1 exon 11 ccaccatcgattatggtttccagaggt CSF1R exon 14 tggctcatgatcttcagctcggaca
ETV6-NTRK3 ETV6 exon5 ggagaataatcactgcccagcgtcct NTRK3 exon 15 atcttgtccttggtcgggctgaggt
ATF7IP-JAK2 ATF7IP exon 12 aacccatacaaccagcaccgcctct JAK2 exon 20 tgttgtcatgctgtagggatttcagga
BCR-JAK2 BCR exon 1 gtgccataagcggcaccggcact JAK2 exon 18 aggcctgaaatctggttcata
EBF1-JAK2 EBF  exon 14 cacgagcatgaacggatacggctct JAK2 exon 20 tgttgtcatgctgtagggatttcagga
ETV6-JAK2 ETV6 exon 3 atggcaaagctctcctgctgctgac JAK2 exon 20 tgttgtcatgctgtagggatttcagga
PAX5-JAK2 PAX5 exon 3 acaatgacaccgtgcctagcgtcag JAK2 exon 19 tcaaaggcaccagaaaac
PPFIBP1-JAK2 PPFIBP1 exon 10 tgcaagatgaaaggagaaggggttga JAK2 exon 20 tgttgtcatgctgtagggatttcagga
SSBP2-JAK2 SSBP2 exon 7 ggcacttggaggtgtcccaggaagt JAK2 exon 20 tgttgtcatgctgtagggatttcagga
STRN3-JAK2 STRN3 exon 7 tgaaggagctggagaagcacggagt JAK2 exon 20 tgttgtcatgctgtagggatttcagga
TPR-JAK2 TPR exon 38 tggaaatgcctcttccaaagaagttga JAK2 exon 20 tgttgtcatgctgtagggatttcagga
TERF2-JAK2 TERF2 exon 10 tggggaaggaaactgg JAK2 exon 20 tgttgtcatgctgtagggatttcagga
EBF1-PDGFRB EBF1 exon 14 ccccagcagaccaactat PDGFRB exon 12 ttccatcggatctcgtaa
TNIP1-PDGFRB TNIP1 exon 13 aagcactgagcatccaaacc PDGFRB exon 13 tttcatcgtggcctgagaatggctc
ZEB2-PDGFRB ZEB2 exon 9 cccaactggagcagctacttttgctga PDGFRB exon 13 tttcatcgtggcctgagaatggctc
SSBP2-PDGFRB SSBP2 exon 7 ggcacttggaggtgtcccaggaagt PDGFRB exon 13 tttcatcgtggcctgagaatggctc
SSBP2-PDGFRB SSBP2 exon 12 tcatgcctagtccagcagattcaacca PDGFRB exon 13 tttcatcgtggcctgagaatggctc
MYB-TYK2 MYB exon 6 tcaggctccgcctacagctcaactc TYK2 exon 19 tccgggttcacagtcaagacgtcag
Supplemental Table S1. Reverse transcription PCR primers used for the detection of tyrosine 
kinase fusion genes
SUPPLEMENTAL DATA
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Supplemental Figure S1. Overview of cohort screened for tyrosine kinase fusion genes
Flowchart showing the number of cases tested for tyrosine kinase fusion genes using an RT-PCR panel 
of 7 fusions3, an RT-PCR panel of 30 fusions1, and targeted  locus amplification for 6 kinases4. Boxes 
at the bottom summarize the number of positive and negative cases per method. ND, not determined.
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Supplemental Figure S2. Sanger sequencing and TLA fusion read of RCSD1-ABL2 in case 
A530
(A) Sequence confirmation of the RCSD1‑ABL2 fusion by Sanger sequencing of RT-PCR product 
indicates fusion of RCSD1 exon 3 to ABL2 exon 5. For primers used in validation RT-PCR see 
Supplemental Table S1. The fusion encodes an in frame fusion protein. (B) Schematic representation 
of the in-frame RCSD1‑ABL2 fusion protein drawn in ProteinPaint5. (C) Targeted locus amplification 
genomic DNA fusion read showing RCSD1 intron 3 (chr1) (red) and ABL2 intron 4 (chr1) in green.
Supplemental Figure S3. Sanger sequencing of TERF2-JAK2 in case A214
(A) Sequence confirmation of the TERF2‑JAK2 fusion by Sanger sequencing of RT-PCR product 
indicates fusion of TERF2 exon 10 to JAK2 exon 19. For primers used in validation RT-PCR see 
Supplemental Table S1. The fusion encodes an in frame fusion protein. (B) Schematic representation of 
the in-frame TERF2‑JAK2 fusion protein drawn in ProteinPaint5. 
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Supplemental Figure S4. FISH with PDGFRA break apart probes on EBF1-PDGFRA fusion 
cases.
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Supplemental Figure S5. Array comparative genomic hybridization 180K Agilent array data 
for tyrosine kinase fusion cases.
The x-axis indicates genomic location on the indicated chromosome, the y-axis shows the called array-
CGH data with 0 representing two copies, 1 representing gain and -1 loss (A-C) or the normalized 
log2 ratios (D-F). The colored triangles on the right indicate gain (orange) and loss (blue). (A-D) 
Rearrangements involving chromosome 5. Beginning and end position of the genes involved in the 
tyrosine kinase fusions are indicated by colored vertical lines: purple, CSF1R; red, PDGFRB; blue, EBF1; 
light-blue, SSBP1. The orientation of the genes is indicated with < for minus strand and > plus strand. (E-F) 
Rearrangements resulting in JAK2 fusions. The complete chromosomes involved in the rearrangements 
are shown. The genes involved in the fusions are indicated in red, the breakpoint is indicated by a red 
arrow. The positions of the centromeres are indicated by black vertical lines. (Continued on the next 
pages)
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Supplemental Figure S5. Array comparative genomic hybridization 180K Agilent array data 
for tyrosine kinase fusion cases. (continued)
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Supplemental Figure S5. Array comparative genomic hybridization 180K Agilent array data 
for tyrosine kinase fusion cases. (continued)
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Supplemental Figure S5. Array comparative genomic hybridization 180K Agilent array data 
for tyrosine kinase fusion cases. (continued)
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ABSTRACT
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell precursor 
acute lymphoblastic leukemia (BCP-ALL). In the current study we performed a screening 
for JAK2 mutations and translocations, analyzed the clinical outcome and studied the 
efficacy of two JAK inhibitors in primary BCP-ALL cells. Importantly, we identify a number 
of limitations of JAK inhibitor therapy.
JAK2 mutations mainly occurred in the poor prognostic subtypes BCR‑ABL1-like and non-
BCR‑ABL1-like B-other (negative for sentinel cytogenetic lesions). JAK2 translocations 
were restricted to BCR‑ABL1-like cases. Momelotinib and ruxolitinib were cytotoxic in 
both JAK2 translocated and JAK2 mutated cells, although efficacy in JAK2 mutated cells 
highly depended on cytokine receptor activation by TSLP. However, our data also suggest 
that the effect of JAK inhibition may be compromised by mutations in alternative survival 
pathways and microenvironment-induced resistance. Furthermore, inhibitors induced 
accumulation of phosphorylated JAK2Y1007, which resulted in a profound re-activation of 
JAK2 signaling upon release of the inhibitors. This preclinical evidence implies that further 
optimization and evaluation of JAK inhibitor treatment is necessary prior to its clinical 
integration in pediatric BCP-ALL. 
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INTRODUCTION
Janus kinase 2 (JAK2) is a member of the non-receptor tyrosine kinase family and mediates 
intracellular signaling upon activation of cytokine receptors, which lack an intrinsic tyrosine 
kinase domain, such as cytokine receptor-like factor 2 (CRLF2). Ligand binding (e.g. TSLP 
for CLRF2) induces dimerization of cytokine receptors chains, resulting in activation of 
JAK proteins via cross-phosphorylation. JAKs activate signal transducers of transcription 
(STATs), which, upon dimerization, migrate to the nucleus and induce transcription of genes 
involved in differentiation and proliferation of hematopoietic cells.1
JAK2 has seven homologous domains (JH1-JH7). The JH1 and JH2 domains are 
C-terminally located and comprise the catalytic kinase (JH1) and pseudokinase (JH2) 
domain. The JH2 domain has a dual regulatory function: exerting a negative regulatory 
effect on the kinase domain, and facilitating JAK2 activation upon receptor activation 
by ligand binding.2 The JH3-JH4 domains share homology with Src homology 2 (SH2) 
domains and mediate protein-protein interactions. The N-terminal located JH6 and JH7 
domains, also known as the FERM domain, are required for binding of JAK2 to cytokine 
receptors.1
In pediatric BCP-ALL patients, gain of function mutations and translocations affecting JAK2 
have been identified.3-15 Genomic translocations of JAK2 have been observed in high-
risk BCR‑ABL1-like patients. For several of these fusion genes, constitutive JAK2 kinase 
activation has been demonstrated.12-14, 16 Point mutations often occur in Down Syndrome ALL, 
mainly affect exon 16 (located in the pseudokinase domain), and functionally cooperate 
with overexpression of the type I cytokine receptor CRLF2.6, 9, 10 Indeed, requirement for 
the interaction of mutant JAK2 with a cytokine receptor was shown in cell lines models by 
several groups.6, 8, 9
Mutations and translocations represent biologically distinct entities, but both are potential 
targets for precision medicines. JAK inhibitors were shown to be effective against mutant 
and translocated JAK2 in vitro.3, 5, 7, 8, 12, 13, 16, 17 However, in vivo mouse studies show 
conflicting data and none has been reported to be curative.13, 17-21 To date, clinical data with 
JAK inhibitors are scarce. The Children’s Oncology Group performed a phase 1 dosing 
study of the JAK inhibitor ruxolitinib, but no cases harboring JAK2 activating mutations or 
translocations were included.22
Several papers have reported data with a focus on either fusion genes or mutations of 
JAK2, although often with small sample size or only in specific subtypes of BCP-ALL. 
Furthermore, most reports lack ex vivo efficacy data of JAK inhibitors in primary leukemic 
cells. To assess the clinical potential of JAK inhibitors in pediatric BCP-ALL, we performed 
a comprehensive study to determine the frequency and prognosis of JAK2 mutations 
and translocations among different subtypes of childhood BCP-ALL. Furthermore, the 
biological efficacy of the JAK inhibitors momelotinib and ruxolitinib was studied in primary 
leukemic cells harboring JAK2 aberrations, and the clonal stability of JAK2 mutations was 
investigated in ALL patient derived xenograft models. We show that JAK inhibitors are 
overall effective towards BCP-ALL cells, but also identified a number of limitations of JAK 
inhibitor therapy. 
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RESULTS
Frequency and type of JAK2 aberrations in BCP-ALL patients
JAK2 mutation status was analyzed in 461 newly diagnosed BCP-ALL cases representing 
all major subtypes seen in children, with a distribution that is comparable to the general 
pediatric BCP-ALL population. JAK2 exons 16, 20, 21 and 23 were examined by targeted 
amplicon sequencing at a median read depth of 673, 577, 711 and 944, respectively. 
Analyses revealed that 3.5% (16/461) of these BCP-ALL cases harbored JAK2 mutations, 
which were detected in 7.6% (6/79) of BCR‑ABL1-like cases, 11.9% (8/67) of non-BCR‑
ABL1-like B-other cases, and 1.6% (2/124) of high hyperdiploid cases. No JAK2 mutations 
were detected in KMT2A‑ALL1 (0/15), BCR‑ABL1 (0/26), ETV6‑RUNX1 (0/124) or 
TCF3‑PBX1 (0/26) cases. The variant allele frequency (VAF) ranged from 1.0% to 56% 
(Figure 1A). Seven patients carried two different JAK2 mutations, and one patient even 
harbored three different JAK2 mutations. Mutations involved amino acid residue R683 in 
13 of 16 mutated cases, which is an important amino acid for the JH2 domain mediated 
negative auto-regulation of JAK2 activity.23 CRLF2 overexpression was detected in 87.5% 
(14/16) of these cases (Figure 1A, Supplementary Figure 1). One CRLF2 low expressing 
case harbored a subclonal JAK2 mutation, suggesting that CRLF2 overexpression might 
be subclonal as well. The other case harbored a JAK2R923H with a VAF of 50 %, suggesting 
that this mutation in the kinase domain is not associated with CRLF2 overexpression. 
The screen for JAK2 fusion genes was confined to 153 BCP-ALL cases, negative for sentinel 
BCP-ALL associated lesions (KMT2A‑rearranged, BCR‑ABL1, ETV6‑RUNX1, TCF3‑PBX1, 
high hyperdiploid), as JAK2 translocations were previously reported in this group of 
patients.12,13,24 No JAK2 translocations were detected in 76 non-BCR‑ABL1-like B-other 
cases, whereas in 5 of the 77 (6.5%) BCR‑ABL1-like cases JAK2 tyrosine kinase activating 
fusion genes were identified. The cases involved 3 PAX5‑JAK2 cases, 1 BCR‑JAK2 case and 
1 TERF2‑JAK2 case (Figure 1A). The PAX5‑JAK2 and BCR‑JAK2 fusions contained identical 
exons as reported before.12,13 The TERF2‑JAK2 case displayed an in frame fusion of TERF2 
exon 10 to JAK2 exon 19. All JAK2 fusion genes harbored an intact JH1 kinase domain 
(Supplementary Figure 2). Gene expression data revealed high expression levels of JAK2 
in these cases (Supplementary Figure 3). Absence of the cytokine receptor-binding FERM 
domain in JAK2 fusion protein suggests that they signal independent of a cytokine receptor.
Clinical characteristics and prognosis of patients harboring JAK2 lesions
Ten out of sixteen (62.5%) JAK2-mutated patients remained in continuous complete 
remission at more than 5 years of follow up. The median time to relapse in the six other 
patients was 2.1 years [range 0.71-7.8 years]. Minimal residual disease (MRD) data were 
available for nine out of fourteen patients. The four patients with high MRD levels (≥10-3) 
at day 29/33 of treatment (time point 1 of COALL and DCOG protocol, respectively) 
relapsed, whereas the remaining five mutated patients with low MRD levels remained in 
continuous complete remission (p=0.008, Fisher exact test).
Three out of the five cases harboring JAK2 fusion genes remained in continuous complete 
remission at more than 5 years of follow up, whereas two cases suffered from a relapse 
within 2.4 years of diagnosis (Figure 1A). Both patients who relapsed were assigned to the 
High Risk arm of the COALL-03 study protocol because of unfavorable age (>10 years) or 
high white blood cell count at diagnosis (>50 WBC/nl).
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Figure 1. JAK2 aberrations in BCP-ALL patients
(A) Type of lesions, clinical characteristics and follow-up of JAK2 lesion positive patients. Treatment 
protocol and risk group assigned to each patient per protocol have been listed (HR-S: High Risk 
Standard. HR: High Risk. MR: Median Risk. SR: Standard Risk. LR-S: Low Risk Standard. LR-R: Low 
Risk Reduced. NHR: Non-High Risk). WBC indicates white blood cell count. Minimal residual 
disease (MRD) levels at day 29/33 of treatment of COALL and DCOG protocol, respectively. Type 
of translocation or mutation is listed. VAF indicates the variant allele frequency (%). CRLF2 status 
indicates gene expression below (low) or above (high) the 90th percentile levels. Right panel: Bar 
plot represents years from diagnosis to event or last contact. In blue: cases in complete clinical 
remission. In red: cases with an event (relapse or death). (B) Cumulative incidence of relapse 
curves for patients with JAK2 lesions (green line), JAK2 wildtype BCR‑ABL1‑like and B-other 
cases (grey line), and JAK2 wildtype remaining BCP-ALL cases (black line; ETV6‑RUNX1, high 
hyperdiploid, TCF3‑PBX1). Patients were treated according to ALL8, ALL9, ALL10, COALL97 or 
COALL03 protocol. Cumulative incidence of relapse (CIR) was estimated using a competing risk 
model. Relapse and non-response were considered as event, and death as competing event. Non-
response was counted as event at day 79. The Gray’s test was applied to test for equality of CIRs 
(JAK2 lesion versus remaining BCP-ALL p=0.04; JAK2 wildtype B-other/BCR‑ABL1-like versus 
remaining BCP-ALL p=0.04). 
Patient Protocol Risk group
Age 
(years)
WBC 
(x109/L)
Down 
Syndrome
MRD 
(d29/d33) Subtype Translocation
Mutation 1 
(VAF)
Mutation 2 
(VAF)
Mutation 3 
(VAF)
CRLF2 
status
A20 ALL9 HR 14 75 <10 -^3 BCR-ABL1 -like p.R873N 40% p.R683S 2% p.R683G 2% High
A35 ALL9 NHR 1 44 NA BCR-ABL1 -like p.R683T 56% p.R683G 13% High
A38 ALL9 HR 6 128,8 NA BCR-ABL1 -like p.R683G 32% p.T875N 10% High
A129 COALL03 HR-S 4 450 Yes NA B-other p.R683G 2% p.K914E 1% High
A159 COALL03 HR-S 4 39 NA High Hyperdiploid p.R683G 1% Low
A160 COALL03 LR-S 3 4,3 NA B-Other p.R683G 24% High
A167 COALL03 HR-S 9 30 NA B-other p.D873N 10% p.R683G 8% High
A178 COALL03 LR-R 7 10 ≥10 -^3 B-other p.R683T 30% p.R683G 4% High
A186 COALL97 HR-S 11 9,9 ≥10 -^3 BCR-ABL1 -like p.T875N 37% High
A251 COALL97 HR-S 7 115 NA BCR-ABL1 -like p.R683G 63% High
A282 ALL10 SR 3 21 <10 -^3 B-Other p.R683S 25% p.R683G 7% High
A315 ALL10 MR 3 3,6 Yes <10 -^3 B-Other p.R683G 41% High
A359 ALL10 MR 8 390 Yes ≥10 -^3 B-other p.R683G 27% p.R683S 25% High
A404 ALL10 MR 8 222,6 <10 -^3 BCR-ABL1 -like p.R683G 26% High
A433 ALL10 MR 2 1,9 Yes ≥10 -^3 High Hyperdiploid p.R683G 25% High
A521 ALL10 MR 11 12,1 <10 -^3 B-Other p.R923H 50% Low
A31 ALL9 HR 1 53,8 <10 -^3 BCR-ABL1 -like PAX5-JAK2 Low
A204 COALL03 HR-S 14 4,5 <10 -^3 BCR-ABL1 -like PAX5-JAK2 Low
A286 ALL10 SR 1 3,4 <10 -^3 BCR-ABL1 -like PAX5-JAK2 Low
A214 COALL03 HR-S 11 19,5 ≥10 -^3 BCR-ABL1 -like TERF2-JAK2 Low
A216 COALL03 HR-S 5 204 <10 -^3 BCR-ABL1 -like BCR-JAK2 Low
JA
K
2 
Tr
an
sl
oc
at
io
n
JA
K
2 
M
ut
at
io
n
0 5 10 15
Follow-up in years
A
B
Remaining BCP-ALL 
JAK2wt B−other and BCR-ABL1-like 
JAK2 lesions
n=279
n=141
n=21
p=0.04
p=0.04
0 2 4 6 8
0
20
40
60
80
100
Time from initial diagnosis (years)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 
re
la
ps
e 
an
d 
no
n−
re
sp
on
se
 (%
)
48
Chapter 3
Cumulative incidence of relapse in these JAK2 aberrant patients did not differ from JAK2 
wildtype BCR‑ABL1-like and B-other cases. Both displayed an unfavorable outcome 
compared to remaining BCP-ALL cases (p=0.04; Figure 1B). These findings underline the 
clinical relevance of JAK2 lesions. Mutations and translocations represent biologically 
distinct entities, but both may be targetable by JAK-inhibitors.
Leukemic cells with JAK2 lesions can be targeted by JAK inhibitors
Primary leukemic and patient-derived-xenograft (PDX) cells (Supplementary Figure 4, 
reference 25) were exposed to momelotinib and ruxolitinib. JAK2 translocated cells were 
more sensitive to both momelotinib and ruxolitinib compared to JAK2 wildtype cases 
(p<0.05; Figure 2A-B, Supplementary Figure 5). JAK2 mutated cells were less sensitive to 
these inhibitors than JAK2 fusion positive cells, and were only marginally more sensitive than 
wildtype cells (P<0.05). Leukemic cells without genetic JAK2 aberrations were resistant to 
ruxolitinib, but showed some sensitivity to momelotinib. Importantly, normal bone marrow 
mononuclear cells were resistant to both inhibitors (Supplementary Figure  5). Both JAK 
inhibitors effectively reduced levels of phosphorylated STAT5Y694 and/or STAT1Y701 (Figure 
2C-D, Supplementary Figure 6). 
The marginal sensitivity for both inhibitors and the low levels of phosphorylated STAT5 in JAK2 
mutated cells may be explained by lack of human TSLP ligand to activate the CRLF2 pathway 
in our culture conditions. Addition of human TSLP sensitized JAK2 mutated cells to ruxolitinib, 
but not to momelotinib (p<0.01, Figure 3A-B, Supplementary Figure 7-8). TSLP exposure did 
not change the efficacy of JAK inhibitors in JAK2-fusion positive cells, confirming cytokine-
independent signaling (Figure 3C-D, Supplementary Figure 7). JAK2 wildtype leukemic 
cells were not sensitized to JAK inhibitors by TSLP treatment (Figure 3E-F, Supplementary 
Figure 7). In the presence of TSLP both JAK2 translocated and JAK2 mutated cells were 
sensitive to JAK inhibitors (Figure 3G-H). At the protein level, TSLP exposure upregulated 
the levels of phosphorylated STAT1Y701 and STAT5Y694 in JAK2R683S mutated cells, whereas 
no effect was observed in JAK2 fusion positive and JAK2-wildtype leukemic cells (Figure 
3I-K, Supplementary Figure 9). Notably, TSLP triggered the phosphorylation and hence 
activation of the MEK/ERK pathway in JAK2R683S mutated cells, but not in JAK2R683G mutated 
cells (Figure 3I, 3L), suggesting that this activation is context-dependent. Phosphorylation of 
STAT1Y701 and STAT5Y694 was inhibited by momelotinib and ruxolitinib (Figure 3L).
JAK2 inhibition results in accumulation of phosphorylated JAK2
Exposure of primary leukemic cells, harboring TERF2‑JAK2 or PAX5‑JAK2, to momelotinib and 
ruxolitinib resulted in accumulation of phosphorylated JAK2Y1007 fusion proteins (Figure 2C). 
Wash out of both inhibitors induced a slight rebound effect with upregulation of pSTAT1Y701 
and pSTAT5Y694 in TERF2‑JAK2 cells (Figure 4A, Supplementary Figure 10).
This rebound effect was also observed in the JAK2V617F-positive leukemic cell line HEL 
(Supplemental Figure 11-12). Phosphorylated JAK2Y1007 accumulated upon exposure to 
ruxolitinib. Removal of the inhibitor resulted in reactivation of JAK2 signaling, observed by 
a clear increase in phosphorylated STAT5Y694 levels within 4 hours (time point 100 hours; 
Supplementary Figure 11A-B). The inhibitory effect of momelotinib was more transient 
compared to ruxolitinib, resulting in an earlier reactivation of JAK2, observed by high levels of 
phosphorylated STAT5Y694 after 48 hours of momelotinib exposure (Supplemental Figure 11A).
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Figure 2. The efficacy of JAK inhibitors on JAK2 translocated and mutated cells
(A-B) Leukemic (PDX or primary patient) cells were incubated for four days with to an increasing 
concentration range of momelotinib or ruxolitinib, after which cell viability was measured using an MTT 
assay. Sensitivity of exposed cells was calculated relative to vehicle treated controls. Individual samples 
were tested in duplicate. Mean±SEM of five JAK2 translocated cases, six JAK2 mutated cases and 
four JAK2 wildtype cases is shown. Cell viability of samples was compared using independent sample 
T-test. **p≤0.01, *p≤0.05, 1JAK2 translocations versus JAK2 wildtype, 2JAK2 translocations versus 
JAK2 mutations, 3JAK2 mutations versus JAK2 wildtype. (C-E) TERF2‑JAK2, PAX5‑JAK2, and JAK2R683G 
PDX cells were exposed for four hours to vehicle control medium, 1.5 µM momelotinib or 0.75 µM 
ruxolitinib, after which (phosphorylated) TERF2-JAK2, PAX5-JAK2, JAK2, STAT1 and STAT5 levels were 
analysed using western blot (25 µg lysate).
Mesenchymal stromal cells protect against JAK inhibitors
Leukemic cells reside in the bone marrow microenvironment, where they disrupt 
normal hematopoietic stem cell niches.26 This abnormal niche protects ALL cells against 
chemotherapy.27,28 To study whether the bone marrow microenvironment protects against 
JAK inhibitors, we mimicked this niche by co-culturing PDX cells with bone marrow 
mesenchymal stromal cells (MSCs) derived from a leukemia patient. Survival of leukemic 
cells was improved in co-cultures together with MSCs compared to leukemic cells cultured 
without MSCs (Figure 5A). In these PDX/MSC co-cultures, JAK inhibitors decreased 
leukemic cell survival (Supplementary Figure 13A-G). However, leukemic cells were 
more resistant to ruxolitinib in PDX/MSC co-culture compared to culture without MSCs 
(p<0.05). A similar trend was observed for momelotinib (Figure 5B-C, Supplementary 
Figure 13H-I). 
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Different outgrowth pattern in xenografts 
The outgrowth patterns of primary leukemic cells (>90% blast purity) in three NSG mice 
per patient was determined by paired-end deep-sequencing of JAK2 hotspot regions 
(exon 16, 20, 21 and 23; median read depth 554, 465, 411 and 593, respectively). PDX 
cells originating from a JAK2R683G mutated case had a different VAF profile compared to 
the original patient sample (Figure 6A, Supplementary Figure 14A). The primary sample 
contained a major JAK2R683G clone at a VAF of 63% and a minor KRASG12D clone at 
VAF 14%. In two out of three PDX samples generated, the VAF of the JAK2R683G mutation 
increased to 98% (PDX1) and 99% (PDX3), whereas in the remaining PDX sample the VAF 
decreased to 49% (PDX2). In contrast, the KRASG12D mutation increased to a VAF 23% in 
this PDX2 sample, whereas this mutation was not detected in PDX1 and PDX3. The reduced 
VAF of the JAK2 clone in PDX2 did not result in a decreased efficacy of momelotinib or 
ruxolitinib (Figure 6B). However, levels of pMEK1/2S217/221 and pERK1/2T202/Y204 in this 
sample were increased compared to the other two PDX samples (Figure 6C). Exposure to 
both JAK inhibitors did not decrease the levels of phosphorylated MEK and ERK.
Sanger sequencing of JAK2R683S and JAK2R683T PDX models also indicated a change in the 
VAF of PDX cells compared to the primary sample. In PDX cells from three NSG mice injected 
with JAK2R683S cells, the A/T peak ratio at nucleotide position 2049 differed, suggesting 
heterogeneity in frequency of JAK2 mutations between samples (Supplementary Figure 
14B). Strikingly, two mice injected with JAK2R683T mutated leukemic cells developed JAK2 
wildtype leukemia (Supplementary Figure 14C). Although the JAK2 mutation was lost, 
CRLF2 expression levels remained high (Supplementary Figure 14D-E). TSLP stimulation 
activated the JAK2 pathway signaling (Supplementary Figure 14F), but cells were not 
sensitive for JAK2 inhibition (Supplementary Figure 14G-H).
Figure 3. The effect of TSLP stimulation on the efficacy of JAK inhibitors .
Cells (PDX or primary ALL) were pre-incubated for 1 hour with or without 25 ng/ml TSLP, after which cells 
were exposed for four days to indicated concentrations of momelotinib or ruxolitinib. Cell viability was 
measured using an MTT assay. Sensitivity was calculated relative to vehicle treated controls. Individual 
samples were tested in duplicate. (A-B) Efficacy of momelotinib and ruxolitinib on JAK2 mutated cells 
with or without TSLP pre-incubation. Mean±SEM of six independent samples is shown. (C-D) Efficacy of 
momelotinib and ruxolitinib on cells with JAK2 translocations. Mean±SEM of two independent samples 
is shown. (E-F) Efficacy of momelotinib and ruxolitinib on JAK2 wildtype PDX cells. Mean±SEM of 
three independent samples is shown. (G-H) Combined graph of the efficacy of momelotinib (G) and 
ruxolitinib (H) on TSLP stimulated cells with JAK2 mutations (n=6), JAK2 translocations (n=2), or JAK2 
wildtype cells (n=3). Mean±SEM of independent samples is shown. Cell viability of samples was 
compared using the independent sample T-test. **p≤0.01, *p≤0.05. 1JAK2 translocations versus JAK2 
wildtype, 2JAK2 wildtype versus JAK2 mutations. (I-K) Western blot of JAK2R683S, TERF2‑JAK2 and 
JAK2wt PDX cells with or without TSLP stimulation (25 ng/ml for 1 hour). (L) JAK2R683G cells were pre-
incubated for 1 hour with or without 25 ng/ml TSLP, after which cells were exposed for four hours to 
vehicle control medium, 1.5 µM momelotinib or 0.75 µM ruxolitinib. Levels of (phosphorylated) JAK2, 
STAT1, STAT5, MEK1/2 and ERK1/2 were analysed using western blot.
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Figure 4. Accumulation of pJAK2 Y1007 results in a rebound effect of JAK2
TERF2‑JAK2 PDX cells were incubated for four hours with or without 1.5 µM momelotinib or 0.75 µM 
ruxolitinib, after which cells were washed to remove the JAK inhibitors. Half of the cells were exposed 
for another 1.5 hours to 1.5 µM momelotinib or 0.75 µM ruxolitinib, whereas the other cells were 
incubated in vehicle control (Ctr) medium. Protein expression levels were examined by western blot 
(25 µg lysate). 
DISCUSSION
This study aimed to evaluate the clinical need (frequency of lesions and prognostic value) 
and potential of JAK inhibitors in pediatric BCP-ALL. For this purpose pediatric BCP-ALL 
patients were screened for JAK2 lesions. JAK2 point mutations were found in 3.6% of 
our BCP-ALL patients, of which the majority were JAK2R683 mutations. These mutations 
were solely detected in BCR‑ABL1-like, B-other and high hyperdiploid patients, but not 
in KMT2A‑AFF1, BCR‑ABL1, ETV6‑RUNX1 or TCF3‑PBX1 patients. JAK2 translocations 
were detected in the poor prognostic BCR‑ABL1-like group, but not in non-BCR‑ABL1-
like B-other cases. The prognosis of patients with JAK2 aberrations was as poor as JAK2 
wildtype BCR‑ABL1-like and non-BCR‑ABL1-like B-other patients. 
JAK2 mutations were not detected as frequently in our DCOG/COALL sequencing cohort 
as reported for COG high-risk cohorts.5, 10 Two independent classifiers are used to describe 
BCR‑ABL1-like BCP-ALL.29-31 Differences in genetic ancestry between the American COG 
and European DCOG/COALL cohorts likely affected the signatures to classify patients 
as BCR‑ABL1-like. Hence, genetic differences, or more specifically the lack of Hispanic/
Latino cases10, 32 might explain the lower frequencies of JAK2 mutations, as well as the 
difference in treatment outcome. 
A targeted approach was used to detect JAK2 translocations. All cases with high JAK2 
expression levels harbored one of the known fusion genes, making it therefore unlikely that 
novel fusion genes were missed. 
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The poor outcome of cases harboring JAK2 lesions underline the clinical relevance of 
activated JAK2. The therapeutic potential of JAK2 was demonstrated by efficacy of JAK 
inhibitors in JAK2 mutated and JAK2 translocated primary BCP-ALL cells. JAK2 translocated 
cells were sensitive to both JAK inhibitors, independent of cytokine activation. In contrast, 
the efficacy of JAK inhibitors in JAK2 mutated cells highly depended on CRLF2 activation 
by TSLP, which is in concordance with previous reports.3, 5, 7, 8, 17 These results highlight the 
importance of TSLP in in vitro and in vivo studies involving JAK2 mutations. Since human 
CRLF2 cannot be activated by mouse TSLP, conventional mouse xenograft models are 
not suitable to test the efficacy of ruxolitinib and other JAK inhibitors on JAK2 mutated 
cells. Absence of human TSLP in ALL xenograft mouse models might therefore explain 
the disappointing efficacy of JAK inhibitors in in vivo models.18-21 The recently engineered 
xenograft model which synthesizes human TSLP may overcome this limitation.33 
Figure 5. Efficacy of JAK inhibitors in co-culture
The response of CD19+ PDX cells, co-cultured with MSCs (hCD19-), to increasing concentrations of 
momelotinib and ruxolitinib, was assessed after four days of culture using flow cytometry. Cells were 
stained with Brilliant Violet 421 anti-human CD19 antibody, FITC Annexin V, and PI. Viability was 
calculated relative to vehicle controls. (A) Survival of PDX cells in mono-culture, or PDX/MSC co-
culture. Individual samples were tested in duplicate. Bars represent the mean±SEM of two BCR‑JAK2, 
two TERF2‑JAK2, one PAX5‑JAK2, three JAK2R683G, and two JAK2 wildtype samples. Cell viability 
of samples in mono-culture versus co-culture was compared using the independent sample T-test. 
*p≤0.05. (B-C) The effect of 1.5 µM and 3.0 µM momelotinib or ruxolitinib on the viability of PDX 
cells with JAK2 translocations in mono-culture, or in co-culture with primary MSCs. Mean±SEM of three 
JAK2 translocated samples is shown. Cell viability of samples was compared using independent sample 
T-test. *p≤0.05.
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Despite the need for human TSLP, we and others observed engraftment of primary JAK2 
mutated cells in NSG mice, giving rise to leukemia within months after intra-femoral 
injection.18, 19, 21 This implies that the proliferation of JAK2 mutated leukemic cells in the 
mouse bone marrow does not (solely) depend on CRLF2 signaling, but may be supported 
by activation of alternative pathways.34, 35 This argues against targeted monotherapy, as 
cells might escape via an alternative pathway, such as the RAS pathway.35, 36 This is further 
strengthened by a study in Down syndrome ALL, in which a switch was observed from a 
JAK2 mutation at initial diagnosis to a RAS-mutation at relapse.37 In the current study, we 
also observed co-occurrence of JAK2 and KRAS lesions in non-Down syndrome BCP-ALL 
cells. More importantly, these JAK2 and KRAS mutations showed different outgrowth 
patterns in NSG xenograft models. Co-occurrence of these mutations suggests that a 
combination of JAK and RAS pathway inhibitors may be more effective for JAK2-aberrant 
Figure 6. Outgrowth pattern of JAK2 mutated samples in xenografts
(A) VAF of JAK2R683G and KRASG12D in primary leukemic cells and three PDX samples of the same patient 
was determined using targeted amplicon sequencing. (B) PDX cells were pre-incubated for 1 hour with 
25 ng/ml TSLP, after which they were exposed for four days to indicated concentrations of momelotinib 
or ruxolitinib in the presence of TSLP. Cell viability was measured using an MTT assay. Cell survival was 
calculated relative to vehicle treated controls. Samples were tested in duplicate. Mean±SD of each 
sample is shown. (C) Protein expression levels of PDX samples, exposed to 1.5 µM momelotinib or 0.75 
µM ruxolitinib for four hours.
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cases. Moreover our results indicate that JAK2 mutations by itself might not be drivers 
of leukemic outgrowth, which is also corroborated by the outgrowth of JAK2 wildtype 
leukemic cells in mice injected with JAK2R683T cells. Taken together, these data imply that 
1) the expansion properties of JAK2 mutated leukemic cells vary, 2) other subclones 
(e.g. KRASG12D) can grow out at the expense of the major JAK2 mutated clone, 3) JAK2 
mutations can get lost while leukemia progresses. Therefore, JAK2 mutations are most 
likely secondary lesions, in contrast to JAK2 translocations, which are primary lesions. The 
selection of alternative pathways indicates a potential risk for use of JAK inhibitors in JAK2 
mutated cases without detailed monitoring of the mutational status of leukemic cells in time.
Interestingly, we observed a difference in the cytotoxicity of momelotinib and ruxolitinib. 
Both agents fully inhibited JAK/STAT signaling by downregulation of phosphorylation 
levels of STAT1 and STAT5. However, only momelotinib affected JAK2 wildtype and 
non-TSLP stimulated JAK2 mutated cells, regardless of activation of STAT5. Therefore, 
it is likely that momelotinib also affects alternative targets.38, 39 In addition, our data 
revealed that exposure to JAK inhibitors, especially ruxolitinib, resulted into accumulation 
of phosphorylated JAK2Y1007, which consequently induced a profound re-activation of 
downstream STAT signaling. Accumulation of phosphorylated JAK2Y1007 is in concordance 
with other reports.20, 40-42 The rebound effect observed in the present study identifies an 
important limitation of these agents. As type I inhibitors bind JAK2 in its active conformation, 
reactivation of JAK2 may be overcome by type II inhibitors, which bind JAK2 in its inactive 
conformation.17, 43 Preclinical in vitro and in vivo data indicate high efficacy of the type II 
inhibitor CHZ868. Clinical data of this inhibitor and other novel inhibitors are warranted.
Besides studying the mechanism of action, we showed influences of the bone marrow 
microenvironment on the efficacy of JAK inhibitors. Microenvironment-induced resistance 
of leukemic cells has been reported for conventional drugs, e.g. prednisolone and 
asparaginase, for imatinib in BCR‑ABL1-positive cells, and for JAK inhibitors in the present 
study.44-46 These data imply that the local tumor environment can stimulate a survival 
program, which may provide leukemic cells a way to escape from JAK inhibitors.
Taken together, JAK2 lesions are infrequently found in children with newly diagnosed BCP-
ALL and are mainly restricted to BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases 
(negative for sentinel cytogenetic lesions). Although mutations and translocations represent 
biologically distinct entities, both may be targetable by JAK-inhibitors. Indeed, we showed 
efficacy of momelotinib and ruxolitinib in both cell types. As both momelotinib and 
ruxolitinib have a short half-life (less than half a day), the observed rebound effect may be 
therapeutically of risk.47, 48 Although it should be confirmed by functional in vivo studies, our 
data suggest that the effect of JAK inhibition may be compromised by microenvironment-
induced resistance and induction of alternative survival pathways. In conclusion, JAK 
inhibitors may be considered to be added to, but not substitute, chemotherapy for patients 
with JAK2 aberrations, especially for those at high risk of relapse due to high MRD levels 
upon induction therapy. Therapeutic monitoring for activation of alternative pathways (e.g. 
RAS) is highly recommended.
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METHODS
Primary patient-derived material
Bone marrow and/or peripheral blood samples were obtained from children (1-18 
years) with newly diagnosed ALL. Written informed consent was obtained from parents 
or guardians to use excess diagnostic material for research purposes, as approved by the 
institutional review board. These studies were conducted in accordance with the Declaration 
of Helsinki. Mononuclear cells were isolated and processed as described previously.49 
Samples were enriched towards > 90% leukemic cells by depletion of non-leukemic 
cells using immunomagnetic beads. The major cytogenetic subtypes were determined 
using fluorescent in situ hybridization, (RT-)PCR, and the 110-probeset gene expression 
classifier.30 Patients were treated according to the DCOG ALL8, ALL9 or ALL10 protocol, 
or the COALL-06-97 and COALL-07-03 study protocols.50-54 Patient characteristics were 
provided by the central study centers of DCOG (The Hague, the Netherlands) and COALL 
(Hamburg, Germany).
Mesenchymal stromal cells (MSCs) were isolated from the bone marrow aspirate of a 
BCR‑ABL1-like patient as described previously.55 Purity of MSCs was assessed by 
negativity for the hematopoietic markers CD34, CD45, and CD19, and positivity for the 
mesenchymal markers CD13, CD29, CD44, CD54, CD73, CD90, CD105, CD146 and 
CD166, as detected by flow cytometry (MACS Quant). Expression was measured using 
the human mesenchymal stem cell marker antibody panel (R&D Systems, Minneapolis, 
Minnesota, USA), and CD13-APC, CD29-APC, CD34-PE, CD54-PE, CD73-PE, IgG1-PE, 
and IgG1-APC (BD Biosciences, San Jose, California, USA).
Cell lines
The human erythroleukemia cell line HEL was obtained from the German Collection 
of Microorganisms and Cell lines (DSMZ, Braunschweig, Germany) and cultured in 
RPMI-1640 medium, supplemented with 10% fetal calf serum (Bodinco BV, Alkmaar, 
Netherlands), 100 units/ml penicillin, 100 µg/ml streptomycin and 0.125 µg/mL 
fungizone (Life Technologies, Bleiswijk, Netherlands). The identity of the cell line was 
routinely verified by DNA fingerprinting. Additionally, presence of Mycoplasma was 
excluded every 25 passages by PCR.
Patient-derived-xenograft cells
Primary leukemic cells were transplanted by intra-femoral injection in 7-12 weeks old female 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles River, Wilmington, Massachusetts, 
USA; three NSG mice per patient), as approved by the animal ethics committee (EMC 
2863). Mice were sacrificed upon overt leukemia or 6 months after injection. Leukemic 
cells were isolated from bone marrow and spleen. The percentage of human leukemic 
cells was analyzed by flow cytometry (APC anti-human CD19, PE anti-human CD45 and 
FITC anti-mouse CD45; Biolegend, London, UK) and May-Grünwald-Giemsa staining. 
Patient-derived-xenograft cells (PDX) were enriched for > 90% human leukemic cells using 
anti-human-CD19 immunomagnetic beads (MACS Miltenyi, Leiden, Netherlands). 
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JAK2 mutations
JAK2 mutations status was analyzed in 461 BCP-ALL cases, representing the major 
cytogenetic subtypes (6% BCR‑ABL1, 17% BCR‑ABL1-like, 15% non-BCR‑ABL1-like 
B-other, 27% ETV6‑RUNX1, 27% high hyperdiploid, 3% MLL‑AF4, 6% TCF3‑PBX1). 
Genomic DNA was isolated using Trizol reagent (Life Technologies), or in some cases using 
the DNeasy blood and tissue kit (Qiagen) according to manufacturer’s instructions, and 
quantified using the Qubit dsDNA Broad Range Assay Kit (Life Technologies). 100-250ng 
genomic DNA was used to prepare sequencing libraries according to manufacturer’s 
instructions. Successful library preparation, correct amplicon length and concentration 
were assessed using the Labchip GX genomic analyzer (Caliper Life Sciences Benelux 
N.V.) with the HT DNA 12K Reagent Kit, Version 2. Samples were pooled equi-molarly 
and sequenced on an Illumina MiSeq in paired-end reads of 250bp each. The custom 
amplicons covered the exons 16, 20, 21 and 23 and represent the mutational hotspot 
region of JAK2.
Sequence reads were exported in fastq format and, aligned to the standard 1000 
genomes human reference sequences (version b37, from the GATK resource bundle 
provided by the Broad institute, USA), using BWA version 0.7.10 and the GATK indel 
realigner version 3.3-0. Freebayes version 0.9.18-24, Varscan version 2.3.7, Bcftools 
version 1.0, and GATK version 3.3-0 were used to call single nucleotide variants. The 
resulting variant call format files were annotated using snpEff and snpSift version 4.1a 
and the dbNSFP version 2.7 database. Variants were combined and filtered based on 
several criteria using an in-house developed pipeline: variants were excluded if they were 
not located in targeted regions, were reported by only one caller, had coverage of < 100 
reads, or had < 10 reads supporting the variant allele. Furthermore, variants had to occur 
at least once with a VAF above 2% in any sample and to be distributed equally between 
runs according to a chi-square test. Additionally only variants were taken into account 
if they were reported in the COSMIC V73 GRCh37 database, lead to an amino acid 
change, were unlikely to be a germline variant and not a known SNP. SNPs were defined 
as having a mean population frequency of ≥ 5% across the 1000Gp1 complete human 
population, 1000Gp1 population of European decent, and the ESP-6500 population of 
European decent allele frequency databases. Variants found in ≥ 10 samples with a mean 
and median VAF > 40% were labelled as possible germline. Sufficient coverage was 
crucial to detect subclonal mutations, which could be reliably detected ≥ 5% VAF in on 
average 91% of the cases. Detection of variants with a frequency of 1% was limited to a 
smaller group (26%), and is therefore a conservative estimate in the present study.
Genomic DNA of PDX cells was used to identify JAK2 mutations in exon 16. Samples 
were analyzed by Baseclear B.V. using Sanger sequencing (forward primer 
5’-ATGCCTCCAAATTATTATACTATCA-3’, reverse primer 5’-ATCACCTCACAGTCCATG 
GTTAT-3’).
JAK2 translocations 
Presence of ten recurrently reported JAK2 translocations was examined by RT-PCR in 
153 BCP-ALL cases, negative for sentinel BCP-ALL associated lesions (n=77 BCR‑ABL1-
like, n=76 non-BCR‑ABL1-like B-other). Total RNA was extracted from leukemic cells 
using Trizol reagents (Life Technologies). cDNA was synthesized using random hexamers 
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and oligodT primers, and M-MLV reverse transcriptase (Promega, Leiden, Netherlands). 
RT-PCR was performed in a final volume of 25 µl, containing 0.3 µM forward primer, 
0.3 µM reverse primer, 200 µM dNTPs, 1x PCR buffer II, 4 mM MgCl2, 0.125 µl 
AmpliTaq DNA polymerase (Promega) and 2.5 µl cDNA. Primer sequences are shown 
in Supplementary Table 1. PCR products were Sanger sequenced by Baseclear B.V. 
(Leiden, Netherlands). 
CRLF2 status
CRLF2 expression levels were determined by Affymetrix gene expression microarrays 
(U133 Plus 2.0; Santa Clara, California, USA), of a previously published cohort of pediatric 
BCP-ALL patients at initial diagnosis.56 High CRLF2 expression levels are indicative P2RY8 
CRLF2 and IGH-CRLF2 translocations in different studies, though not all cases with high 
CRLF2 mRNA expression levels harbor CRLF2 rearrangements.10, 56-58 Of 406 cases, both 
CRLF2 gene expression data and JAK2 mutation status was available. Signal intensity of 
probeset 208303_s_at above the 90th percentile levels was classified as CRLF2 high, as 
described previously.56
In addition, CRLF2 expression in primary leukemic and PDX samples was 
determined using RT-qPCR and SYBR green. CRLF2 expression (forward primer 
5’-ACGGGGATCTCCTCTATG-3’, reverse primer:  5’-GAGGCGTTGG TGTCTCT-3’) was 
calculated relative to RSP20 expression (forward primer 5’-AAGGGCTGAGGATTTTTG-3’, 
reverse primer  5’-CGTTGCGGCTTGTTAG-3’), using the comparative cycle time (Ct) 
method; 2-ΔCt x 100%, whereby ΔCt = CtCRLF2 – CtRPS20. RT-qPCR expression values were 
correlated to Affymetrix microarray data of probeset 208303_s_at. 
JAK2 expression levels
JAK2 expression levels were analyzed using Affymetrix gene expression microarrays, in a 
previously published pediatric BCP-ALL cohort.56 Signal intensity of probeset 205841_at 
was used to quantify JAK2 gene expression.
Ex vivo drug cytotoxicity assays
Cell-intrinsic resistance towards momelotinib and ruxolitinib (Selleck Chemicals, Kirby 
Drive, Houston, USA) was evaluated as described previously.49 Briefly, leukemic cells 
were exposed to a concentration range (24µM to 750nM) of these compounds for 
four days and cytotoxicity was quantified using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). For TSLP stimulation, cells were pre-incubated for 1 
hour with 25 ng/ml TSLP (R&D systems, Oxon, UK).  In addition to single cell cultures, 
leukemic cells (1×106 cells) were co-cultured with primary MSCs (5×104 cells) for four 
days in a 24 well plate in the presence of a dilution series of momelotinib and ruxolitinib. 
Cell survival was quantified using flow cytometry (MACSQuant, FlowJo 10.0.8r1), and 
cells were stained with Brilliant Violet 421 anti-human CD19 antibody (Biolegend), FITC 
Annexin V (Biolegend), and Propidium Iodide (PI; Invitrogen, Bleiswijk, Netherlands), as 
described previously.44
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Western blotting
Leukemic cells were lysed in lysis buffer supplemented with freshly added protease and 
phosphatase inhibitors. 25µg (BCA method; Thermo Scientific) lysate was loaded on 
10% mini protean precast gels (BioRad, Veenendaal, Netherlands), and transferred to a 
nitrocellulose membrane (Biorad). Primary antibody incubation was performed according 
to manufacturer’s protocol. Anti-JAK2 (#3230), anti-phospho-JAK2Y1007 (#4406), anti-
phospho-STAT5Tyr694 (#9351), anti-phospho-STAT1Tyr701 (#9167), anti-Stat1 (#9175), anti-
phospho-MEK1/2Ser217/221 (#9154), anti-MEK1/2 (#4694), anti-phospho-Erk1/2T202/
Y204 (#4370), anti-Erk1/2 (#91078), and anti-αTubulin (#2144) were obtained from 
Cell Signaling Technology (Danvers, Massachusetts, USA). Anti-β-actin (ab6276) was 
obtained from Abcam (Cambridge, UK), and anti-STAT5 (sc-835) from Santa Cruz 
(Heidelberg, Germany). Blots were stained with secondary antibodies (IRDye 680RD- or 
800CW-labelled anti‐rabbit and IRDye 680RD- or 800CW‐labelled anti‐mouse; Li‐Cor 
Biosciences, Leusden, Netherlands) and scanned using the Odyssey infrared imaging 
system (Li-Cor Biosciences). To reprobe membranes, they were stripped in NewBlot 
Nitrocellulose stripping buffer (Li-Cor Biosciences) according to manufacturer’s protocol. 
BCR‑JAK2, PAX5‑JAK2 and TERF2‑JAK2 proteins were separated from wildtype JAK2 
based on size (~94, 57, 95 and 125 kDa, respectively). 
Statistics
Cumulative incidence of relapse (CIR) was estimated using a competing risk model. 
Relapse and non-response (counted at day 79) were considered as event, and death 
as competing event. The Gray’s test was applied to test for equality of CIRs.59 Outcome 
analyses were performed in R 3.0.1, using the packages cmprsk version 2.2-760, mstate 
version 0.2.761, and survival version 2.37-462.
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SUPPLEMENTAL DATA
Supplementary Figure 1. CRLF2 expression values
2log expression levels of Affymetrix probeset 205841_at in 405 pediatric BCP-ALL cases, which were 
tested for JAK2 aberrations. * represents patient A159. ** represents patient A521.
Gene fusion Forward Primer ID Forward sequence(5’to 3’) Reverse Primer ID
Reverse sequence
(5’to 3’)
ATF7IP-JAK2 ATF7IP exon 12 aacccatacaaccagcaccgcctct JAK2 exon 20 tgttgtcatgctgtagggatttcagga
BCR-JAK2 BCR exon 1 gtgccataagcggcaccggcact JAK2 exon18 aggcctgaaatctggttcata
EBF1-JAK2 EBF1exon 14 cacgagcatgaacggatacggctct JAK2 exon 20 tgttgtcatgctgtagggatttcagga
ETV6-JAK2 ETV6 exon 3 atggcaaagctctcctgctgctgac JAK2 exon 20 tgttgtcatgctgtagggatttcagga
PAX5-JAK2 PAX5 exon 3 acaatgacaccgtgcctagcgtcag JAK2 exon 19 tcaaaggcaccagaaaac
PPFIBP1-JAK2 PPFIBP1 exon 10 tgcaagatgaaaggagaaggggttga JAK2 exon 20 tgttgtcatgctgtagggatttcagga
SSBP2-JAK2 SSBP2 exon 7 ggcacttggaggtgtcccaggaagt JAK2 exon 20 tgttgtcatgctgtagggatttcagga
STRN3-JAK2 STRN3 exon 7 tgaaggagctggagaagcacggagt JAK2 exon 20 tgttgtcatgctgtagggatttcagga
TPR-JAK2 TPR exon 38 tggaaatgcctcttccaaagaagttga JAK2 exon 20 tgttgtcatgctgtagggatttcagga
TERF2-JAK2 TERF2 exon 10 tggggaaggaaactgg JAK2 exon 20 tgttgtcatgctgtagggatttcagga
Supplementary Table 1: RT-PCR primers used for the dectetion of JAK2 translocations
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Supplementary Figure 2. Sequencing results of JAK2 translocations 
(A-C) Presence of fusion genes was examined on cDNA level using RT-PCR, followed by Sanger 
sequencing to detect BCR‑JAK2, PAX5‑JAK2 and TERF2‑JAK2 translocations.
AAG GA T CGC T GG CGG ACC A T G AAA AGA C T T GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA TTERF2e10-JAK2e19
Sequence
AAG GA T CGC T GG CGG ACC A T G AAA AGA C T T GGC A TG AAC TGA
A T A CGA GA T C T T AAC AGT T T G T T T AC T CCA GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA T
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GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GA T T A T GAA C T A T T A ACA GAA AA T GAC A T G T T A CCA AA TPAX5e5-JAK2e19
Sequence
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GGT A T T CAG GAG T C T CCG GT G CCG AAC GGC CAC T CG C T T
A T A CGA GA T C T T AAC AGT T TG T T T AC T CCA GA T T A T GAA C T A T T A ACA GAA AA T GAC A T G T T A CCA AA T
PAX5
JAK2
AAC GA T GGC GAG GGC GCC T T C CA T GGA GAC GCA GT T C T T CAG GAG AGA A T A CCA T GG GT A CCA CC T GAA T GC A T TBCRe1-JAK2e17
Sequence
AAC GA T GGC GAG GGC GCC T T C CA T GGA GAC GCA GA T GGC T CG T T C GGA ACA CCA CC T GGA T AC GGC T GC GC T GCA
CC T GGC A T T AGT A T T ACA GT T T TG CCA AAG GAC A T T C T T CAG GAG AGA A T A CCA T GG GT A CCA CC T GAA T GC A T T
BCR
JAK2
A
B
C
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Supplementary Figure 3. JAK2 
expression values
2log expression levels of Affymetrix 
probeset 205841_at in 77 BCR‑
ABL1-like and 76 B-other cases, 
which were tested for JAK2 
translocations. JAK2 mutation status 
is also indicated. Information was 
added to the three cases with high 
JAK2 expression levels, without 
JAK2 translocations.
Supplementary Figure 4. JAK2 aberrations in PDX cells
(A-C) Presence of JAK2 translocation in PDX cells was validated on cDNA level using Sanger 
sequencing of cDNA. 
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AAG GA T CGC TGG CGG ACC A TG AAA AGA C T T GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA TTERF2e10-JAK2e19
A219_PDX1
AAG GA T CGC TGG CGG ACC A TG AAA AGA C T T GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA TTERF2e10-JAK2e19
A219_PDX2
AAG GA T CGC TGG CGG ACC A TG AAA AGA C T T GGC A TG AAC TGA
A T A CGA GA T C T T AAC AGT T TG T T T AC T CCA GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA T
TERF2
JAK2
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA T
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GGT A T T CAG GAG T C T CCG G TG CCG AAC GGC CAC T CG C T T
A T A CGA GA T C T T AAC AGT T T G T T T AC T CCA GA T T A T GAA C T A T T A ACA GAA AA T GAC A TG T T A CCA AA T
PAX5e5-JAK2e19
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AAC GA T GGC GAG GGC GCC T T C CA T GGA GAC GCA GT T C T T CAG GAG AGA A T A CCA TGG G T A CCA CC T GAA TGC A T TBCRe1-JAK2e17
A216_PDX1
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Supplementary Figure 4 continued. JAK2 aberrations in PDX cells (continued)
(D-E) Genomic DNA of PDX cells was used to identify the absence (D) or presence (E) of JAK2 
mutations in exon 16. 
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Supplementary Figure 5. The efficacy of JAK inhibitors on JAK2 translocated and mutated 
cells per type of aberration
Leukemic (PDX or primary patient) cells were incubated for four days to indicated concentrations 
of momelotinib or ruxolitinib, after which viability was measured using an MTT assay. Sensitivity of 
exposed cells was calculated relative to vehicle treated controls. Individual samples were tested in 
duplicate. Data derived from samples with identical JAK2 lesions were grouped for analyses. (A-B) 
Efficacy of momelotinib and ruxolitinib on PDX cells with JAK2 translocations: BCR‑JAK2 (n=2), TERF2‑
JAK2 (n=2) and PAX5‑JAK2 (n=1). Mean±SD of individual samples (in duplicate) are shown. (C-D) 
Efficacy of momelotinib and ruxolitinib on JAK2 mutated cells: JAK2R683G (n=4) and JAK2R683S (n=2) 
Mean±SEM of individual samples is depicted. (E-F) Efficacy of momelotinib and ruxolitinib on JAK2 
wildtype PDX cells and normal bone marrow cells. Mean±SD of individual samples (in duplicate) are 
shown. (H-I) Efficacy of momelotinib and ruxolitinib on Down syndrome and non-Down syndrome 
JAK2R683G cells. Mean±SD of individual samples (in duplicate) are shown.
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Supplementary Figure 6. Quantified expression levels western blots Figure 2
(A-C) TERF2‑JAK2, PAX5‑JAK2 and JAK2R683G PDX cells were exposed for four hours to vehicle control 
medium, 1.5 µM momelotinib or 0.75 µM ruxolitinib, after which (phosphorylated) TERF2-JAK2, PAX5-
JAK2, JAK2, STAT1 and STAT5 levels were analyzed using western blot (25 µg lysate). Expression 
levels of phospho-proteins were quantified relative to total protein or loading control.
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Supplementary Figure 7. The effect of TSLP stimulation on the efficacy of JAK inhibitors per 
type of aberration
Leukemic (PDX or primary patient) cells were pre-incubated for 1 hour without or with 25 ng/ml TSLP, 
after which they were exposed for four days to indicated concentrations of momelotinib or ruxolitinib. 
Viability was measured using an MTT assay. Sensitivity was calculated relative to vehicle treated controls. 
Individual samples were tested in duplicate. (A-B) Efficacy of momelotinib and ruxolitinib on JAK2 
mutated samples with or without TSLP pre-incubation: Mean±SEM four JAK2R683G and two JAK2R683S 
samples is shown. (C-D) Efficacy of momelotinib and ruxolitinib on cells with JAK2 translocations (n=2). 
Mean±SD of sample duplicates from a TERF2‑JAK2 and PAX5‑JAK2 sample are shown. (E-F) Efficacy 
of momelotinib and ruxolitinib on JAK2 wildtype PDX cells (n=3). Mean±SD of sample duplicates are 
shown.
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Supplementary Figure 8. Down syndrome and the efficacy of JAK inhibitors on JAK2 mutated 
cells
Cells were exposed for four days to indicated concentrations of momelotinib or ruxolitinib. Viability was 
measured using an MTT assay. Sensitivity of exposed cells was calculated relative to vehicle treated 
controls. Individual samples were tested in duplicate. Mean±SD of sample duplicates is shown.
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Supplementary Figure 9. Quantified expression levels western blots Figure 3
(A-C) Western blot of JAK2R683S, TERF2‑JAK2 and JAK2wt PDX cells with or without TSLP stimulation 
(25 ng/ml for 1 hour). Expression levels of phospho-proteins were quantified relative to total protein 
or loading control (β-actin). (D) JAK2R683G cells were pre-incubated for 1 hour with or without 25 ng/
ml TSLP, after which cells were exposed for four hours to vehicle control medium, 1.5 µM momelotinib 
or 0.75 µM ruxolitinib. Levels of (phosphorylated) JAK2, STAT1, STAT5, MEK1/2 and ERK1/2 were 
analyzed using western blot. Expression levels of phospho-proteins were quantified relative to total 
protein or loading control (α-Tubulin). 
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Supplementary Figure 10. Quantified expression levels western blots Figure 4
TERF2-JAK2 PDX cells were incubated for four hours with or without 1.5 µM momelotinib or 0.75 µM 
ruxolitinib, after which cells were washed to remove the JAK inhibitors. Half of the cells were exposed 
for another 1.5 hours to 1.5 µM momelotinib or 0.75 µM ruxolitinib, whereas the other cells were 
incubated in vehicle control (Ctr) medium. Protein expression levels were examined by western blot (25 
µg lysate). Expression levels of phospho-proteins were quantified relative to total protein.  
Supplementary Figure 11. Accumulation of pJAK2 Y1007 results in a rebound effect of JAK2
(A) HEL cells were incubated with or without 1.5 µM momelotinib or 0.75 µM ruxolitinib for 4 hours, 24 
hours, 48 hours, 72 hours and 96 hours, after which cells were lysed and protein expression levels were 
examined using western blot (25 µg lysate). (B) After 96 hours of exposure to JAK inhibitors (indicated 
by * in panel A), cells were washed in normal culture medium, to remove momelotinib and ruxolitinib. 
Subsequently, half of the cells were incubated with 1.5 µM momelotinib or 0.75 µM ruxolitinib for 
another 4 hours, or 24 hours, whereas the remaining cells were incubated in vehicle control (Ctr) 
medium. Protein expression levels were examined using western blot (25 µg lysate).
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Supplementary Figure 12. Quantified expression levels western blots Supplementary Figure 
8 (continued on next page)
(A-N) HEL cells were incubated with or without 1.5 µM momelotinib or 0.75 µM ruxolitinib for 4 
hours, 24 hours, 48 hours, 72 hours and 96 hours. After 96 hours of exposure to JAK inhibitors, cells 
were washed in normal culture medium, to remove momelotinib and ruxolitinib. Subsequently, half of 
the cells were incubated with 1.5 µM momelotinib or 0.75 µM ruxolitinib for another 4 hours, or 24 
hours, whereas the remaining cells were incubated in vehicle control (Ctr) medium. Protein expression 
levels were examined using western blot (25 µg lysate). Expression levels of phospho-proteins were 
quantified relative to total protein.
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Supplementary Figure 12. Quantified expression levels western blots Supplementary Figure 
8 (continued)
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Supplementary Figure 13. The efficacy of JAK inhibitors in PDX/MSC co-cultures
The response of PDX cells (CD19+) co-cultured with MSCs (CD19-) to increasing concentrations of 
momelotinib and ruxolitinib was assessed after four days of culture using flow cytometry. Viability was 
calculated relative to untreated controls. Mean±SEM is shown. (A) Gating strategy. (B-G) Percentage 
of viable PDX cells being JAK2 translocated (BCR‑JAK2 n=2; TERF2‑JAK2 n=2; PAX5‑JAK2 n=1), 
JAK2 mutated (JAK2R683G n=3), or JAK2 wildtype cells (JAK2 wildtype n=2), co-cultured with patient 
MSCs, after four days exposure to momelotinib and ruxolitinib. (H-I) The effect of 1.5 µM and 3.0 
µM momelotinib or ruxolitinib on the viability of JAK2 translocated PDX cells in mono-culture, or in co-
culture with patient MSCs. TERF2‑JAK2 n=2; PAX5‑JAK2 n=1, JAK2 wildtype n=2. 
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Supplementary Figure 14. JAK2 mutations in primary leukemic and PDX cells
(A-C) Primary patient cells (A251, A282, and A178) were injected intra-femoral into three NSG 
mice per patient. After engraftment, leukemic cells were harvested from these mice (PDX1, PDX2, 
and PDX3). Genomic DNA was used to identify JAK2 mutations in exon 16 (forward primer 
5’-ATGCCTCCAAATTATTATACTATCA-3’, reverse primer 5’-ATCACCTCACAGTCCA TGGTTAT-3’) in 
these PDX cells and primary leukemic cells, using Sanger sequencing. (D) CRLF2 expression in primary 
leukemic samples was determined using qRT-PCR and SYBR green. qRT-PCR expression values were 
correlated to Affymetrix microarray data of probeset 208303_s_at. Spearman correlation coefficient is 
reported. (E) CRLF2 expression levels in the primary leukemic and PDX samples was determined using 
qRT-PCR. CRLF2 expression was calculated relative to RSP20 expression levels. (F) JAK2 wildtype 
cells were incubated for 1h with 25 ng/ml TSLP. Effect of TSLP on protein expression levels was 
examined using western blotting. (G-H) JAK2 wildtype cells were exposed for four days to indicated 
concentrations of momelotinib or ruxolitinib. Viability was measured using an MTT assay, after which 
cell survival was calculated relative to vehicle treated controls. Mean±SD of duplicates are shown. 
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ABSTRACT
Approximately 25% of the pediatric B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL) cases are genetically unclassified. More thorough elucidation of the 
pathobiology of these genetically unclassified (B-other) cases may identify novel treatment 
options. 
We analyzed gene expression profiles of 572 pediatric BCP-ALL cases, representing all 
major ALL subtypes. High expression of STAP1, an adaptor protein downstream of the 
B-cell receptor (BCR), was identified in BCR‑ABL1-like and non-BCR‑ABL1-like B-other 
cases. Limma analysis revealed an association between high expression of STAP1 and 
BCR signaling genes. However, STAP1 expression and pre-BCR signaling were not 
causally related: cytoplasmic Igµ levels were not abnormal in cases with high levels of 
STAP1 and stimulation of pre-BCR signaling did not induce STAP1 expression. To elucidate 
the role of STAP1 in BCP-ALL survival, expression was silenced in two human BCP-ALL 
cell lines. Knockdown of STAP1 did not reduce the proliferation rate or viability of these 
cells, suggesting that STAP1 is not a likely candidate for precision medicines. Moreover, 
high expression of STAP1 was not predictive for an unfavorable prognosis of BCR‑ABL1-
like and non-BCR‑ABL1-like B-other cases. Remarkably, DUX4-rearrangements and 
intragenic ERG deletions, were enriched in cases harboring high expression of STAP1.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children. 
Survival rates have improved during the last decades and nowadays is approaching 
90%. This dramatic increase in survival was achieved mostly because of risk-adjusted 
treatment, therapy intensification, and stem cell transplantations.1 B-cell precursor ALL 
(BCP-ALL) can be subdivided in different genetic subtypes, which have different long-
term clinical outcome. However, approximately 25% of the BCP-ALL cases lack sentinel 
genetic aberrations (KMT2A-rearrangements, BCR‑ABL1, ETV6‑RUNX1, TCF‑PBX1, high 
hyperdiploidy) and are classified as ‘B-other’. We and others showed that part of this 
B-other group has a gene expression profile similar to that of BCR‑ABL1-positive ALL 
cases, and is associated with an unfavorable clinical outcome.2,3 Although these patients 
are known to lack the BCR‑ABL1 fusion gene, the underlying pathobiology of this subtype 
remains poorly understood. Cases are enriched for copy number alterations (CNAs) in 
genes involved in B-cell development, intrachromosomal amplification of chromosome 21, 
dicentric chromosome (9;20), and a subgroup of cases harbors kinase activating lesions.2-7 
Likewise, the remaining non-BCR‑ABL1‑like B-other cases are a very heterogeneous group. 
Only very recently, chromosomal translocations involving DUX4, ZNF384, and MEF2D 
were identified in these non-BCR‑ABL1-like B-other cases.8-10 Although kinase activating 
lesions offer a potentive attractive target for precision medicine, for the remaining group 
of BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases, no druggable targets have yet 
been identified.
BCP-ALL cells are immature B-cells in which differentiation is arrested at early immature 
stages. The precursor B-cell receptor (pre-BCR), an immature immunoglubulin (Igµ) heavy 
chain with ‘surrogate’ light-chain components, is involved in the expansion and maturation 
of pre-B cells. For a short period of time,  in-frame rearranged VHDJH gene segments are 
expressed to pass the pre-BCR checkpoint. In absence of this expression, pre-B cells are 
eliminated by programmed cell death.11,12 Malignant pre-B cells can evade this pre-B cell 
checkpoint via activation of alternative pathways.12 In mature B-cells PI3K-AKT signaling 
can rescue BCR deficient cells.13 Signaling of pre-BCR and mature BCR are largely similar.14 
Targeting BCR signaling is an attractive treatment strategy in mature B-cell malignancies 
and is also being explored in BCP-ALL.15-20
Advanced understanding of the pathobiology of genetically unclassified BCP-ALL cases 
may identify novel treatment options. To identify dysregulated genes in these cases, 
we analyzed gene expression profiles in leukemia cells of cohort of BCP-ALL patients 
at initial diagnosis.21 High expression levels of the adapter protein signal transducing 
adaptor family member 1 (STAP1) were identified in a subgroup of BCR‑ABL1-like and 
non-BCR‑ABL1-like B-other patients. STAP1 is a relatively unknown protein, consisting 
out of Peckstrin homology (PH) domains and unique Src homology 2 (SH2) domains, 
suggesting that STAP1 recruits signaling proteins to receptor tyrosine kinases.22,23 STAP1 
is reported to be a docking protein downstream of Tec protein tyrosine kinase (TEC), 
which is involved in BCR signaling.24,25 In addition, reports show enriched expression in 
hematopoietic stem cells and a potential role of STAP1 in microglia activation has been 
suggested.26,27 The current study aimed to establish the therapeutic potential of inhibiting 
STAP1 in the subset of BCP-ALL cases that express high levels of STAP1.
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METHODS
A detailed description of all methods can be found in the supplement.
Processing of primary patient material
Bone marrow and/or peripheral blood samples were obtained from children (1-18 
years) with newly diagnosed ALL. Written informed consent was obtained from parents or 
guardians to use excess of diagnostic material for research purposes, as approved by the 
Medical Ethics Committee of the Erasmus Medical Center, The Netherlands. Studies were 
conducted in accordance with the Declaration of Helsinki. Mononuclear cells were isolated 
using Lymphoprep gradient separation and the leukemic blast percentage was determined 
microscopically by May-Grünwald Giemsa stained cytospin preparations, as described 
previously.28 Samples were enriched to >90% leukemic cells by depleting normal cells, 
using anti-CD marker coated magnetic beads, i.e. anti CD3, anti-CD14, anti-CD15, anti-
CD33, and/or H1 beads (IQ Products, Groningen, The Netherlands) combined with pan 
mouse IgG dynabeads (Invitrogen, Bleiswijk, Netherlands). Primary leukemic cells were 
maintained in RPMI-1640 Dutch modification  (Life Technologies, Breda, Netherlands) 
supplemented with 20% fetal calf serum (Integro, Zaandam, Netherlands), with 0.1% 
insulin-transferrin-sodium selenite (Sigma Aldrich, Zwijndrecht, Netherlands), 0.4 mM 
glutamine (Invitrogen), 0.25 µg/ml gentamycine (Thermo Scientific, Breda, Netherlands), 
100 IU/ml penicillin (Thermo Scientific), 100 µg/ml streptomycin (Thermo Scientific), 
0.125 µg/ml fungizone (Thermo Scientific).
Patients were treated according to the Dutch Childhood Oncology Group ALL8, ALL9, 
ALL10 protocol, or the COALL-06-97 and COALL-07-03 study protocols.29-33 The major 
subtypes (high hyperdiploid (51-65 chromosomes), ETV6‑RUNX1, TCF3‑PBX1, KMT2A‑
rearranged, BCR‑ABL1) were determined using fluorescent in situ hybridization and RT-PCR 
by reference laboratories. Cases negative for these lesions were classified as B-other. 
Among these B-other cases, BCR‑ABL1-like cases were identified using the 110-probeset 
gene expression classifier.2 In addition, immunophenotyping was performed, including 
cytoplasmic Igµ (CyIgµ) expression. Samples containing more than 30% leukemic cells 
expressing CyIgµ were labelled as CyIgµ-positive.
Cell lines
The human BCP-ALL cell lines Nalm6 and Kasumi-2 were obtained from the German 
Collection of Microorganisms and Cell lines (DSMZ, Braunschweig, Germany). Cells were 
cultured in RPMI-1640 medium, supplemented with 10% fetal calf serum (Bodinco BV, 
Alkmaar, Netherlands), 100 units/ml penicillin, 100 µg/ml streptomycin and 0.125 µg/
mL fungizone (Life Technologies). The identity of cell line was routinely verified by DNA 
fingerprinting. The B-other cell line Nalm6 expressed high levels of STAP1 and TCF3‑PBX1 
positive Kasumi-2 cells had low expression levels of STAP1. For stimulation experiments, 
cells were exposed to 1µg anti-IgM F(ab')2 (SouthernBiotech, Birmingham, AL, USA).
STAP1 expression status
Microarrays (Affymetrix U133 Plus 2 Santa Clara, California, USA) were analyzed of a 
previously published cohort of 572 BCP-ALL patients at initial diagnosis (GSE13351),21 in 
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which all major ALL subtypes were represented (BCR‑ABL1-positive n=24, BCR‑ABL1-like 
B-other n=92, non-BCR‑ABL1-like B-other n=113, ETV6‑RUNX1-positive n=172, high 
hyperdiploid n=141, KMT2A-rearranged n=11, TCF3‑RUNX1‑positive n=19). Gene 
expression profiles of BCR‑ABL1-like and non-BCR‑ABL1-like B-other samples were 
compared to remaining BCP-ALL cases, using Limma R Package (version 3.26.9) in R 
3.0.1. BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases with signal intensity values 
of both STAP1 probesets (220059_at and 1554343_a_at)  above the 80th percentile of 
BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases were classified as STAP1-high (see 
also Fig. 1A). Remaining BCR‑ABL1‑ like and non-BCR‑ABL1-like B-other cases were 
classified as STAP1-low.
Quantitative reverse transcription PCR (RT-qPCR)
mRNA expression levels of STAP1 and RPS20 were quantified using real-time PCR analysis 
on an ABI Prism 7700 sequence detection system (PE Applied Biosystems). RNA was 
extracted using the RNeasy mini kit (Qiagen, Hilden, Germany), after which cDNA was 
synthesized. STAP1 and RPS20 mRNA levels were quantified by incorporation of SYBR 
Green (Thermo Scientific) by quantitative real-time PCR, using STAP1-specific primers 
(5’-ccaggaaaggttaaagattact-3’ and 5’-ttccccactttctgtgtt-3’) and RPS20-specific primers 
(5’-aagggctgaggatttttg-3’ and 5’-cgttgcggcttgttag-3’). Relative STAP1 mRNA levels 
as percentage of RPS20 levels were calculated using the comparative cycle time (Ct) 
method; 2-ΔCt x 100%, whereby ΔCt = CtSTAP1 – CTRPS20.
Transfection, virus production and transduction
To knockdown STAP1 expression, four pLKO.1-puro Mission® vectors (Sigma-Aldrich) 
containing a short hairpin RNA (shRNA) targeting STAP1 (TRCN0000065083, 
TRCN0000065084, TRCN0000065085, TRCN0000065087; shRNA-1, shRNA-2, 
shRNA-3, shRNA-4, respectively) were used. The Mission ® pLKO.1-puro Non-Mammalian 
shRNA Control Plasmid DNA (SHC002) and Mission® pLKO.1-puro Luciferase shRNA 
Control Plasmid DNA (SHC007) were used as scrambled control vectors (NSC-1 and 
NSC-2, respectively).
Vectors were transfected in HEK293T cells, using XtremeGene, 3.7 µg psPAX2 (Addgene 
plasmid 12260; Addgene, Cambridge, MA, USA), 1.6 µg pMD2.G (Addgene plasmid 
12259) and 10.7 µg of one of the pLKO.1 puro Mission® vectors. The second and third 
day after transfection virus was harvested and concentrated using ultracentrifugation 
for 2 hours at 32.000 rpm and 4°C. Concentrated virus was aliquoted and stored at 
-80°C. Leukemic cells were spin-infected and puromycin selection was initiated 24 
hours after transduction. Transduction efficiency was determined using a titration range. 
After 48 hours of puromycin selection (1 µg/ml) cell viability was measured using flow 
cytometry (MACSQuant) and propidium iodide (PI; Invitrogen). Viability of transduced 
cells as percentage of viability of non-transduced cells was defined as the transduction 
efficacy. Proliferation was measured for 5 days using flow cytometry (MACSQuant) and 
PI staining. At day 5, viability was quantified using Annexin V (Biolegend, London, UK) 
and PI staining.
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Ex vivo drug resistance
Ex vivo cytotoxicity of prednisolone, vincristine, L-asparaginase, daunorubicin, 
6-mercaptopurine and 6-thiguanine in primary samples was evaluated using 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), as previously 
described.28 After four days of culture, viability was quantified by measuring the optical 
density values after 6 hours of incubation with MTT. LC50 values were compared using 
the Mann-Whitney U test. In vitro cytotoxicity of prednisolone, ibrutinib and rapamycin in 
cell lines was evaluated using 3-(4,5-dimethylthiazolyl-2)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium; MTS) and phenazine methosulfate (PMS). Cells were 
exposed to a dilution series of agents (prednisolone: 0.06 to 250 µg/mL; ibrutinib: 0.16 
to 40 µM; rapamycin: 4 nM to 40 µM) in a 96 wells plate for four days at 37°C and 5% 
CO2, after which viability was quantified. 
Multiplexed fluorescent bead-based immunoassay (Luminex) 
Cells were lysed in RIPA buffer (ThermoFisher Scientific) with freshly added protease and 
phosphatase inhibitors. Protein concentration was determined using the BCA method 
(Thermo Scientific). Expression of 17 proteins was determined in 10µg lysate, using a 
fluorescent bead-based immunoassay (multi-pathway magnetic bead 9-plex and the 
8-plex human Src family kinase kit; Merck Millipore, Amsterdam, Netherlands) according 
to the manufacturer’s protocol. GAPDH beads (Merck Millipore) were used as internal 
reference for each sample.
Multiplex Ligation-Dependent Probe Amplification (MLPA)
To identify genomic lesions in IKZF1, CDKN2A, CDKN2B, ETV6, PAX5, RB1, BTG1, EBF1, 
and PAR1 (CSF2RA/IL3RA/CRLF2), the SALSA P335 ALL-IKZF1 (a3) and the SALSA 
P202 Multiplex Ligation-dependent Probe Amplification (MLPA) assays (MRC-Holland, 
Amsterdam, Netherlands) were used as described previously.4,21,34 A peak ratio < 0.75 
was used to determine  deletions, 0.75 ≤ peak ratio ≤ 1.3 for normal copy number, and 
peak ratio > 1.3 for gain. Loss of either CDKN2A or CDKN2B was coded as CDKN2A/B 
deletion and intragenic amplifications of PAX5 were coded as aberration. 
Genome-wide DNA copy number arrays (array-CGH)
To identify ERG deletions, genome-wide DNA copy number arrays were performed 
as described previously.4 Briefly, Agilent SurePrint G3 Hmn 4x180K arrays (Agilent 
Technologies, Amstelveen, the Netherlands) were co-hybridized with 1 µg patient DNA 
labeled with ULS-Cy5 and 1 µg reference genomic DNA male pool (G147A, Promega, 
Leiden, the Netherlands) labeled with ULS-Cy3 (Agilent Genomic DNA ULS Labeling 
Kit). Using median log ratios, data were normalized using the CGHcall35 version 2.14.0, 
centralized using CGHnormaliter36 version 1.8.0, and segmented and called using 
CGHcall default settings (-1 for loss, 0 for diploid, 1 for gain and 2 for amplification) in 
R version 2.14.1.
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Clinical characteristics and statistics
To identify whether copy number alterations (CNAs), clinical characteristics or CyIgµ 
expression were depleted or enriched in cases harboring high expression levels of STAP1, 
the Fisher’s exact test in R (version 3.2.1) was applied. Cumulative incidence of relapse 
(CIR) was estimated using a competing risk model and significance was determined 
using the Gray’s test. Relapse and non-response (counted at day 79 of therapy) were 
considered as events and death as competing event. Event-free survival (EFS) probabilities 
were estimated using cox regression and compared using the Wald test. Relapse, non-
response, secondary malignancies and death were counted as events. Outcome analyses 
were performed in R (version 3.2.1), using the packages cmprsk version 2.2-7 37, mstate 
version 0.2.7 38, and survival version 2.37-4 39. Five-year EFS and CIR are reported.
SNP arrays
Genome-wide human SNP arrays 6.0 (Affymetrix) were performed according to the 
manufacturer’s protocol. Raw probe values were extracted from CEL files and processed 
with the R package aroma.affymetrix version 3.1.0. Samples were compared to reference 
values, which was the average of 53 diploid BCP-ALL and T-ALL samples. To correct for 
bias introduced by differences in GC content of DNA fragments, the R package ArrayTV 
version 1.12.0 was used. To compare the logR values of the copy numbers between 
samples a centralization step was performed, using the R package CGHnormaliter version 
1.28.0. Data were called using CGHcall version 2.36.0  default settings (-2 for double 
loss, -1 for loss, 0 for diploid, 1 for gain and 2 for amplification) in R version 3.3.3.
RNAseq
mRNA was extracted from total RNA and amplified using random hexamer primers. 
Further Library construction was done using a strand-specific protocol. Sequencing was 
performed on a HiSeq 2000 producing 151bp paired-end reads with a median library 
size of 50 million read pairs per sample. Fastq-files with paired-end data were aligned 
to the GRCh37 reference sequence using STAR 2.5.0b. Read counts were determined 
with HTSeq-count version 0.6.1p1. To determine DUX4 expression, the fastq-files were 
aligned to the DNA sequence of the gene ENSG00000259128.1 plus 200bp down- 
and upstream. DUX4-partner genes were identified using NCBI blast, in which unknown 
sequences after the breakpoint were aligned.40
RESULTS
Discriminative expression profile of STAP1 in BCR-ABL1-like and B-other cases
To identify differentially expressed genes in BCR‑ABL1-like and non-BCR‑ABL1-like 
B-other cases, microarrays were performed of a representative pediatric BCP-ALL cohort 
of 572 cases at initial diagnosis.21 Limma analyses revealed STAP1 to be the probeset 
with the highest fold-change in BCR‑ABL1-like and non-BCR‑ABL1-like B-other patients 
compared to remaining BCP-ALL cases (fold change = 2.88, adjusted p-value < 0.0001; 
Supplementary Table S1). Strikingly, this elevated expression was characteristic for a 
subset of patients reflecting about 20% of BCR‑ABL1-like and non-BCR‑ABL1-like B-other 
cases (Fig. 1A, henceforth: STAP1-high cases). The remaining BCR‑ABL1-like and non-
88
Chapter 4
BCR‑ABL1-like B-other cases (henceforth: STAP1-low) had STAP1 expression levels 
comparable to those observed in other ALL subtypes and mononuclear bone marrow cells 
of healthy controls (Supplementary Fig. S1). Microarray results were validated using RT-
qPCR (Fig. 1B, Supplementary Fig. S1). Subsequently, we analyzed which genes were 
associated with high expression levels of STAP1. Limma analyses revealed 8894 probesets 
to be differentially expressed between STAP1-high and STAP1-low cases (adjusted 
p-value < 0.05; Supplementary Table S2). Ingenuity pathway analysis was performed 
to identify pathways associated with these differentially expressed genes. EIF2 signaling, 
mTOR signaling, regulation of eIF4 and p70S6K signaling, B cell receptor signaling 
(BCR), and AMPK signaling included the top five differentially regulated canonical 
pathways (Supplementary Fig. S1). Identification of the BCR signaling pathway was a 
striking observation, as STAP1 is reported to be a docking protein downstream of TEC 
in this pathway.24,25 Since the signaling pathways activated by pre-BCR and mature BCR 
are highly overlapping,14 we hypothesized a similar function for STAP1 in the downstream 
signaling cascade of the pre-BCR. Taken together, the association between STAP1 and the 
BCR signaling cascade may suggest an activated pre-BCR signaling pathway in a subset 
of BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases. This hypothesis was further 
explored since it may offer a targeted treatment strategy for these cases.17-20
High levels of STAP1 and pre-BCR signaling are not causally connected 
We studied whether high levels of STAP1 associated with high expression of the pre-
BCR complex. To determine in-frame rearrangements of immunoglobulin heavy chain 
VHDJH  gene segments (indicative for a functional pre-BCR), cytoplasmic Igµ (CyIgµ) levels 
were measured in 142 BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases. 14 of the 
32 (44%) STAP1-high cases showed positivity (> 30% CyIgµ+ cells) compared with 31 
of the 110 (28%) STAP1-low cases (Fisher exact test. p=0.13). This result suggests that 
STAP1-high and STAP1-low cases do not differ in the number of pre-BCR positive cells. 
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Figure 1. Discriminative expression of STAP1 in BCR-ABL1-like and B-other cases.
(A) 2log expression levels of Affymetrix probeset 220059_at in 572 BCP-ALL cases. The dotted line 
represents the 80th percentile of BCR‑ABL1-like and B-other cases. Grey lines represent the median 
expression values of subtype groups. (B) Microarray expression levels were validated using RT-qPCR, 
as shown by a high spearman correlation coefficient. (C) Expression values of STAP1 in 6 STAP1-high 
and 17 STAP1-low cases detected by RT-qPCR. Independent samples T-test. The grey lines represent the 
median of the STAP1-high and the STAP1–low group. Mann-Whitney U test. ** p<0.01.
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Figure 2. Pre-BCR signaling and STAP1 expression
The BCP-ALL cell lines Nalm6 and Kasumi-2 were stimulated with 1 µg anti-IgM for 1, 24, 48, 72 or 96 
hours. Expression levels of STAP1 were examined using RT-qPCR. Linear values normalized to RPS20 
expression are shown. Mean±SEM of three independent experiment. Independent samples T test. 
* p<0.05.
In addition, we examined whether STAP1 expression itself may be induced by pre-BCR 
signaling. Therefore, the BCP-ALL cell lines Nalm6 and Kasumi-2 (high and low STAP1 
expression, respectively) were stimulated for 4 days with 1µg anti-IgM antibody. To 
confirm activation of pre-BCR signaling by the anti-IgM antibody, phosphorylation levels 
of AKTSer473 were analyzed (Supplementary Fig. S2). Stimulation of the pre-BCR did not 
increase STAP1 expression levels in the STAP1-high cell line Nalm6. In the STAP1-low cell 
line Kasumi-2 only a slight increase was detected in time (~1.3-1.6 fold; Fig. 2). Taken 
together, these results suggest that high levels of STAP1 and pre-BCR signaling are not 
causally connected.
Silencing of STAP1 does not affect cell viability and drug sensitivity
To elucidate the role of STAP1 in BCP-ALL survival, STAP1 expression was silenced by four 
different shRNAs in the BCP-ALL cell lines Nalm6 and Kasumi-2. The knockdown efficiency 
at mRNA level ranged from 50-80% for both cell lines and was confirmed on protein 
level (Fig. 3A, Supplementary Fig. S3-4). Three out of four shRNA constructs did not alter 
the proliferation rate and viability of Nalm6 cells, despite effective knockdown. Only 
shRNA-2 reduced those parameters in Nalm6 cells, but not in Kasumi-2 cells (Fig. 3B). 
Seven days after transduction, the majority of  leukemic cells remained alive in both cell 
lines and in all knockdown conditions (Fig. 3C). These data suggest that STAP1 is not 
essential for the survival of BCP-ALL cells. 
Next, we studied whether silencing of STAP1 affected sensitivity for inhibitors of pre-BCR 
(ibrutinib) and mTOR signaling (rapamycin), and the ALL spearhead drug prednisolone. 
Silencing of STAP1 did not alter the sensitivity to these compounds in the Nalm6 or 
Kasumi-2 cell lines (Fig. 4). To elucidate in which other signaling pathway STAP1 may be 
involved, the phosphorylation status of 17 proteins covering multi-signaling pathways was 
examined (Fig. 5). Silencing STAP1 did not alter the phosphorylated levels/ activation 
of Src-family, PI3K, Ras, Stat, JNK, p38 and NFκB kinase signaling members, nor of the 
reported STAP1 target in Ramos cells, i.e. phosphorylated level of CREBSer133.25 Taken 
together, STAP1 inhibition did not affect the survival and proliferation of the BCP-ALL 
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cell lines Nalm6 and Kasumi-2 or the phosphorylated levels of downstream signaling 
molecules, nor did knockdown result into sensitization for prednisolone or signaling 
inhibitors (ibrutinib and rapamycin).
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Figure 3. STAP1 knockdown does not affect leukemic cells survival.
Nalm6 and Kasumi-2 cells were transduced via spin-infection with shRNAs targeting STAP1 or 
scrambled control vectors. Values represent mean±SEM of four independent experiments. Independent 
sample T test. ** p<0.01; *p<0.05. (A) Knockdown efficacy was determined three and seven days after 
transduction using RT-qPCR. STAP1 expression relative to RPS20 was calculated. Relative expression 
values towards the two scrambled controls are depicted. (B) Proliferation of Nalm6 and Kasumi-2 
cells was measured for four days. At day 0 (3 days after transduction) cells were plated at equivalent 
concentrations. The next four days cell concentrations were detected using the MACSQuant and PI 
staining. Cell numbers (x106) are shown on the y-axis. (C) Seven days after transduction, viability of the 
cells was determined using AnnexinV and PI staining. Viability relative to scrambled control samples is 
shown.
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Figure 4. STAP1 knockdown does not sensitize cells towards prednisolone, ibrutinib or 
rapamycin.
(A-C) The efficacy of prednisolone (A), ibrutinib (B), and rapamycin (C) was tested in Nalm6 and 
Kasumi 2 cells, in which STAP1 was silenced. Three days after transduction, Nalm6 and Kasumi-2 
cells were exposed to a concentration range of the indicated compounds. After four days, viability 
was quantified using an MTS assay. Values represent mean±SEM of four independent experiments of 
Nalm6 and three independent experiments of Kasumi-2.
Aberrations in B-cell development genes and clinical characteristics
Genes involved in B-cell development are frequently altered in BCR‑ABL1-like patients.2,3 
Therefore, frequencies of lesions in genes involved in lymphoid differentiation, proliferation, 
cell cycle, and transcription were studied in STAP1-high and STAP1-low BCR‑ABL1-like 
and non-BCR‑ABL1-like B-other cases. Copy number alterations affecting EBF1, PAR1, 
and ETV6 were virtually absent in STAP1-high cases compared to a frequency ranging 
from 10.9-22.4% in STAP1-low cases (Fisher exact test, p<0.05; Table 1). More strikingly, 
high expression of STAP1 was associated with intragenic deletion of the ETS transcription 
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Figure 5. STAP1 knockdown does not affect common signaling pathways.
Expression of 17 proteins was determined using a fluorescent bead-based immunoassay in Nalm6 cells 
after knockdown of STAP1. Fluorescent intensity values relative to GAPDH are depicted. Expression was 
measured three and seven days after transduction. Infection and selection for stably transduced cells 
required three days. Subsequently, proliferation, viability and MTS assays were initiated, which took 
four days. mRNA and protein expression levels were examined after selection (day 3) and at the end 
of these functional experiments (day 7). At day 7, not enough material was available of Nalm6 cells, 
which were transduced with shRNA-2. Values represent mean±SEM of four independent experiments 
at three days after transduction and three independent experiments at seven days after transduction.
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  STAP1 high cases STAP1 low cases
P-value
Odds 
Ratio
95% 
Confidence 
Interval  Number Percentage Number Percentage
IKZF1 deletion 8/36 22.2 58/156 37.2 0.120  
EBF1 deletion 0/36 0.0 17/156 10.9 0.046 0.00 0.00-1.00
PAX5 aberration 10/36 27.8 69/156 44.2 0.091 0.49 0.20-1.13
CDKN2A/B deletion 15/36 41.7 77/156 49.4 0.460    
RB1 deletion 1/36 2.8 14/156 9.0 0.310  
BTG1 deletion 1/36 2.8 10/156 6.4 0.690    
ETV6 deletion 1/36 2.8 35/156 22.4 0.004 0.10 0.00-0.64
PAR1 deletion 0/36 0.0 19/156 12.2 0.027 0.00 0.000.87
ERG deletion 8/29 27.6 1/131 0.8 3.80E-06 47.68 5.91-2183.65
Table 1: Copy Number Alterations in B-cell development genes
factor ERG: 27.6% (8/29) in STAP1-high cases compared to 0.8% (1/133) in STAP1-low 
cases (p < 0.0001, odds ratio = 47.7; Table 1). Deletions of ERG are associated with a 
favorable prognosis in genetically unclassified high-risk pediatric BCP-ALL.41-43 The five-
year CIR and EFS of STAP1-high and STAP1-low BCR‑ABL1-like and non-BCR‑ABL1-like 
B-other cases did not significantly differ in our cohort, although STAP1-high cases showed 
a trend for a more favorable outcome (Fig. 6A-B). STAP1-high cases had a higher median 
age (Mann-Whitney U test; p=0.013; 9 years, range 2-16) than STAP1-low cases (6 
years, range 1-18). Remaining clinical characteristics, i.e. white blood cell count, in vivo 
prednisolone response at day 8, gender, and MRD levels did not differ (Supplementary 
Table S3). In addition, ex vivo cytotoxicity of prednisolone, vincristine, daunorubicin, 
l-asparaginase, 6-thioguanine, 6-mercaptopurine was measured in primary leukemic 
cells. No difference in cytotoxicity of these compounds was observed in STAP1-high and 
STAP1-low BCR‑ABL1-like and non-BCR‑ABL1-like B-other cells (Fig. 6C-H).
Interestingly, ERG deletions were very recently shown to be a hallmark of a newly identified 
BCP-ALL subtype, involving rearrangements of the double homeobox transcription factor 
DUX4.8-10,44 The association between high STAP1 levels and ERG deletions prompted us to 
investigate the presence of DUX4 rearrangements in our cases. To this aim, we screened 
an independent BCP-ALL cohort (n=2 KMT2A-rearranged, n=1 BCR‑ABL1, n=21 B-other, 
n=17 ETV6‑RUNX1, n=21 high hyperdiploid) for DUX4-rearrangements and ERG 
deletions. Four DUX4-rearranged cases were detected in the B-other group, of which 
two showed high expression levels of STAP1 (Fig. 7). None of these DUX4-rearranged 
cases or remaining B-other cases harbored an ERG deletion. In addition, we analyzed 
the association between STAP1, ERG, and DUX4 using a publically available dataset 
of 304 BCP-ALL cases.10,45 Similar to the observation made in our own patients, DUX4-
rearranged cases displayed higher levels of STAP1 mRNA (Supplementary Fig. S6), which 
was independent of intragenic ERG deletions. 
Taken together, high expression of STAP1 is not associated with (long-term) clinical 
outcome parameters or ex vivo drug resistance. However, the STAP1-high group is 
enriched for DUX4-rearrangements and intragenic ERG deletions.
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Figure 6. Ex vivo drug response and outcome is not affected by STAP1 overexpression.
(A-B) The association between high expression levels of STAP1, and cumulative incidence of relapse 
(CIR) and event-free-survival (EFS) was examined. Patients were stratified according to treatment 
protocol (i.e. COALL-97 or -03, or the DCOG protocols ALL8, ALL9, or ALL10). CIR was estimated using 
a competing risk model with relapse and non-response as event and death as competing event. The 
Gray’s test was applied. Relapse, non-response, secondary malignancies and death were considered 
as events for EFS. EFS rates were determined using Cox regression, and compared using the Wald test. 
(C-H) Leukemic cells were exposed for four days to an increasing concentration range of prednisolone 
(µg/ml), vincristine (µg/ml), L-asparaginase (IU/ml), daunorubicin (µg/ml), 6-mercaptopurine (µg/
ml), and 6-thioguanine (µg/ml). Cell survival was measured using an MTT assay. To compare LC50-
values, the Mann-Whitney U test was applied. BO = non-BCR‑ABL1-like B-other BCP-ALL cases. 
BAL = BCR‑ABL1-like BCP-ALL cases.
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DISCUSSION
The aim of the current study was to assess the potential of STAP1 as a therapeutic target in 
BCP-ALL cases. High expression of STAP1 was detected in a subset of BCR‑ABL1-like and 
non-BCR‑ABL1-like B-other patients. Interference with STAP1 did not induce cell death 
or block proliferation, nor did it make cells more sensitive to BTK (ibrutinib) and mTOR 
(rapamycin) inhibitors. In addition, high expression levels of STAP1 were not associated 
with a poor five-year EFS, high MRD levels, or ex vivo resistance to chemotherapeutic 
Figure 7.  STAP1 expression and DUX4-rearrangements
RNAseq analyses were used to determine DUX4 and STAP1 expression levels in an independent 
BCP-ALL cohort (n=2 KMT2A-rearranged, n=1 BCR‑ABL1, n=21 B-other, n=17 ETV6 RUNX1, n=21 
high hyperdiploid). Fastq-files with paired-end data were aligned to one DUX4 gene and the STAP1 
GRCh37 reference sequence using STAR 2.5.0b. Read counts were determined with HTSeq-count 
version 0.6.1p1. Grey lines represent the median expression values. (A) DUX4 expression values are 
depicted as Fragments Per Kilobase per Million mapped (FPKM). DUX4-partner genes were identified 
using NCBI blast, in which unknown sequences after the breakpoint were aligned.40 DUX4-alignement 
of 4 DUX4-rearranged cases and 4 non-DUX4-rearranged B-other cases is shown. (B) STAP1 
expression values are depicted as FPKM.
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drugs that are traditionally used in the treatment of BCP-ALL. Taken together, these results 
suggest that STAP1 is not a likely target for precision medicines in childhood ALL.
STAP1 is a relatively unknown gene. A potential role for the protein in neuronal apoptosis 
and degeneration has been suggested.26 However, involvement of the protein in cancer 
thus far remains elusive. We studied the gene expression profiles of STAP1-high BCP-ALL 
cases. The observed association between high expression of STAP1 and BCR signaling 
is in concordance with the few reports suggesting that STAP1 is a docking protein 
downstream of the BCR.24,25 Targeting the BCR pathway is an effective treatment strategy 
for mature B-cell malignancies and this approach is also being explored in BCP-ALL.15-20 
The overlap in downstream molecules involved in pre-BCR and BCR signaling,14 prompted 
us to investigate the connection between STAP1 expression and the pre-BCR pathway. 
However, CyIgµ expression (indicative for a functional pre-BCR) was not enriched in 
STAP1-high cases, and stimulation of leukemic cell lines with IgM only marginally induced 
expression STAP1 in one cell line. In addition, silencing of STAP1 did not reduce the 
proliferation rate and viability of leukemic cells in the majority of shRNAs tested. Strikingly, 
knockdown of STAP1 did also not affect phosphorylation levels of marker proteins involved 
in pre-BCR signaling (SRC) or other signaling pathway (PI3K, Ras, Stat, JNK, p38, NFκB), 
which are important for proliferation and survival of cells. In addition, silencing of STAP1 
did not affect the phosphorylated levels of CREB, which is a downstream target of STAP1 
in the Ramos/Burkitt lymphoma cell line.25 The question remains regarding the signaling 
pathway in which STAP1 is involved. Nevertheless, our results imply that STAP1 is not an 
oncogenic driver and that the high expression is most likely a consequence of another 
transforming event.
Interestingly, we observed intragenic deletions of the transcription factor ERG in a part 
of the STAP1-high cases. The proto-oncogene ERG is a regulator of hematopoiesis, 
including B-cell development,46,47 and is implicated in the pathogenesis of Ewing 
sarcoma, prostate cancer, and acute myeloid leukemia.48-50 Recently, ERG deletions were 
shown to be a hallmark of a novel identified subtype of BCP-ALL, i.e. DUX4-rearranged 
ALL.8-10 DUX4 encodes a double homeobox transcription factor and is located within 
the D4Z4 macrosatellite repeat array on 4q35 and 10q26. This pro-apoptotic gene is 
normally expressed in germline and testis cells, but epigenetically silenced in somatic 
cells.51,52 DUX4-fusion proteins, but not wildtype DUX4, were shown to have oncogenic 
potential in NIH3T3 fibroblasts.9 The pathway induced by DUX4-rearrangements is yet 
unknown. In the present work we show that high expression of STAP1 is characteristic for 
DUX4-rearranged cases (Fig. 7, Supplementary Fig S6). The association between STAP1 
and DUX4 was independent of ERG deletions. Therefore, upregulation of STAP1 may be 
a consequence of the oncogenic signaling pathway induced in DUX4-rearranged cases 
which is independent of concomitant ERG deletions. Further unraveling of the signaling 
pathway downstream of DUX4 will be crucial for the development of targeted treatment 
strategies for this genetic BCP-ALL subtype. 
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SUPPLEMENTARY METHODS
Microarray data analysis
Gene expression profiles of BCR‑ABL1-like and non-BCR‑ABL1-like B-other STAP1-high 
and STAP1-low samples were compared, using Limma R Package (version 3.26.9) in R 
3.0.1. To identify canonical pathways that were more significantly different, Ingenuity 
Pathway Analysis software was used (IPA; Ingenuity Systems Inc., Redwood City, CA).
Western Blotting
Leukemic cells were lysed in lysis buffer supplemented with freshly added protease 
and phosphatase inhibitors. 25µg (BCA method; Thermo Scientific) lysate was loaded 
on 10% mini protean precast gels (BioRad, Veenendaal, Netherlands), and transferred 
to a nitrocellulose membrane (Biorad). Primary antibody incubation was performed 
according to manufacturer’s protocol. Anti-pAKTSer473 and anti-αTubulin (#2144) were 
obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). Anti-STAP1 
(H00026228-M01) was obtained from Abnova (Aachen, Germany) and anti-β-actin 
(ab6276) was obtained from Abcam (Cambridge, UK). Blots were stained with secondary 
antibodies (IRDye 680RD- or 800CW-labelled anti‐rabbit and IRDye 680RD- or 
800CW‐labelled anti‐mouse; Li‐Cor Biosciences, Leusden, Netherlands) and scanned 
using the Odyssey infrared imaging system (Li-Cor Biosciences). 
Ex vivo drug resistance
Ex vivo cytotoxicity of prednisolone, vincristine, L-asparaginase, daunorubicin, 
6-mercaptopurine, and 6-thiguanine in primary samples was evaluated using 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT). Cells were 
exposed to increasing concentrations of chemotherapeutic agents (prednisolone: 
0.008 to 250 µg/mL; vincristine: 0.05 to 50 µg/mL; L asparaginase: 0.003 to 10 IU/
mL; daunorubicin: 0.002 to 2 µg/ml, 6-mercaptopurine: 0.015625 to 0.5 µg/ml, and 
6-thioguanine: 0.001625 to 0.0.05 µg/ml) at 37°C and 5% CO2. After four days of 
culture, the percentage of leukemic cells in control wells without chemotherapeutic agents 
was determined. Moreover, the optical density values of all wells was measured using a 
spectrophotometer after 6 hours of incubation with MTT. Samples were included if control 
wells harbored more than 70% leukemic cells and an optical density higher than 0.050 
arbitrary units (adjusted for blank values). The concentration of drug lethal to 50% of the 
cells (LC50) was calculated. LC50 values were compared using the Mann-Whitney U test. 
In vitro cytotoxicity of prednisolone, ibrutinib and rapamycin in cell lines was evaluated 
using 3-(4,5-dimethylthiazolyl-2)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium; MTS) and phenazine methosulfate (PMS). Cells were exposed to a dilution 
series of agents (prednisolone: 0.06 to 250 µg/mL; ibrutinib: 0.16 to 40 µM; rapamycin: 
4 nM to 40 µM) in a 96 wells plate for four days at 37°C and 5% CO2, after which 
viability was quantified as described above.
 
 
 
101
High expression of STAP1 in pediatric BCP-ALL
 4
Multiplex Ligation-Dependent Probe Amplification (MLPA)
To identify genomic lesions in IKZF1, CDKN2A, CDKN2B, ETV6, PAX5, RB1, BTG1, EBF1, 
and PAR1 (CSF2RA/IL3RA/CRLF2), the SALSA P335 ALL-IKZF1 (a3) and the SALSA 
P202 Multiplex Ligation-dependent Probe Amplification (MLPA) assays (MRC-Holland, 
Amsterdam, Netherlands) were used as described previously.1-3 Briefly, to generate DNA 
fragments with incorporated FAM nucleotides, 125 ng gDNA was used according to the 
manufacturer’s protocol. Amplified fragments were quantified using an ABI-3130 genetic 
analyzer (Applied Biosystems, Carlsbad, CA). Manufacturer’s control probes and a 
synthetic control reference, generated from five normal DNA samples in the same MLPA 
run, were used to normalize peak intensities (peak ratio < 0.75 for deletions, 0.75 ≤ peak 
ratio ≤ 1.3 for normal copy number, peak ratio > 1.3 for gain). Loss of either CDKN2A or 
CDKN2B was coded as CDKN2A/B deletion and intragenic amplifications of PAX5 were 
coded as deletions. 
SNP arrays
Genome-wide human SNP arrays 6.0 (Affymetrix) were performed to determine copy 
number and SNP genotype status according to the manufacturer’s protocol. Raw probe 
values were extracted from CEL files and processed with the R package aroma.affymetrix 
version 3.1.0. This package contains a method to prepare the raw data for analysis using 
the CRMA v2 method. Arrays were processed individually to reduce the effects of probe 
crosstalk, nucleotide-position probe sequence and fragment-length. In addition, probe 
summarization, including copy number values from the SNP probesets, were acquired. 
Samples were compared to a reference values, which was the average of 53 diploid 
BCP-ALL and T-ALL samples. Copy number arrays can contain a very large bias between 
probes caused by differences in GC content of DNA fragments. This bias is likely introduced 
by the many amplification steps used in the protocols for the arrays. We corrected for 
this bias using the R package ArrayTV version 1.12.0. To compare the logR values of the 
copy numbers between samples a centralization step was performed, using the R package 
CGHnormaliter version 1.28.0. Data were called using CGHcall version 2.36.0 default 
settings (-2 for double loss, -1 for loss, 0 for diploid, 1 for gain and 2 for amplification) 
in R version 3.3.3.
To determine the specificity and sensitivity of these SNP arrays, data were compared to 
array-CGH and MLPA data. The methods is excellent to call large copy number changes 
(larger than 1Kb, if many probes are present). However, it is difficult to see deletion of a 
single exon even in a large exon.
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Supplemental Figure 1. Discriminative expression of STAP1 in BCR-ABL1-like and B-other 
cases
(A-B) 2log expression levels of Affymetrix probeset 220059_at in 572 BCP-ALL and 80 T-cell ALL 
(T ALL) cases. The dotted line represents the 80th percentile of BCR‑ABL1-like and B-other cases (A). 
Expression levels of nBM (n=6) samples were determined in another microarray batch, in which also 
T ALL samples (n=105) were present (B). Grey lines represent the median expression values. (C-E) 
2log expression levels of Affymetrix probeset 1554343_a_at in 654 BCP-ALL cases. The dotted line 
represents the 80th percentile of BCR‑ABL1-like and B-other cases (C). Expression levels of nBM 
samples were determined in another microarray batch, in which also T-ALL samples were present (D). 
Grey lines represent the median expression values. Microarray expression levels were validated using 
qRT-PCR. Correlation between microarray values of probeset 1554343_a_at and qRT-PCR values 
is depicted by the spearman coefficient of correlation (E). (F) Ingenuity pathway analysis software 
(Qiagen) was used to identify differentially regulated pathways between  STAP1-high and STAP1-low 
BCR‑ABL1-like and B-other cases was performed. Limma was applied to unravel different expressed 
probeset. Adjusted p-values below 0.05 were used to perform analysis.
C D E
F
A B
0.0001 0.001 0.01 0.1
10
100
1000
10000
Rs=0.9417
qRT-PCR
Relative to RPS20
m
ic
ro
ar
ra
y
(1
55
43
43
_a
_a
t)
Ingenuity canonical pathways Overlapping genes P-value
EIF2 Signaling 66.5% (129/194) 2.18E-21
mTOR Signaling 58.8% (117/199) 1.08E-13
Regula�on of eIF4 and p70S6K Signaling 59.9% (94/157) 6.50E-12
B Cell Receptor Signaling 54.6% (101/185) 1.68E-09
AMPK Signaling 52.4% (99/189) 4.10E-08
KM
T2
A-
rea
rra
ng
ed
BC
R-
AB
L1
BC
R-
AB
L1
-lik
e
no
n-B
CR
-A
BL
1-l
ike
 B-
oth
er
ET
V6
-R
UN
X1
Hig
h H
yp
erd
ipl
oid
TC
F3
-P
BX
1
T-A
LL
4
6
8
10
12
m
RN
A 
ex
pr
es
si
on
2l
og
220059_at
T-A
LL nB
M
4
6
8
10
12
m
RN
A 
ex
pr
es
si
on
22
00
59
_a
t
1554343_a_at
T-A
LL nB
M
4
6
8
10
12
m
RN
A 
ex
pr
es
si
on
15
54
34
3_
at
T-A
LL
4
6
8
10
12
m
R
NA
 e
xp
re
ss
io
n
2l
og
KM
T2
A-
rea
rra
ng
ed
BC
R-
AB
L1
BC
R-
AB
L1
-lik
e
no
n-B
CR
-A
BL
1-l
ike
 B-
oth
er
ET
V6
-R
UN
X1
Hig
h H
yp
erd
ipl
oid
TC
F3
-P
BX
1
 Ingenuity canonical pathways Overlapping genes P-value
EIF2 Signaling 66.5% (129/194) 2.18E-21
mTor Signaling 58.8% (117/199) 1.08E-13
Regulation of eIF4 and p70S6K Signaling 59.9% (94/157) 6.50E-12
B Cell Receptor Signaling 54.6% (101/185) 1.68E-09
AMPK Signaling 52.4% (99/189) 4.10E-08
103
High expression of STAP1 in pediatric BCP-ALL
 4
C
tr 
m
ed
iu
m
1µ
g 
an
ti-
Ig
M
 a
nt
ib
od
y
C
tr 
m
ed
iu
m
1µ
g 
an
ti-
Ig
M
 a
nt
ib
od
y
pAKTS473
β-actin
Nalm6 Kasumi-2
pAKTSer473
Na
lm
6
Ka
su
mi
-2
0.00
0.01
0.02
0.03
0.04
0.05
Ctr medium
1 µg/ml anti-IgM
Ex
pr
es
si
on
 le
ve
ls
re
la
tiv
e 
to
β
-a
ct
in
Supplemental Figure 2. Stimulation of pre-BCR signaling
Nalm6 and Kasumi-2 cells were stimulated for 1 hour with 1 µg/ml anti-IgM. Phosphorylation levels 
of pAKTSer473 were detected using western blotting, to confirm the stimulatory effect of the anti-IgM 
antibody. Expression levels relative to β-actin are depicted.
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Supplemental Figure 3. Virus titration to determine the amount of virus required to infect 80% 
of cells.
Nalm6 and Kasumi-2 cells were exposed to indicated dilution series of virus. Cells were transduced via 
spin-infection. Puromycin selection (1 µg/ml) was initiated 24 hours after infection. After 48 hours of 
selection, cell viability was assessed using flow cytometry. PI staining was used to discriminate viable 
from dead cells. Transduction efficacy was calculated: (%viability of transduced cells)/(%viability 
of non-transduced cells)*100%. Obtained values of four independent experiments are depicted in 
graphs. The virus amounts used for subsequent experiments are indicated by enlarged symbols.
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Supplemental Figure 4. Silencing of STAP1 in BCP-ALL cell lines.
Nalm6 and Kasumi-2 cells were transduced via spin-infection with shRNAs targeting STAP1 or scrambled 
control vectors. (A) Target sequences and regions of the shRNAs are depicted in the Table. (B) Western 
blot analysis of 15µg lysate of Nalm6 samples, which was collected 3 days after transduction. The 
blot was probed overnight with anti-STAP1 (mouse) and anti-αTubulin (rabbit). Protein expression was 
visualized using secondary antibodies (IRDye 680RD-labelled anti-rabbit and IRDye 800CW‐labelled 
anti‐mouse) and scanned using the Odyssey infrared imaging system (Li-Cor Biosciences). The cropped 
blot is shown, and the full length blot is depicted in panel d. Quantified expression levels are depicted 
above band. (C) Knockdown efficacy of the different shRNAs determined on protein level (western blot) 
and mRNA level (RT-qPCR), 3 days after transduction. Expression levels of STAP1 were normalized 
towards house-keeping genes (α-Tubulin and RPS20). Relative expression values towards the two 
scrambled controls are depicted. (D) Full western blot image of cropped image that are depicted in 
panel b.
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Supplemental Figure 5. Fluorescent bead-based immunoassay.
Expression of 17 proteins was determined using a fluorescent bead-based immunoassay in Nalm6 cells 
after knockdown of STAP1. Fluorescent intensity values relative to GAPDH are depicted. Expression 
was measured three and seven days after transduction. At day 7, not enough material was available of 
Nalm6 cells, which were transduced with shRNA-2. Values represent mean±SEM of four independent 
experiments at three days after transduction and three independent experiments at seven days after 
transduction. In addition, positive and negative cell line samples were included to validate the assay 
and antibodies. For the 8-plex human Src family kinase kit control samples included Hela-unstimulated 
lysate, Ramos-Pervanadate lysate, HL60- Pervanadate lysate, and HEK293 serum. For the multi-
pathway magnetic bead 9-plex control samples included HeLa-unstimulated lysate, HeLa-TNFα/
Calyculin lysate, A431-EGF lysate, MCF7-IGF1 lysate.
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Supplemental Figure 6. STAP1 expression and DUX4-rearrangemets.
STAP1 expression levels in 304 BCP-ALL cases, obtained ProteinPaint.4,5 Fragments Per Kilobase per 
Million mapped (FPKM) expression values are depicted on the y-axis. Lines represent the median 
expression values. NOS = not other specified.
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ABSTRACT
Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is associated with a 
high frequency of copy number alterations (CNAs), mostly deletions, in genes involved 
in B-cell development, cell cycle, and cytokine receptors (henceforth: B-cell development 
genes). We performed an explorative study to gain insight in the association between 
CNAs in these B-cell development genes, clinical outcome parameters, and cellular drug 
resistance. 
CNAs in IKZF1, EBF1, PAX5, CDKN2A/B, RB1, BTG1, ETV6, and/or the PAR1 region 
were detected in 71% of newly diagnosed pediatric BCP-ALL cases. The distribution and 
clinical relevance of the CNAs in these eight genes was highly subtype-dependent. In the 
DCOG-ALL10 cohort, only loss of IKZF1 associated as single marker with unfavorable 
outcome parameters and cellular drug resistance. Deletion of IKZF1 was connected to 
high minimal residual disease (MRD) levels after induction therapy, an unfavorable long-
term prognosis, and ex vivo resistance to prednisolone and thiopurines. This cellular drug 
resistance depended on the genetic subtype of the BCP-ALL cells: extreme prednisolone 
resistance (~1500-fold) was observed in primary IKZF1-deleted high hyperdiploid cells, 
while thiopurine resistance (~1.7-fold) was predominantly detected in primary BCR‑ABL1-
like and non-BCR‑ABL1-like B-other IKZF1-deleted cells. These results indicate that the 
biological consequence of CNAs in B-cell development genes depends on the concomitant 
oncogenic driving lesion present in leukemic cells. Therefore, the genetic context in which 
lesions occur should be taken into account for risk stratification of patients with BCP-ALL 
and functional studies focusing on potential causes of cellular drug resistance.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. 
The introduction of risk-adjusted treatment protocols has significantly improved survival 
rates, which nowadays is approaching 90% survival.1-3 Outcome of B-cell precursor ALL 
(BCP-ALL) differs by genetic subtype, i.e. ETV6‑RUNX1, high hyperdiploid, and TCF3‑PBX1 
cases have favorable prognosis, whereas BCR‑ABL1, and KMT2A-rearranged BCP-ALL is 
associated with an unfavorable treatment outcome.3 Approximately 25% of the patients has 
a genetically unclassified disease, which is defined as ‘B-other’. This heterogeneous group 
can be subdivided in BCR‑ABL1-like patients and non-BCR‑ABL1-like B-other patients.4,5 
Within the BCR‑ABL1-like subtype intrachromosomal amplification of chromosome 
21, dicentric chromosome (9;20), and kinase activating lesions are reported.4-9 In non 
BCR‑ABL1-like B-other cases chromosomal translocations involving DUX4, ZNF384, 
and MEF2D were identified.10-12 In addition to the major classifying abnormalities, 
secondary aberrations have been observed, including copy number alterations (CNAs) 
in genes involved in B-cell development (e.g. IKZF1, EBF1, PAX5, ETV6), cell cycle and 
proliferation (e.g. CDKN2A/B, RB1, BTG1), and cytokine receptors (e.g. CRLF2).4, 5, 8, 9, 
13-16 Interestingly, some of these genetic lesions (e.g. IKZF1) were shown to predict clinical 
outcome.5, 14, 17 The Dutch Childhood Oncology Group (DCOG) implemented IKZF1 status 
as risk factor in the ongoing DCOG-ALL11 protocol. In addition, risk stratification strategies 
were designed by integration of CNA profiles and genetic subtypes.18, 19
Cellular drug resistance is an important cause of relapse. Ex vivo drug resistance 
at diagnosis is associated with high risk of early treatment failures.20-22 In addition, 
BCP-ALL cells at relapse are more resistant towards glucocorticoids, L-asparaginase, 
anthracyclines, and thiopurines.23 IKZF1 deletions are reported to mediate resistance 
towards glucocorticoids, but the relationship between remaining CNAs and cellular 
drug resistance is yet unknown.24-26 Therefore, we performed an explorative study, which 
aimed to gain insight in associations between CNAs, cellular drug resistance and clinical 
outcome.
METHODS
Processing of primary patient material
Bone marrow and/or peripheral blood samples were obtained from children (1-18 
years) with newly diagnosed ALL. Written informed consent was obtained from parents 
or guardians to use excess of diagnostic material for research purposes, as approved 
by the institutional review board. These studies were conducted in accordance with the 
Declaration of Helsinki. Mononuclear cells were isolated using Lymphoprep gradient 
separation and the leukemic blast percentage was determined microscopically by May-
Grünwald Giemsa stained cytospin preparations, as described previously.20 Samples 
were enriched to over 90% purity of leukemic cells by depletion of non-leukemic 
cells using immunomagnetic beads. Primary leukemic cells were maintained in RPMI-
1640 Dutch modification supplemented with 20% fetal calf serum (Integro), with 0.1% 
insulin-transferrin-sodium selenite (Sigma), 0.4 mM glutamine (Invitrogen), 0.25 µg/ml 
gentamycine (Gibco), 100 IU/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco), 
0.125 µg/ml fungizone (Gibco). 
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The major cytogenetic subtypes, i.e. high hyperdiploid (>50 chromosomes), ETV6‑RUNX1, 
TCF3‑PBX1, KMT2A-rearranged, BCR‑ABL1, BCR‑ABL1-like and B-other (negative for all 
before mentioned genomic lesions), were determined using fluorescent in situ hybridization 
and (RT-)PCR. The 110-probeset gene expression classifier was used to identify 
BCR‑ABL1-like cases.4 Patients were treated according to the Dutch Childhood Oncology 
Group (DCOG)-ALL8, -ALL9, -ALL10 or -EsPhALL protocol, or the COALL-06-97 and 
COALL-07-03 study protocols.3, 27-29 Patient characteristics were provided by the central 
study centers of DCOG, The Hague, the Netherlands and COALL, Hamburg, Germany.
Multiplex Ligation-Dependent Probe Amplification
To identify genomic lesions in IKZF1, CDKN2A, CDKN2B, ETV6, PAX5, RB1, BTG1, EBF1 
and PAR1 (CSF2RA/IL3RA/CRLF2), the SALSA P335 ALL-IKZF1 (a3) and the SALSA 
P202 Multiplex Ligation-dependent Probe Amplification (MLPA) assays (MRC-Holland, 
Amsterdam, Netherlands) were used as described previously.14 In short, DNA fragments 
with incorporated FAM nucleotides were generated using 125 ng of genomic DNA, 
according to the manufacturer's protocol. To quantify the amplified fragments, an ABI-
3130 genetic analyzer (Applied Biosystems, Carlsbad, CA) was used. The manufacturer’s 
control probes were used to normalize peak intensities, as well as a synthetic control 
reference generated from five normal DNA samples in the same MLPA run (normal copy 
number = 0.75 ≤ peak ratio ≤ 2.0; deletions = peak ratio < 0.75; gain = peak ratio > 
2.0). A deletion was defined by a peak ratio below 0.75 for at least one MLPA-probe 
per gene. CDKN2A/B deletions included loss of either CDKN2A or CDKN2B. The effect 
of intragenic amplifications and/or deletions in PAX5 were analyzed within one group, 
as they were predicted to be functionally equivalent.18, 30 Loss of the PAR1 region was 
defined by deletion of both IL3RA and CSF2RA probes while expression of the CRLF2 and 
SHOX AREA probes was maintained. MLPA analyses were performed in 515 BCP-ALL 
cases, representing the major genetic subtypes in childhood ALL, i.e. 3.9% (20/515) BCR‑
ABL1, 17.3% (89/515) BCR‑ABL1-like, 20.2% (104/515) non-BCR‑ABL1-like B-other, 
28.7% (148/515) ETV6‑RUNX1, 24.5% (126/515) high hyperdiploid, 1.6% (8/515) 
KMT2A-rearranged, 3.9% (20/515) TCF3‑PBX1.
Clinical characteristics and statistics
To identify whether CNAs were underrepresented or enriched in a subtype, the Fisher’s 
exact test was applied using R software (version 3.2.1). Obtained odds ratios (ORs), 95% 
confidence interval, and p-values are reported. The Fisher’s exact test was also applied 
to compare minimal residual disease (MRD) levels after induction and first consolidation 
therapy between patients groups with CNAs and wildtype patients. Cumulative incidence 
of relapse (CIR) was estimated using a competing risk model and significance was 
determined using the Gray's test. Relapse and non-response (counted as event at day 
79) were considered as event, with death as competing event. Event-free survival (EFS) 
probabilities were estimated using cox regression and compared using the Wald test. 
Relapse, non-response, secondary malignancies and death were counted as events. 
Outcome analyses were performed in R (version 3.2.1), using the packages cmprsk version 
2.2-744, mstate version 0.2.745, and survival version 2.38-446. Five-year EFS and CIR are 
reported. A multivariate Cox proportional hazard analysis was performed in SPSS version 
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22 to determine the independent prognostic value of risk factors. The DCOG-ALL10 trial 
is the most recently completed nationwide trial in which patients were risk-stratified by 
minimal residual disease (MRD) levels and for whom sufficient long-term follow-up data 
were available. Therefore, we restricted the analysis of associations between CNA and 
clinical response parameters (MRD, clinical outcome) to this cohort. In addition, the genetic 
subtypes are represented with a distribution that is comparable to the general pediatric 
BCP-ALL population (excluding BCR‑ABL1-positive cases since these patients are eligible 
for the EsPhALL protocol), i.e.12.2% BCR‑ABL1-like, 13.9% non-BCR‑ABL1-like B-other, 
33.5%  ETV6‑RUNX1, 32.7%  high hyperdiploid, 2.0%  KMT2A-rearranged, and 5.7% 
TCF3‑PBX1 positive cases.
Ex vivo drug resistance assays
Ex vivo cytotoxicity of prednisolone, vincristine, L-asparaginase, daunorubicin, 
6-mercaptopurine and 6-thioguanine was evaluated using 3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazolium bromide (MTT), as previously described.20 In brief, cells were 
exposed to a concentration range of chemotherapeutics (prednisolone: 0.008 to 250 
µg/mL; vincristine: 0.05 to 50 µg/mL; L-asparaginase: 0.003 to 10 IU/mL; daunorubicin: 
0.002 to 2 µg/ml; 6-mercaptopurine: 15.6 to 500 µg/ml; and 6-thioguanine: 1.56 to 
500 µg/ml) in a 96 wells plates for four days at 37°C and 5% CO2. After four days of 
culture, samples were included if control wells harbored more than 70% leukemic cells 
and an optical density higher than 0.050 arbitrary units (adjusted for blank values). The 
concentration of drug lethal to 50% of the cells (LC50) was calculated. LC50-values were 
compared by the Mann-Whitney U test and adjusted for tied ranks if applicable.
RESULTS
A pediatric BCP-ALL cohort of 515 newly diagnosed cases, representing all major ALL 
subtypes, was screened for CNAs in eight genes involved in transcription of lymphoid 
genes and the differentiation and proliferation of precursor B-cells (henceforth: B-cell 
development genes). In total, 71% of the pediatric BCP-ALL cases harbored one or more 
CNAs in these B-cell development genes (Figure 1). The CNA frequency differed between 
genetic BCP-ALL subtypes. The percentage of CNAs was the highest in BCR‑ABL1-like 
cases and the lowest in TCF3‑PBX1 cases (Supplementary Figure 1A).
CNAs in B-cell transcription factors
IKZF1
Deletions of the transcription factor IKZF1 were detected in 20% of the BCP-ALL cases. This 
frequency differed between subtypes: IKZF1 deletions were enriched in BCR‑ABL1 (65%) 
and BCR‑ABL1-like (44%) cases, whereas deletions were low or absent in ETV6‑RUNX1 
(3%) and TCF3‑PBX1 (0%), respectively (Figure 1A; Supplementary Figure 1B). In 
addition, 76% (78/102) of the cases with an IKZF1 deletion harbored CNAs in additional 
genes, which mainly involved PAX5 and CDKN2A/B (Figure 2). This co-occurrence was 
subtype dependent: a strong association (OR>2, p<0.001) was observed in BCR‑ABL1, 
BCR‑ABL1-like and B-other cases, whereas in high hyperdiploid cases IKZF1 deletions 
mainly occurred independent of CNAs in PAX5 and/or CDKN2A/B.
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IKZF1-deleted cases more often showed high MRD levels (≥10-3) after induction 
therapy (TP1; p=0.013), and intermediate MRD levels (10-4 ≤ MRD < 10-3) after the first 
consolidation course (TP2; p=0.028), compared to IKZF1-wildtype cases (Figure 3A). 
This association could be predominantly attributed to high MRD levels in BCR‑ABL1-like 
and B-other cases, but was not observed in high hyperdiploid or ETV6‑RUNX1 cases 
(Supplementary Figure 3). In addition, IKZF1-deleted cases more often suffered from a 
non-response or relapse compared to IKZF1-wildtype cases (5-year CIR: 30.4% versus 
9.0%; p<0.001; Figure 4A-B), confirming previous findings.5, 14, 17 An IKZF1 deletion 
was an independent risk factor in a multivariate Cox proportional hazard model, 
including prednisolone response at day 8 of treatment and MRD levels after induction 
and first consolidation course (Supplementary Table 1). In addition, IKZF1 remained 
a predictor of a poor outcome in the medium risk (MR) treatment group of the DCOG-
ALL10 cohort (Figure 4B). These observations indicate that the poor long-term clinical 
outcome of IKZF1-deleted cases is not caused by the association of IKZF1 with current 
risk stratification factors based upon early treatment response.
As cellular drug resistance might underlie this poor outcome, we examined the ex vivo 
efficacy of chemotherapeutic agents that are commonly used during induction and 
consolidation therapy. Primary BCP-ALL cells harboring IKZF1 deletions were more 
resistant to prednisolone and thiopurines compared to IKZF1 wildtype cells (p<0.05; 
Figure 5A-B). Resistance against these agents was subtype dependent, as visualized in 
Figure 5B: prednisolone resistance was predominantly observed in high hyperdiploid 
cells (~1500-fold, p=0.009), whereas thiopurine resistance (6-thioguanine (1.6 fold, 
p=0.011) and 6-mercaptopurine (1.7 fold, p<0.001)) was mainly identified in IKZF1-
deleted BCR‑ABL1-like and B-other cells (Figure 5B). Moreover, in high hyperdiploid 
cells deletion of IKZF1 was predictive for L-asparaginase resistance (Supplementary 
Figure 7A).
EBF1
The transcription factor EBF1 was deleted in a minority (6%) of the BCP-ALL cases (Figure 
1B). Deletions were enriched in BCR‑ABL1-like cases (15%), but absent in KMT2A-
rearranged and TCF3‑PBX1 cases (Figure 1B). Cases that harbored an EBF1 deletion 
showed a trend towards higher MRD levels after induction therapy compared to non-EBF1 
deleted cases (OR=5.16, p=0.057; Figure 3B). However, power was low to study the 
association with cellular drug resistance, as drug resistance data were only available for 
six EBF1-deleted cases.
Figure 1. CNA landscape of B-cell development genes in the different subtypes of pediatric 
BCP-ALL.
CNA profile of 515 newly diagnosed pediatric BCP-ALL patients, representing all major BCP-ALL 
subtypes, was determined using MLPA. Association between CNAs and subtypes was studied using the 
Fisher Exact test. The frequency of specific CNAs per subtype is shown. CNAs tested included IKZF1 
(A), EBF1 (B), PAX5 (C), ETV6 (D), CDKN2A/B (E), RB1 (F), BTG1 (G), PAR1 (H). 
**p≤0.01, *p≤0.05. del = deletion
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PAX5
CNAs of the transcription factor PAX5 were observed in 28% of the BCP-ALL cases (Figure 
1C). CNAs were detected throughout all BCP-ALL subtypes, although the frequency was 
relatively high in BCR‑ABL1 (50%) and BCR‑ABL1-like (46%) cases (Figure 1C). The 
strong co-occurrence of PAX5 and CDKN2A/B CNAs (Figure 2, OR=6.36, p<0.001) is 
likely caused by the high frequency of chromosome 9p deletions observed in these cases31; 
the chromosome arm on which PAX5 and CDKN2A/B are located. Despite of the strong 
association between PAX5 CNAs and IKZF1 deletions (Figure 2, OR=2.94, p<0.001), 
CNAs in PAX5 were not predictive for high MRD levels (Figure 3C) nor a poor prognosis 
in pediatric BCP-ALL cases (Figure 4A). Strikingly, leukemic cells harboring CNAs in PAX5 
showed an increased sensitivity (~5.1 fold, p=0.008) to prednisolone compared to PAX5-
wildtype cells (Figure 5C). This difference in sensitivity was only significant (p=0.031) in 
ETV6‑RUNX1 cases, but  a similar pattern was also observed in the remaining BCP-ALL 
subtypes (Figure 5C). Interestingly, this association depended on the IKZF1 status: cells 
with both an IKZF1 deletion and a CNA in PAX5 were equally sensitive to prednisolone 
as IKZF1 and PAX5 wildtype cells, whereas cells with only an IKZF1 deletion were more 
resistant to prednisolone (Supplementary Figure 7B). These results suggest that CNAs in 
PAX5 might compensate for prednisolone resistance induced by loss of IKZF1.
Figure 2. Co-occurence of CNAs in B-cell development genes in the different BCP-ALL subtypes.
(A) Heatmap of CNA profile of 515 newly diagnosed pediatric BCP-ALL patients, representing the major 
BCP-ALL subtypes. CNAs are shown per subtype. Colors indicate presence of a CNA and absence of 
CNAs is shown in white. The heatmap is sorted on IKZF1 deletions followed by CNAs in PAX5. Each column 
represents an individual patient. (B) The co-occurrence between the different CNAs in all BCP-ALL cases was 
calculated using the Fisher Exact test. Odds ratios and p-values of significant associations are shown.
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Figure 3. The association between CNAs and MRD levels after induction therapy and the first 
consolidation course in newly diagnosed BCP-ALL.
MRD levels of DCOG-ALL10 treated BCP-ALL cases (all risk groups) after induction (TP1; n=183) 
and first consolidation course (TP2; n=183). The percentage of cases with high (≥10-3), medium 
(10-4 ≤ MRD < 10-3), and undetectable MRD levels (<10-4) is depicted per CNA. The Fisher’s Exact test 
was applied to study associations between CNAs and MRD levels.
**p≤0.01, *p≤0.05. del = deletion.
118
Chapter 5
A
B
0 2 4 6 8
0
20
40
60
80
100
IKZF1 DCOG ALL10
All risk groups
Time from initial diagnosis (years)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e 
(%
) Not deleted, n=180, relapses=17
Deleted, n=30, relepases=9
p = 4.45e-4
0 2 4 6 8
0
20
40
60
80
100
IKZF1 DCOG ALL10
All risk groups
Time from initial diagnosis (years)
Ev
en
t−
fre
e 
su
rv
iv
al
 (%
)
Not deleted, n=180, events=22
Deleted, n=30, events=10
p = 0.001
0 2 4 6 8
0
20
40
60
80
100
IKZF1 DCOG ALL10
Medium Risk only
Time from initial diagnosis (years)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e 
(%
)
Not deleted, n=100, relapses=8
Deleted, n=18, relapses=8
p = 1.29e−05
0 2 4 6 8
0
20
40
60
80
100
IKZF1 DCOG ALL10
Medium Risk only
Time from initial diagnosis (years)
Ev
en
t−
fre
e 
su
rv
iv
al
 (%
)
Not deleted, n=100, events=10
Deleted, n=18, events=8
p = 2.37e-04
IK
ZF
1
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IKZF1  no deletion 180 9.0 (2.3) 88.2 (2.5)
IKZF1 deletion 30 30.4 (9.9) 66.3 (9.8)
EBF1  no deletion 192 11.9 (2.5) 85.5 (2.7)
EBF1 deletion 18 11.5 (7.9) 83.0 (9.0)
PAX5  no CNA 165 10.6 (2.6) 85.8 (2.8)
PAX5 CNA 44 17.1 (6.1) 83.3 (6.0)
ETV6  no deletion 151 12.1 (2.8) 83.8 (3.1)
ETV6  deletion 59 11.1 (4.4) 88.9 (4.4)
CDKN2A/B  no deletion 160 10.4 (2.6) 87.1 (2.8)
CDKN2A/B  deletion 50 16.6 (5.5) 79.3 (5.9)
RB1 no deletion 194 10.7 (2.4) 86.7 (2.6)
RB1  deletion 16 25.6 (11.5) 68.2 (11.8)
BTG1  no deletion 193 11.9 (2.5) 85.6 (2.7)
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Figure 4. Prognostic value of CNAs in DCOG-ALL10 treated cases.
(A) The association between CNAs in all risk groups and cumulative incidence of relapse (CIR) and event 
free-survival (EFS) was examined. BCP-ALL patients (n=210) were treated according to DCOG-ALL10 
protocol. CIR was estimated using a competing risk model. Relapse and non-response were considered 
as event, and death as competing event. To test equality of the CIRs, the Gray’s test was applied. Non 
response, relapse, and death were considered as events for EFS. EFS rates were determined using Cox 
regression, and compared using the Wald test. For reliable test results, groups should contain at least 5 
cases. (B) CIR and EFS curves of cases without or with an IKZF1 deletion. Curves contain either all risk 
groups, or the medium risk arm only.
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ETV6
Deletions of the transcription factor ETV6 were detected in all BCP-ALL subtypes, but were 
especially enriched in ETV6‑RUNX1 cases (71%; Figure 1D). After induction therapy 
(TP1), ETV6-deleted cases more often showed low (<10-4) MRD levels compared to ETV6-
wildtype cases (Figure 3D; OR=2.6, p=0.02). However, this association was subtype 
dependent: in BCR‑ABL1-like and B-other cases an adverse association between ETV6 
deletions and MRD levels was observed (Supplementary Figure 2). Prognosis of cases 
with loss of ETV6 was not different compared to ETV6-wildtype cases (Figure 4). ETV6-
deleted cells appeared to be more sensitive to prednisolone (~3.2 fold, p=0.046), and 
more resistant to vincristine (~1.8 fold, p<0.01) and daunorubicin (~1.9 fold, p=0.028). 
Remarkably, loss of the wildtype ETV6 allele in ETV6‑RUNX1-positve cells associated with 
a high sensitivity to vincristine instead of resistance (p=0.013, Figure 5D), suggesting that 
associations of vincristine resistance differ between genetic subtypes of ALL. Moreover, 
deletion of ETV6 was associated with L-asparaginase resistance in high hyperdiploid cells 
and high 6-thioguanine sensitivity in ETV6‑RUNX1 cells (Supplementary Figure 7C).
CNAs in cell cycle and proliferation genes
CDKN2A/B
Deletions of the cell cycle regulators CDKN2A and/or CDKN2B were often observed 
(33%) in the pediatric BCP-ALL cohort (Figure 1E). Similar to PAX5, the deletions in 
CDKN2A/B were found in all BCP-ALL subtypes, but were especially enriched in 
BCR‑ABL1 (65%, OR=3.95, p=0.003), BCR‑ABL1-like (54%, OR=2.88, p<0.001), and 
B-other cases (OR=1.67, p=0.026). No association with clinical outcome parameters or 
cellular drug resistance was observed (Figure 3-5).
RB1
The cell cycle regulator RB1 was deleted in a minority (~7%) of the BCP-ALL cases (Figure 
1F) and deletions were detected in all BCP-ALL subtypes. Within the DCOG-ALL10 cohort, 
RB1-deleted cases showed a trend towards a poor event free survival (5- year EFS: 68.2% 
versus 86.7%, p=0.057), which was caused by an unfavorable response in the medium 
risk (MR) treatment group (5-year EFS: 46.9% versus 88.3%, p=0.003; Supplementary 
Figure 6A). No association with MRD levels or cellular resistance to the tested drug panel 
was observed (Figure 5).
BTG1
The anti-proliferative gene BTG1 was deleted in a minority (~8%) of the BCP-ALL cases. No 
deletions were detected in KMT2A-rearranged or TCF3‑PBX1 cases, whereas the highest 
frequency was observed in BCR‑ABL1 (30%) and ETV6‑RUNX1 (16%) cases (Figure 1G). 
Four out of five BTG1-deleted BCR‑ABL1-like and B-other cases also harbored an IKZF1 
deletion. These four cases all experienced an event and only the patient with wildtype 
IKZF1 remained in remission (Supplementary Figure 6B). This finding underlines an earlier 
report, in which a cooperative effect of BTG1 and IKZF1 lesions in leukemogenesis was 
observed.26
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Figure 5. The association between CNAs and the ex vivo cellular drug response.
(A) Leukemic cells were incubated for four days with a concentration range of prednisolone (µg/ml), 
vincristine (µg/ml), L-asparaginase (IU/ml), daunorubicin (µg/ml), 6-mercaptopurine (µg/ml), and 6 
thioguanine (µg/ml), after which cell viability was measured using an MTT assay. The Mann-Whitney 
U test was applied to compare LC50-values. No association is depicted in grey, resistance in blue (p 
<0.05, fold induction (FI) > 1), sensitive in green (p < 0.05, FI < 1), and not determined in white. The 
number of cases that were tested for prednisolone is depicted, and represent the maximum number of 
cases. For reliable test results, groups should contain at least 5 cases. Results are depicted for all risk 
groups and for BCR‑ABL1-like/ B-other cells, high hyperdiploid cells, and ETV6‑RUNX1 cells. (B) 
LC50 values for prednisolone (µg/ml), 6-thiogunanine (µg/ml), and 6-mercaptopurine (µg/ml) of 
cases without or with IKZF1 deletion. Columns include all BCP-ALL subtypes (grey), BCR‑ABL1-like/ 
B-other cells (blue), and high hyperdiploid cells (green). (C) LC50 values for prednisolone (µg/ml) 
of cases without or with PAX5 CNAs. Columns include all BCP-ALL subtypes (grey), BCR‑ABL1-like/ 
B-other cells (blue), high hyperdiploid cells (green), and ETV6‑RUNX1 cells (yellow). (D) LC50 values 
for prednisolone (µg/ml), vincristine (µg/ml), and daunorubicin (µg/ml) of primary leukemic cells 
without or with ETV6 deletion. Columns include all BCP-ALL subtypes (grey), BCR‑ABL1-like/ B-other 
cells (blue), high hyperdiploid cells (green), and ETV6‑RUNX1 cells (yellow). 
* p < 0.05, ** p < 0.01; Mann-Whitney U test.
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CNAs in cytokine receptors
PAR1
Deletions in the pseudoautosomal region 1 (PAR1) were the least prevalent (~4%) in this 
pediatric BCP-ALL cohort. CNAs in this region indicate presence of interstitial deletions 
or a translocation, which both induce overexpression of CRLF2.32 Deletions of the PAR1 
region were detected in BCR‑ABL1-like (11%), B-other (10%), and high hyperdiploid 
cases (2%), but not in remaining BCP-ALL subtypes (Figure  1H). Unfortunately, power 
was lacking to reliable study the association between deletions in the PAR1 region, MRD 
levels, clinical prognosis, and cellular drug resistance.
Taken together, with the exception of loss of the IKZF1 gene, none of the CNAs in the 
remaining B-cell development genes strongly associates with clinical outcome and cellular 
drug resistance as single marker. Our results show that the clinical value of CNAs in B-cell 
development genes is highly context dependent and differs between the diverse oncogenic 
drivers of pediatric BCP-ALL.
DISCUSSION
BCP-ALL cases harbor various genetic aberrations in genes involved in lymphoid 
maturation, cell cycle regulators, tumor suppressors, and tyrosine kinases. We performed 
an explorative study to gain insight in the association between CNAs in B-cell development 
genes, MRD levels, long-term prognosis, and cellular drug resistance. Interestingly, 
the distribution and clinical relevance of these CNAs was subtype-dependent. A high 
frequency of CNAs in these B-cell development genes was found in the poor prognostic 
subtypes BCR‑ABL1, BCR‑ABL1-like and B-other. Cooperative lesions may favor the 
aggressive phenotype of a leukemia, such as exemplified by the synergistic effect between 
loss of IKZF1 and the BCR‑ABL1 fusion gene in leukemogenesis33, and the antagonizing 
effect of IKZF1 deletions in the response to imatinib.34 In contrast, the prognosis of 
ETV6‑RUNX1, DUX4-rearranged, and ERG-deleted BCP-ALL is probably not affected by 
IKZF1 deletions, but numbers with IKZF1 deletions in these subtypes are low.11, 12, 15, 35, 
36 These observations indicate that the genetic context influences the functional effect of 
CNAs in B-cell development genes. The importance of the genetic context is exemplified 
by the fact that isolated deletions of BTG1 do not affect cellular drug resistance or the 
prognosis of BCP-ALL cases, whereas all four patients with concomitant loss of BTG1 and 
IKZF1 experienced an event. Moreover, combined loss BTG1 and IKZF1 was shown to 
enhance glucocorticoid resistance.26 In contrast to BTG1‑IKZF1 synergy, we observed that 
CNAs in PAX5 may counteract the effect of an IKZF1 deletion on prednisolone resistance. 
Various combinations of cooperative lesions may therefore have different effects on the 
pathobiology of B cell precursor ALL cells.
In the present study we observed an association between deletion of IKZF1 and prednisolone 
resistance, especially in high hyperdiploid cells. These results are in concordance with 
other studies, which indicate that there is a direct association between IKZF1 and 
glucocorticoid-induced cell death.24, 37 IKZF1 functions as a metabolic gatekeeper and 
consequently loss of IKZF1 results in increased intracellular ATP and glucose levels.37 
Interestingly, we previously observed a direct relation between an increased glycolytic 
rate and prednisolone resistance in primary BCP-ALL cells.38, 39 In these leukemic cells, 
inhibition of glycolysis restored the efficacy of prednisolone.39 Hence, inhibition of 
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glycolysis might also be a potential treatment strategy to re-sensitize IKZF1-deleted cells 
to prednisolone and should be explored in more detail in future studies, also in the context 
of BTG1 and PAX5 CNAs.
In contrast to high hyperdiploid cells, deletion of IKZF1 did not affect prednisolone 
sensitivity in primary BCR‑ABL1-like and B-other ALL cells, suggesting that additional 
factors (e.g. differentiation stage, oncogenic drivers) are important for the functional effect 
of a deletion of the IKZF1 gene in these type of cells. Instead of prednisolone resistance, 
we observed thiopurines resistance in these BCR‑ABL1-like and B-other ALL cells. 
Thiopurine resistance might be caused by deficiencies in the DNA mismatch repair system 
and indeed DNA repair genes were reported to be downregulated in IKZF1-deleted 
cells.40, 41 Interestingly, this characteristic might offer opportunities to target these leukemic 
cells via the DNA mismatch repair apparatus, e.g. by PARP inhibitors. The mechanism of 
thiopurines resistance and the condition of the DNA mismatch apparatus in these leukemic 
cells therefore requires further investigation.
Besides IKZF1, deletion of RB1 was predictive for a poor outcome in the MR-risk group 
of the DCOG ALL10 cohort. RB1 deletions are known to be enriched in poor prognostic 
iAMP21 and hypodiploid cases, which might explain the unfavorable outcome of RB1-
deleted cases.13, 42, 43 However, the unfavorable outcome could not be explained by or 
cellular resistance against induction therapy drugs.
In conclusion, results obtained in the present study revealed that, with the exception of an 
IKZF1 deletion, none of the remaining CNAs as single marker associated both with an 
unfavorable clinical prognosis and cellular drug resistance. Our results indicate that the 
biological and clinical importance of CNAs in B-cell development genes (and presumably 
also other genetic aberrations) is highly context dependent and differs between the diverse 
oncogenic drivers of pediatric BCP-ALL. Functional studies that focus on potential causes 
of cellular drug resistance should therefore take the oncogenic driver and additional 
genetic aberrations into account.
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SUPPLEMENTARY DATA
 
Number of patients
Cox multivariate model
  p-value HR 95% CI
IKZF1 30/210 0.003 3.406 1.523 - 7.618
PRED response 11/204 0.153 2.529 0.709 -9.024
MRD TP1 41/210 0.067 2.08 0.951 - 4.548
MRD TP2 8/210 0.503 0.495 0.063 - 3.883
Supplementary Table 1: COX multivariate analysis of risk factors within the DCOG-ALL10 cohort
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Supplementary Figure 1. CNA landscape of B-cell development genes in the different subtypes 
of pediatric BCP ALL.
CNA profile of 515 newly diagnosed pediatric BCP-ALL patients, representing the major BCP-
ALL subtypes, was determined using MLPA. (A) The frequency of any CNA (IKZF1, EBF1, PAX5, 
CDKN2A/B, RB1, BTG1, ETV6, and/or PAR1) is shown per subtype. One CNA was sufficient to be 
quantified as altered. **p≤0.01 (B) The association between IKZF1 deletions and BCP-ALL subtypes. 
IKZF1 deletions are depicted as deletion of exon 4-7, deletions of exon 1-8, or remaining deletions.
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Supplementary Figure 2. The association between CNAs and MRD levels after induction 
therapy and the first consolidation course in BRC-ABL1-like and B-other patients.
MRD levels of DCOG-ALL10 treated BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases after 
induction (TP1; n=47) and first consolidation course (TP2; n=46). The percentage of cases with high 
(≥10-3), medium (10-4  ≤  MRD  <  10-3), and undetectable MRD levels (<10-4) is depicted per CNA. 
Fisher’s Exact test. **p≤0.01, *p≤0.05. del = deletion.
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Supplementary Figure 3. The association between CNAs and MRD levels after induction 
therapy and the first consolidation course in high hyperdiploid patients.
MRD levels of DCOG-ALL10 treated high hyperdiploid cases after induction (TP1; n=60) and first 
consolidation course (TP2; n=59). The percentage of cases with high (≥10-3), medium (10-4 ≤ MRD < 10-3), 
and undetectable MRD levels (<10-4) is depicted per CNA. Fisher’s Exact test. **p≤0.01, *p≤0.05. 
del = deletion.
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Supplementary Figure 4. The association between CNAs and MRD levels after induction 
therapy and the first consolidation course in ETV6-RUNX1 patients.
MRD levels of DCOG-ALL10 treated ETV6‑RUNX1 cases after induction (TP1; n=65) and first 
consolidation course (TP2; n=66). The percentage of cases with high (≥10-3), medium (10-4 ≤ MRD < 10-3), 
and undetectable MRD levels (<10-4) is depicted per CNA. Fisher’s Exact test. **p≤0.01, *p≤0.05. 
del = deletion.
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Supplementary Figure 5. The association between any CNA and MRD levels after induction 
therapy and the first consolidation course.
MRD levels of DCOG-ALL10 treated BCP-ALL cases after induction (TP1; n=183) and first consolidation 
course (TP2; n=183). The MRD levels of cases with any or no CNA are depicted for all subtypes, 
BCR‑ABL1-like and non-BCR‑ABL1-like B-other, high hyperdiploid, and ETV6‑RUNX1.
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Supplementary Figure 6. Prognostic value of CNAs in DCOG-ALL10 treated cases.
The association between CNAs and cumulative incidence of relapse (CIR) or event-free-survival (EFS) 
was examined. Patients were treated according to DCOG-ALL10 protocol. CIR was estimated using a 
competing risk model. Relapse and non-response were considered as event, and death as competing 
event. To test equality of the CIRs, the Gray’s test was applied. Non-response, relapse, and death were 
considered as events for EFS. EFS rates were determined using Cox regression, and compared using the 
Wald test. (A) CIR and EFS curves of cases without or with a RB1 deletion. Curves contain either all risk 
groups, or the medium risk arm only. (B) CIR and EFS curves of BCR‑ABL1-like and non-BCR‑ABL1-like 
B-other cases without or with BTG1 deletions.
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Supplementary Figure  7. Cellular drug response and CNAs.
Leukemic cells were incubated for four days with an increasing concentration range of prednisolone 
(µg/ml), vincristine (µg/ml), L-asparaginase (IU/ml), daunorubicin (µg/ml), 6-mercaptopurine (µg/
ml), and 6-thioguanine (µg/ml), after which cell viability was measured using an MTT assay. Association 
between indicated CNAs and ex vivo cytotoxicity was studied. The Mann-Whitney U test was applied to 
compare LC50-values. * p < 0.05, ** p < 0.01 (A) LC50 values of L-asparaginase (IU/ml) of primary 
leukemic cells without or with IKZF1 deletion. Columns include all BCP-ALL subtypes, BCR‑ABL1-like/ 
B-other cells, and high hyperdiploid cells. (B) LC50 values of prednisolone (µg/ml) of primary leukemic 
cells without an IKZF1 or PAX5 CNA, with IKZF1 and PAX5 CNA, a PAX5 CNA without an IKZF1 del, 
or IKZF1 an del without a PAX5 CNA. (C) LC50 values of L-asparaginase (IU/ml) and 6-thiogunanine 
(µg/ml) of primary leukemic cells without or with ETV6 deletion. Columns include all BCP-ALL subtypes, 
BCR‑ABL1-like/ B-other cells, high hyperdiploid cells, and ETV6‑RUNX1‑positive cells.
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ABSTRACT
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells reside in the bone marrow, 
where mesenchymal stromal cells (MSCs) support many of their functions. Unraveling 
the role of the bone marrow niche in pediatric BCP-ALL may provide novel options for 
therapeutic intervention. The present study aimed to unravel whether MSCs derived from 
pediatric BCP-ALL patients at initial diagnosis (leukemic-MSCs) differ from MSCs derived 
from healthy pediatric donors (control-MSCs). Therefore, we studied their supportive 
properties and gene expression profiles.
Co-culture experiments of BCP-ALL cells and MSCs revealed that survival of BCP-ALL cells is 
significantly increased upon co-culture compared to survival in mono-culture. Both control-
MSCs and leukemic-MSCs provided a similar survival benefit. Strikingly, gene expression 
profiles of MSCs were significantly changed after co-culture with BCP-ALL cells. Each 
BCP-ALL sample induced a characteristic gene expression change, which was consistent 
between different MSCs. The interferon/STAT1 pathway was most commonly induced. 
In order to study the persistence of the gene expression changes, MSCs were cultured 
for approximately 14 days without leukemic cells. Microarray analysis of 86 primary 
MSCs revealed only marginal differences in gene expression between leukemic-MSCs 
and control-MSCs, which disappeared in MSCs derived from BCP-ALL patients at time 
of remission. Hence, results suggest that BCP-ALL cells drive gene expression changes in 
MSCs, which convert back to normal upon elimination of leukemic cells.
In conclusion, leukemic-MSCs are intrinsically not different from control-MSCs. Instead, 
BCP-ALL cells enforce a pro-inflammatory expression profile in MSCs, which coincides 
with an increased viability of BCP-ALL cells.
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INTRODUCTION
The effect of chemotherapy is often studied on the cancer cell as a single entity. 
However, the tumor microenvironment has a profound effect on the growth and survival 
of cancer cells and targeting of this niche might therefore offer an attractive treatment 
strategy.1-5 The tumor niche consists of cancer cells and a supporting framework, including 
mesenchymal stromal cells (MSCs), fibroblasts, endothelial cells, pericytes and a variety 
of inflammatory cells.2, 6 Chemokines such as IL-6, IL-1β, and SDF-1α are secreted to 
promote MSC migration toward this niche.1, 2, 7 However, the role of MSCs in the initiation 
and progression of cancer remains unclear. MSCs have been reported to exert stimulatory 
(e.g. induce proliferation) as well as inhibitory (e.g. induce apoptosis) effects on cancer 
cells.1, 8, 9 Unraveling the role of the tumor niche in cancer may provide novel options for 
therapeutic intervention.
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and arises 
from malignant transformation of either B- or T-cell progenitors. B-cell precursor ALL 
(BCP-ALL) accounts for approximately 85% of cases and can be further subdivided in 
genetic subtypes, such as BCR‑ABL1, ETV6‑RUNX1, TCF3‑PBX1, or KMT2A-rearranged 
ALL.10 Leukemic cells reside in the bone marrow microenvironment, where they hijack the 
normal hematopoietic stem cell niches to create a leukemic niche.11 Importance of the 
bone marrow microenvironment for leukemic cells is demonstrated by the protection that 
the niche provides against chemotherapeutic agents.12, 13 In in vitro assays MSCs mimic this 
protective effect.14-19 Unraveling the mechanism of protection may provide novel options for 
therapeutic intervention. Therefore, research is focused on the interaction between MSCs 
and leukemic cells.19-23 We recently showed that MSCs and BCP-ALL cells communicate 
via tunneling nanotubes.14 Disruption of this interaction inhibited leukemogenesis and re-
sensitized BCP-ALL cells to prednisolone.14 These results point to an important role of MSCs 
in ALL. We therefore questioned whether MSCs derived from pediatric BCP-ALL patients 
differ from MSCs obtained from healthy pediatric controls. To address this, the supportive 
properties of these MSCs were compared as well as their gene expression profiles.
METHODS
Processing of primary patient material
Bone marrow and/or peripheral blood samples were obtained from children (1-18 
years) with newly diagnosed ALL. Written informed consent was obtained from parents 
or guardians to use excess of diagnostic material for research purposes, as approved 
by the institutional review board. These studies were conducted in accordance with the 
Declaration of Helsinki. Mononuclear cells were isolated and processed as described 
previously.24 Samples were enriched to over 90% purity of leukemic cells by depletion of 
non-leukemic cells using immunomagnetic beads. Primary leukemic cells were maintained 
in RPMI-1640 Dutch modification (Life Technologies, Breda, Netherlands) supplemented 
with 20% fetal calf serum (Integro, Zaandam, Netherlands), with 0.1% insulin-transferrin-
sodium selenite (Sigma-Aldrich, Zwijndrecht, Netherlands), 0.4 mM glutamine (Invitrogen, 
Bleiswijk, Netherlands), 0.25 µg/ml gentamycine (Thermo Scientific, Breda, Netherlands), 
100 IU/ml penicillin (Thermo Scientific), 100 µg/ml streptomycin (Thermo Scientific), 
0.125 µg/ml fungizone (Thermo Scientific). 
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The major cytogenetic subtypes, i.e. high hyperdiploid (51-65 chromosomes), 
ETV6‑RUNX1, TCF3‑PBX1, KMT2A-rearranged, BCR‑ABL1, BCR‑ABL1-like and B-other 
(negative for all before mentioned genomic lesions), were determined using fluorescent 
in situ hybridization, (RT-)PCR and a 110-probeset gene expression classifier (to identify 
BCR‑ABL1-like cases).25 
Isolation and expansion of BM-MSC 
Bone marrow (BM) aspirates were collected from children with newly diagnosed 
BCP-ALL (leukemic-MSCs), after 79 days of induction and consolidation treatment 
(remission-MSCs), relapsed BCP-ALL (relapse-MSCs) or from children with healthy bone 
marrow (control-MSCs). Written informed consent was obtained from parents or guardians 
to use excess of diagnostic material for research purposes, as approved by the institutional 
review board. MSCs were isolated from these aspirates as described previously.26 Briefly, 
BM aspirates were seeded in MSC expansion medium (DMEM low glucose medium (Life 
Technologies), 15% FCS (Integro), fungizone (Invitrogen), gentamycin (Invitrogen), freshly 
supplemented with 0.1 mM ascorbic acid (Sigma-Aldrich) and 1 ng/ml basic fibroblast 
growth factor (bFGF; Serotec, Kidlington, UK). Non-adherent cells were removed after 24 
hours. After a maximum of 10 days, MSC colonies were harvested using trypsin (Thermo 
Scientific). Cells were further expanded for one or two additional passages in order to 
isolate RNA (Trizol, Invitrogen, Bleiswijk, Netherlands) and freeze cells in liquid nitrogen 
for future experiments. MSCs were negative for the hematopoietic markers (CD14, CD34, 
CD45; BD Biosciences, San Jose, CA, USA), and positive for the mesenchymal markers 
(CD13, CD29, CD54, CD73, and CD166; BD Biosciences) as detected by flow cytometry 
(BD Accuri C6 Plus). Multi-lineage potential was confirmed for adipocyte (Oil Red O 
staining), osteocyte (Alizarin Red S staining), and chondrocyte (Col2a/Thionine/Alcian 
Blue staining) differentiation (Figure S1).
Cell viability assays
Primary BCP-ALL cells (1*106 cells) were co-cultured with or without MSCs (5*104 cells) 
for two or five days in a 24 well plate at 37°C and 5% CO2. To analyze BCP-ALL cell 
viability, cells were stained with Brilliant Violet 421 anti-human CD19 antibody (Biolegend 
San Diego, CA, USA), FITC Annexin V (Biolegend), and propidium iodide (PI; Invitrogen). 
Cell viability was quantified using flow cytometry (MACSQuant). Within the MSC-
negative fraction, the percentage of AnnexinVneg/PIneg/CD19pos cells was determined 
using FlowJo 10.0.8r1, as described previously.14
Fluorescent Activated Cell Sorting
Primary BCP-ALL cells (5*106 cells) from four different patients (n=2 ETV6‑RUNX1 (ALL 
sample 2 and 3), n=2 B-other (ALL sample 1 and 4) were co-cultured with primary MSCs 
(2.25*105 cells) derived from six different donors (n=2 control-MSCs, n=4 leukemic-MSCs 
(n=2 derived from ETV6‑RUNX1 patients, n=2 derived from B-other patients)) in a 6 well 
plate at 37°C and 5% CO2. After 40 hours of culture, BCP-ALL cells and MSCs were 
separated using fluorescent-activated cell sorting (FACS; BD FACSCanto). Cells were 
stained with Brilliant Violet 421 anti-human CD19 (Biolegend), Brilliant Violet 421 anti-
human CD45 antibody (Biolegend), and PI. MSCs and BCP-ALL cells were separated 
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based on size in the FSC/SSC plot, after which we selected for viable (PInegative) cells. 
CD19 and CD45 negativity was the final gating strategy applied to select for MSCs. RNA 
of sorted MSCs was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). RNA 
quality of one MSC sample was poor and therefore not included for microarray analyses.
Microarrays
RNA was extracted using either Trizol (Invitrogen), or the RNeasy mini kit (Qiagen), 
according to the manufacturer’s protocol. RNA quality and integrity was analyzed using the 
2100 Bioanalyzer (Agilent, Amstelveen, Netherlands). Good quality RNA (RIN > 6.9) was 
labeled, fragmented, and linearly amplified with the Affymetrix GeneChip 3’IVT Express Kit 
(Santa Clara, CA, USA), according to the manufacturer’s protocol. Fragmented, amplified 
RNA was hybridized on Affymetrix U133 Plus 2.0 GeneChip arrays for 16 hours. Arrays 
were washed and stained using the GeneChip Fluidics Station 450, and scanned using the 
Affymetrix GeneChip Scanner 3000. Affymetrix Microarray Suite version 5.0 was used 
to assess gene-expression values. Expression signals were scaled to the target intensity of 
500 and log transformed. Arrays were variance stabilization and normalization 2 (VSN2) 
normalized.27 To identify differentially expressed probesets Limma R Package (version 3.26.9) 
was used in R 3.0.1. Principal component analyses were performed in Partek Genomic Suite 
6.6. The data in this paper have been submitted at Gene Expression Omnibus28 and are 
accessible through GEO Series accession numbers GSE101454 and GSE101425. 
Quantitative RT-PCR (RT-qPCR)
STAT1, IFI6 and IFITM1 mRNA levels were quantified by incorporation of SYBR Green 
(Thermo Scientific, Breda, Netherlands) by RT-qPCR. For this purpose the following primer 
pairs were used: 5’-acccaatccagatgtctatg-3’ and 5’-ttttgcatttgaagtcatattc-3’ (STAT1), 
5’-aggccctgaccttcat-3’ and 5’-cagggcaccaatattacc-3’ (IFI6), and 5’-ccaccgtgatcaaca 
tcc-3’ and 5’-ccccgtttttcctgtattatc-3’ (IFITM1), and 5’-gtcggagtcaacggatt-3’ and 5’-
aag cttcccgttctcag-5’ (GAPDH). Relative mRNA levels as percentage of GAPDH levels 
were calculated using the comparative cycle time (Ct) method; 2-ΔCt x 100%, with 
ΔCt = Ctgene - CtGAPDH. 
Multiplexed fluorescent bead-based immunoassay (Luminex) and ELISA
Primary leukemic cells were co-cultured with primary MSCs at 37°C and 5% CO2. After 
two or five days of culture supernatant was collected. To remove cell debris, supernatant 
was centrifuged. The concentration of 64 cytokines/chemokines was analyzed using a 
fluorescent bead-based immunoassay (Luminex Human Cytokine/Chemokine Panel I and 
II; Merck Millipore, Amsterdam, Netherlands) according to the manufacturer’s protocol. 
For ELISA assays, MSCs were cultured for two days in the presence of 10pg or 10ng IFNα 
(Clone: MMHAR-2; PBL Assay Science; Piscataway, NJ, USA). Supernatant was collected 
and IP-10 secretion was determined using an ELISA assay (R&D Systems, Minneapolis, 
MN, USA), according to the manufacturer’s protocol.
Transfection, virus production and transduction
To silence the expression of STAT1 in MSCs, three pLKO.1-puro Mission® vectors 
(Sigma-Aldrich) were used, containing a short hairpin RNA (shRNA) targeting STAT1 
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(TRCN0000004264 (shRNA-3), TRCN0000004265 (shRNA-2) and TRCN0000004267 
(shRNA-1)). The Mission ® pLKO.1-puro Non-Mammalian shRNA Control Plasmid 
DNA (SHC002; NSC-2) and Mission® pLKO.1-puro Luciferase shRNA Control Plasmid 
DNA (SHC007; NSC-1) were used as scrambled controls. Vectors were transfected 
in 70-80% confluent HEK293T cells, using X-tremeGene 9 DNA transfection reagent 
(Roche, Woerden, Netherlands), 3.7 µg psPAX2 (Addgene plasmid 12260; Addgene, 
Cambridge, MA, USA), 1.6 µg pMD2.G (Addgene plasmid 12259) and 10.7 µg of one 
of the pLKO.1-puro Mission® vectors. The second and third day after transfection virus was 
harvested and concentrated using ultracentrifugation for 2 hours at 32.000rpm and 4°C 
(Optima L-90K Ultracentrifuge; Beckman Coulter, Woerden, Netherlands). Concentrated 
virus was aliquoted and stored at -80°C. MSCs were transduced by spin-infection. To 
select for stable transduced cells, puromycin selection was used. 
Western Blotting
Cells were lysed in RIPA lysis buffer (Thermo Scientific) with freshly added protease and 
phosphatase inhibitors. Protein concentration was determined using the BCA method 
(Thermo Scientific). After denaturation, 15µg protein was loaded on a 10% mini protean 
precast gel (BioRad) and proteins were separated by electrophoresis. Proteins were 
transferred to a nitrocellulose membrane and membranes were blocked in 5% milk for 
1 hour at room temperature. Primary antibody incubation was performed according to 
manufacturer’s protocol. Anti-phospho-STAT1Tyr701 (#9167), anti-STAT1 (#9176) and 
anti-αTubulin (#2144) were obtained from Cell Signaling Technology (Danvers, MA, USA). 
Blots were stained with secondary antibodies (IRDye 680RD- or 800CW-labeled anti‐
rabbit and IRDye 680RD- or 800CW‐labeled anti‐mouse (Li‐Cor Biosciences, Leusden, 
Netherlands) for 1 hour at room temperature. Blots were evaluated using the Odyssey 
infrared imaging system (Li-Cor Biosciences). 
RESULTS
MSCs derived from leukemia patients and healthy controls both support the survival 
of ALL cells
Previously we observed that primary MSCs support the viability of primary ALL cells.14 
We questioned whether support given by MSCs derived from pediatric BCP-ALL patients 
at initial diagnosis (leukemic-MSCs) differs from that of MSCs derived from healthy 
pediatric donors (control-MSCs). The percentage of viable leukemic cells (AnnexinV-/
PI-negative, CD19-positive) was measured in mono-culture and co-culture with control-
MSCs or leukemic-MSCs. Primary BCR‑ABL1-positive and TCF3‑PBX1-positive cells 
hardly survived in mono-culture conditions (<2% Annexin-/PI-negative, CD19-positive 
cells), but upon co-culture with leukemic-MSCs or control-MSCs survival was significantly 
increased (p<0.05, Figure 1A-B, Figure S2A-B). Control-MSCs and leukemic-MSCs did 
not differ in their effect on the survival of BCR‑ABL1-positive (13% versus 16%, respectively) 
and TCF3‑PBX1-positive cells (5% versus 5%, respectively). Survival of ETV6‑RUNX1-
positive and KMT2A-rearranged cells was relatively high in mono-culture compared to 
BCR‑ABL1-positive and TCF3‑PBX1-positive cells (56% and 23% Annexin/PI-negative 
CD19-positive cells, respectively), and was even more increased upon co-culture with 
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Figure 1. BCP-ALL cell survival is increased upon co-culture with MSCs obtained from leukemia 
patients and healthy donors.
The survival of primary CD19+ BCP-ALL cells in mono-culture (black) was compared to the survival 
in co-culture with two different control-MSCs or two different leukemic-MSCs (white). BCP-ALL cell 
survival was assessed after five days of culture using flow cytometry. Leukemic cell survival (AnnexinV-/
PI-) was quantified in the CD19-positive fraction. Mean ± SEM of independent samples is shown. 
Paired Samples T-test. ** p ≤ 0.01, * p ≤ 0.05. (A-D) Percentage of viable primary leukemic cells 
(n=3 BCR‑ABL1, n=3 TCF3‑PBX1, n=3 ETV6‑RUNX1, n=2 KMT2A-rearranged) in mono-culture or 
co-culture with control-MSCs (n=2) or leukemic-MSCs (n=2).
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MSCs (Figure 1C-D, Figure S2C-D). Both control-MSCs and leukemic-MSCs provided 
a similar survival benefit for ETV6‑RUNX1-positive (69% versus 70%, respectively) and 
KMT2A-rearranged cells (28% versus 25%, respectively). Taken together, the increased 
survival of primary BCP-ALL cells in co-culture with MSCs does not depend on the source 
of MSCs. 
ALL cells induce an inflammatory-like signature in MSCs
Both leukemic-MSCs and control-MSC supported survival of BCP-ALL cells. To gain 
insight in the mechanism by which MSCs support leukemic cell survival, gene expression 
analyses were performed of MSCs upon co-culture with BCP-ALL cells. MSCs (n=6) were 
cultured for 40 hours in the presence of BCP-ALL cells (derived from 4 pediatric BCP-ALL 
patients). Microarray analyses were performed on sorted MSCs (Figure 2A, Figure S3). 
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Figure 2. Gene expression profiles of MSC change after co-culture with leukemic cells.
(A) Primary BCP-ALL cells (n=2 B-other, n=2 ETV6‑RUNX1 samples) were co-cultured with six different 
primary MSCs (n=2 control-MSCs, n=4 leukemic-MSCs) for 40 hours. Supernatant was collected to 
determine the cytokine/chemokine profile. MSCs were separated from BCP-ALL cells using FACS. 
Purity of sorted samples was assessed afterwards by flow cytometry. RNA from the sorted MSCs was 
isolated and gene expression profiling was performed. (B) Limma analyses were performed to identify 
differentially expressed probesets (adj. p < 0.05) in MSCs upon co-culture with BCP-ALL cells. MSCs 
were compared to the mono-culture of the same MSCs. The Venn Diagram represents differentially 
expressed probesets (adj. p < 0.05). ALL1 (B-other), ALL2 (ETV6‑RUNX1), ALL3 (ETV6‑RUNX1) and 
ALL4 (B-other) altered expression of 257, 8, 1676, 5 probesets, respectively. (C) Increased expression 
levels of STAT1 (probeset:  AFFX-HUMISGF3a) in MSCs upon co-culture with primary BCP-ALL cells. 
Expression values in co-culture were normalized to expression values in mono-culture. ** adj. p < 0.01. 
(D) Increased expression levels of IFI6 (probeset 204415_at), and IFITM1 (probeset: 214022_at) in 
MSCs upon co-culture with primary BCP-ALL cells. Expression values in co-culture were normalized to 
expression values in mono-culture. ** adj. p<0.001. (E) Expression levels of STAT1, IFI6, and IFITM1 
determined by gene expression profiling was correlated with levels determined by RT-qPCR. Spearman 
correlation coefficients are shown. p<0.0001.
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Limma analyses revealed multiple genes to be differentially expressed in MSCs upon 
co-culture with BCP-ALL cells compared to mono-cultures of these MSCs. Alterations were 
independent of the MSC source (leukemic-MSC or control-MSC), but most strikingly, 
the changed gene expression profile depended on the source of the leukemia sample. 
Co-culture of an identical BCP-ALL sample with six different MSCs induced similar changes 
in gene expression in all MSCs. Each BCP-ALL sample induced a specific profile, resulting 
into an altered expression ranging from 5 to 1676 probesets in MSCs (adj. p<0.05; Figure 
2B). Although the number of probesets altered by ALL patient 2 (ALL2) and ALL patient 
4 (ALL4) were low, differentially expressed genes overlapped with those induced by ALL 
patient 1 (ALL1) and ALL patient 3 (ALL3; 7/8 and 5/5, respectively). To study whether 
specific pathways were affected, Ingenuity pathway analysis was performed. Interestingly, 
the interferon pathway was significantly upregulated in MSCs after co-culture with ALL1, 
ALL3, and ALL4 (p < 1E-07; Figure S4). The inflammation-associated transcription factor 
STAT1 was the most upstream gene in the pathway for which expression levels were 
changed (Figure 2C, Figure S4). In addition, also genes more downstream in the pathway 
were affected (e.g. IFI6 and IFITM1, Figure 2D, Figure S4). Upregulation of STAT1, IFI6, 
and IFITM1 was validated using RT-qPCR (Figure 2E). Taken together, gene expression 
profiles of MSCs were significantly changed after co-culture with primary BCP-ALL cells. 
These results indicate that BCP-ALL cells drive gene expression changes in MSCs. Although 
induced changes were leukemia-sample specific, three out of the four ALL samples 
upregulated the interferon/STAT1 pathway in MSCs. 
Gene expression profiles of MSCs from leukemia patients are comparable to 
control-MSCs
In order to study the persistence of the induced changes in the gene expression profile of 
MSCs, MSCs were cultured for approximately 14 days without leukemic cells. Microarray 
analyses were performed of primary MSCs derived from bone marrow samples collected 
at initial diagnose (n=35; leukemic-MSCs), after induction and consolidation therapy 
when patients are in remission of their leukemia (n=29; remission MSCs), and at relapse 
(n=6; relapse-MSCs). These profiles were compared to the gene expression profile of 
16 control-MSCs. Limma analyses revealed 234 probesets to be differentially expressed 
between leukemic-MSCs and control-MSCs (adj. p<0.05; Figure 3A). Strikingly, only 27 
probesets overlapped with the probesets induced in MSCs upon co-culture with BCP-ALL 
cells. In addition, none of the 234 differentially expressed probesets could classify MSCs 
as either healthy or leukemic. Variation between samples was large and fold-changes 
were low, as visualized in Figure 3B-C for the probesets with the highest and lowest fold 
change. Principal component analyses revealed that MSCs could not be classified by origin 
using this gene expression signature (Figure 3D). Additionally, pathway analysis revealed 
a low number of differentially expressed genes per pathway (≤ 5) between control-MSCs 
and leukemic-MSCs (overlap < 11%), suggesting no strong difference between leukemic-
MSCs and control-MSCs. Furthermore, no overlap with pathways induced upon co-
culture with BCP-ALL cells was observed (Figure S5A). In relapse MSCs, one probeset was 
significantly upregulated compared to control-MSCs, though this upregulation was only 
observed in two samples (Figure S5B). Most strikingly, remission-MSCs were similar to 
both control-MSCs and leukemic-MSCs (Figure 3A-B). As these MSCs were isolated after 
induction and consolidation therapy, these results suggest that gene expression changes 
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Figure 3. Gene expression signatures of MSCs derived at various time-point of leukemia or 
healthy controls.
Gene expression profiling of 86 primary MSCs isolated from 35 newly diagnosed BCP-ALL cases 
(leukemic-MSCs), 29 patients after 79 days of (induction and consolidation) therapy (remission-
MSCs), 6 relapse patients (relapse-MSCs), and 16 MSCs healthy controls (control-MSCs). (A) Venn 
Diagram showing Limma results of significant differentially expressed probesets (adj. p < 0.05). 234 
probesets were differentially expressed between leukemic-MSCs and control-MSCs. One probeset 
was differentially expressed between relapse-MSCs and control-MSCs. (B) Significant difference in 
RGS4 expression levels between leukemic-MSCs and control-MSCs. RGS4 represents the probeset 
with the largest positive log fold change. * adj. p < 0.05. (C) Significant difference in CXCR7 expression 
levels between leukemic-MSCs and control-MSCs. CXCR7 represents the probeset with the largest 
negative log fold change. * adj. p < 0.05. (D) PCA analyses of the 234 differentially expressed from 
panel A. Control-MSCs are depicted in black, leukemic-MSCs in green, remission-MSCs in blue, and 
relapse MSCs in grey.
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between control-MSCs and leukemic-MSCs are transient. For example, the expression of 
RGS4 was significantly higher in leukemic-MSCs compared to control-MSC, but reduced 
to almost normal levels after induction and consolidation therapy (remission-MSCs; Figure 
3B). Taken together, changes induced in the gene expression profile of MSCs upon 
co-culture with BCP-ALL cells are not persistent. Furthermore, our results imply that only 
marginal differences exist in gene expression between leukemic-MSCs and control-MSCs. 
Changes are likely induced by the presence of leukemic cells, since elimination of leukemic 
cells (remission-MSCs) restores gene expression profiles.
Interference with the STAT1 pathway
Our results indicate that an increased survival of BCP-ALL cells, coincides with a changed 
gene expression profile in MSCs. These changes are not persistent, but rather restored upon 
elimination of leukemic cells and therefore indicate that BCP-ALL cells drive the altered gene 
expression program of MSCs. The interferon/STAT1 pathway was most frequently induced, 
suggesting importance of the pathway in the interaction between leukemic cells and MSCs. 
Interestingly, in mesenchymal progenitors activation of interferon/STAT1 responses regulate 
the differentiation and proliferation of hematopoietic stem cells (HSCs) and pathway activation 
is characterized by secretion of the pro-inflammatory CXC chemokine ligand 10 (CXCL10, 
IP-10).8 In the leukemia-sample that most strongly induced STAT1 and its downstream targets 
(ALL3), we also observed the secretion of IP-10 upon co-culture with MSCs (Figure 4A). 
As inflammatory signals have been reported to promote proliferation and differentiation of 
HSCs,17, 18, 29, 30 we questioned whether BCP-ALL cells use similar features for their expansion. 
Activation of the interferon/STAT1 pathway in MSCs was mimicked by IFNα exposure, 
inducing expression of STAT1, IFI6 and IFITM1 mRNA expression levels (Figure 4B) and 
secretion of IP-10 (Figure 4C), suggesting that MSCs are the source of the chemokine. To 
further elucidate the therapeutic potential of interferon/STAT1 pathway, STAT1 expression 
was silenced in three MSCs. Efficiency of gene silencing ranged between 60% and 80% 
(Figure 5A-B). Knockdown of STAT1 in MSCs did not affect the increased survival of BCP-ALL 
cells upon co-culture with MSCs, demonstrated by a comparable survival of leukemic cells 
after two and five days of co-culture with STAT1-silenced-MSCs and scrambled-control-
MSCs (Figure 5C). Secretion of IP-10 was only detected after co-culture of MSCs with ALL3. 
Although secretion was below limit of detection in MSCs transduced with shRNA-2, no effect 
on secretion levels was observed in MSCs transduced with shRNA-1 and shRNA 3 (Figure 
S6). Taken together, these preliminary results suggest that knockdown of STAT1 in MSCs does 
not affect the survival benefit of BCP-ALL cells induced by MSCs.
DISCUSSION
In recent years, it has been increasingly recognized that the tumor microenvironment has 
an essential role in cancer initiation and progression.31 Tumor cells can take advantages 
of niche specific signaling, manipulate their microenvironment to promote survival, or 
cancer might even be the consequence of a disrupted microenvironment.32-34 Unraveling 
the role of the bone marrow niche in pediatric BCP-ALL may provide novel options for 
therapeutic intervention. Results presented in this study indicate that leukemic-MSCs are 
not intrinsically different compared to control-MSCs. However, BCP-ALL cells instruct 
MSCs to change their phenotype. 
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Figure 4. STAT1 signaling and IP-10 secretion.
(A) Levels of secreted chemokines/cytokines were determined in the supernatant of MSC and BCP-ALL 
after 40 hours of mono-culture (n=6 MSCs; n=4 ALL samples) or co-culture (n=24; see Figure 2A). 
Supernatant was removed from cell cultures and centrifuged to remove cell debris. IP-10 levels were 
determined using a multiplexed fluorescent bead-based immunoassay. Signal intensity values of MSC 
mono-culture samples was subtracted from corresponding ALL/MSC co-culture fractions. Mean ± SEM 
of IP-10 levels in ALL mono-cultures or ALL/MSC co-cultures is shown. nd=not detectable/ below limit 
of detection. (B) MSCs (n=8) were stimulated for 48 hours with 10 pg or 10 ng IFNα. Expression of 
STAT1, IFI6, and IFITM1 was determined using RT-qPCR. Relative mRNA expression levels towards 
GAPDH are shown. Mean ± SEM of eight independent samples is shown. Paired Samples T-test. ** p 
≤ 0.01. (C) MSCs (n=8) were stimulated for 48 hours with 10 pg or 10 ng IFNα. Levels of IP-10 in the 
supernatant of (non-)IFNα-exposed MSC cultures were determined using ELISA. Mean ± SEM of eight 
independent samples is shown. Paired Samples T-test. ** p ≤ 0.01.
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Figure 5. Knockdown of STAT1 in MSCs does not alter the survival benefit for BCP-ALL cells.
STAT1 was silenced in MSCs (n=3) using three different shRNAs against STAT1. (A) Western blot 
analyses of STAT1 and αTubulin expression levels in 15 µg lysate of the three MSCs. (B) Quantified 
protein expression levels of STAT1 relative to αTubulin. Mean ± SEM of three independent samples 
is depicted. (C) Percentage of viable primary leukemia cells (n=4) in mono-culture compared to the 
survival in co-culture with MSCs (n=3). BCP-ALL cell survival was assessed after two or five days of 
culture using flow cytometry. Leukemic cell survival (AnnexinV-/PI-) was quantified in the CD19+-
positive fraction. Mean ± SEM of three independent samples is depicted.
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Our data revealed that both control-MSCs and leukemic-MSCs promote the survival 
of primary BCP-ALL cells. No difference in support between both sources of MSCs was 
observed. Moreover, gene expression profiles of MSCs were significantly changed after 
co-culture with primary BCP-ALL cells. Each BCP-ALL sample induced a characteristic 
148
Chapter 6
gene expression change, which was consistent between different MSCs. These results 
suggest that BCP-ALL cells drive gene expression changes in MSCs. This change in gene 
expression was only transient, as elimination of leukemic cells (remission-MSCs) restored 
gene expression levels back to levels as observed in control-MSCs. Although conflicting 
results have been reported concerning the genetic background of MSCs in pediatric 
BCP-ALL,21, 35, 36 our results indicate that MSCs derived from pediatric BCP-ALL cases are 
not abnormal. Rather BCP-ALL cells have a transient effect on the gene expression profile 
MSCs, which coincides with an increased survival of leukemia cells. 
Dysfunction of the bone marrow has been reported to contribute to the development of 
myeloid malignancies and vice versa leukemogenesis can induce abnormal bone marrow 
niches.37-41 Moreover, these niche supporting properties seem to be leukemia-type specific: 
osteoblastic cell-specific activation attenuated chronic myeloid leukemia (CML), but in 
turn enhanced acute myeloid leukemia progression.41 In a T-cell ALL mice model, normal 
hematopoiesis was suppressed by leukemic cells that hijacked the proliferative vascular 
space and repressed the endosteal niche.23 In addition, pro-inflammatory cytokines 
are responsible for the reinforcement of the leukemic niche in CML.40 In line with these 
data, results obtained in the present study imply that MSCs are not actively involved in 
the initiation of BCP-ALL nor the induction of a relapse. Rather BCP-ALL cells manipulate 
the bone marrow niche. Further research is required to confirm our findings and unravel 
whether the altered gene expression profile of MSCs attenuates normal hematopoiesis 
and favors leukemogenesis.
The interferon/STAT1 pathway was the most commonly induced pathway in MSCs upon 
co-culture with primary BCP-ALL cells. Induction of a pro-inflammatory expression profile 
in MSCs is in concordance with a study focusing on the interaction between acute myeloid 
cell lines and MSCs.22 The inflammation-associated transcription factor STAT1 is involved 
in a variety of cellular processes and is generally considered as tumor suppressor.42 
However, emerging data suggest a role for STAT1 in tumorigenesis.42, 43 In addition, 
inflammatory signals are reported to promote proliferation and differentiation of HSCs.17, 18, 
29, 30 To preserve self-renewing capacity and prevent stem cell exhaustion, HSCs generally 
remain in a quiescent, dormant state. Though, under certain conditions of stress, HSCs can 
be stimulated to proliferate and differentiate in order to replenish lineages which are lost.17 
It has been postulated that stress, e.g. inflammation, increases the risk of accumulation 
of genetic alterations in HSCs, which can facilitate leukomogenesis.18, 32, 34 Moreover, 
activation of the interferon/STAT1 pathway in murine endosteal mesenchymal progenitors 
induced proliferation and differentiation of HSCs and resulted in an overproduction of 
IP-10.8 BCP-ALL cells may use similar features as HSCs for their expansion, suggesting 
involvement of STAT1 in leukemogenic processes. Our preliminary data did not reveal 
that STAT1 expression is essential for the viability of BCP-ALL cells. However, residual 
expression levels of STAT1 or rescue via alternative pathways may have occurred and 
therefore the role of the interferon/STAT1 pathway in BCP-ALL remains elusive.44
To communicate, leukemic cells and MSCs need to signal, which can occur through 
soluble factors and cellular projections.45 In the present study, we observed secretion 
of IP-10 upon co-culture of MSCs and BCP-ALL cells. IP-10 can be secreted from a 
variety of cells under pro-inflammatory conditions (e.g. stromal cells, monocytes) and 
has been implicated in several types of cancers.46 Co-culture of primary BCP-ALL cells 
with monocytes also resulted in secretion of IP-10, which induced migration and invasion 
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of leukemic cells.47 Our results point to a potential similar mechanism induced by the 
interaction between leukemic cells and MSCs. This is further strengthened by our recent 
study, in which we showed that co-culture of BCP-ALL cells and MSCs creates a niche that 
facilitates migration of additional leukemic cells, but not of healthy CD34+ cells.48 Besides 
interaction via soluble factors, tunneling nanotubes can form a physical connection 
between ALL cells and MSCs.14 These tunneling nanotubes can transfer various cargo, e.g. 
mitochondria and autophagosomes.45, 49, 50 Autophagy is a known regulator of cytokine 
signaling and hence transfer of autophagosomes via these tunneling nanotubes might 
explain the release of CXCL10.49, 51 In addition, transfer of structures via these tunneling 
nanotubes might be an explanation for the altered gene expression observed in MSCs in 
the present study. Targeting this direct communication between BCP-ALL cells and MSCs 
or downstream factors of these processes might offer alternative treatment approaches.
In conclusion, our results indicate that the gene expression profile of leukemic-MSCs 
is intrinsically not different from that of control-MSCs. However, BCP-ALL cells enforce 
changes in the gene expression profile of MSCS, which coincide with an increased 
viability of BCP-ALL cells. These changes are transient and are restored upon removal of 
leukemic cells. Therefore, our results suggest that the bone marrow microenvironment by 
itself is not leukemogenic, but is actively being hijacked by leukemic cells to support the 
pathogenesis of BCP-ALL. Targeting this interplay between leukemic cells and MSCs might 
represent a novel treatment approach. 
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SUPPLEMENTAL DATA
Supplementary Figure 1. Multi-lineage potential of MSCs.
Multi-lineage potential of isolated primary MSCs was confirmed for adipocyte (Oil Red O staining), 
osteocyte (Alizarin Red S staining), and chondrocyte (glycosaminoglycan (GAG) staining and Col2a/
Thionine/Alcian Blue staining) differentiation. A representative experiment is shown, which equals the 
patterns seen for all leukemic-MSCs and control-MSCs used in this study.
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Supplementary Figure 2. BCP-ALL cell survival is supported by control-MSCs and leukemic-
MSCs.
Survival of primary CD19+ BCP-ALL cells, co-cultured with two different sources of control-MSCs 
and leukemic-MSCs (CD19-). BCP-ALL cell survival was assessed after five days of culture using flow 
cytometry. Leukemic cell survival (AnnexinV-/PI-) was quantified in the CD19+-positive fraction. MSCs 
depicted in grey represent control-MSCs. MSCs depicted in black represent leukemic-MSCs. (A-D) 
Survival of three BCR‑ABL1-positive (A), three TCF3‑PBX1-positive (B), four ETV6‑RUNX1-positive (C), 
and two KMT2A-rearranged (D) samples on two different sources of control-MSCs and two different 
sources of leukemic-MSCs. Values of each individual sample are shown.
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Supplementary  3. Gating strategy and flow cytometry of sorted samples.
(A) Primary BCP-ALL cells (n=2 B-other, n=2 ETV6‑RUNX1 samples) were co-cultured for 40 hours 
with six different sources of primary MSCs (n=2 control-MSCs, n=4 leukemic-MSCs) for 40 hours. 
MSCs were separated from BCP-ALL cells using FACS. Purity of sorted samples was assessed by flow 
cytometry. RNA from the sorted MSCs was isolated and gene expression profiling was performed. RNA 
quality of one sample was poor (RIN<6) and therefore excluded from analysis. (B) Gating strategy of 
FACS experiment. A pre-separation was made based on FSC/SSC. Subsequently, we selected for 
viable (PI-) cells, and CD19- and CD45  cells. MSCs are slightly autofluorescent in the APC channel, 
which was also used to separate BCP-ALL cells and MSCs. (C) Purity of two sorted MSCs samples was 
examined using flow cytometry.
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Top Canonical Pathways p-value Overlap
Interferon Signaling 1.71E-14 30.6 % 11/36
Retinoic acid Mediated Apoptosis Signaling 2.20E-05  9.8 % 6/61
Mitotic Roles of Polo-Like Kinase 3.47E-05  9.1 % 6/66
Death Receptor Signaling 2.23E-04  6.5 % 6/92
Activation of IRF by Cytosolic Pattern Recognition Receptors 2.81E-04  8.1 % 5/62
Top Upstream Regulators p-value of overlap Predicted Activation
IFNL1 7.36E-34 Activated
IFNA2 5.08E-31 Activated
IRF7 1.11E-28 Activated
PRL 2.15E-27 Activated
MAPK1 3.81E-24 Inhibited
Summary of Analysis - ALL1
Supplementary Figure 4A. Ingenuity Pathway Analyses results. changes in MSCs induced by 
ALL1.
(A-D) The probesets, which were differentially expressed (Limma; adj. p < 0.05) in MSCs (n=6) after 
co-culture with primary leukemic samples (n=4) compared to MSC monocultures were analyzed using 
Ingenuity Pathway Analysis. Top 5 most significant canonical pathways and upstream regulators are 
shown per BCP-ALL sample (ALL1-ALL4). In the interferon/STAT1 pathway, significantly altered genes 
are depicted in red. (Figure continued on the next pages)
 Top canonical pathways P-value Overlap
Interferon Signaling I 1.71E-14 30.6% (11/36)
Retinoic acid Mediated Apoptosis Signaling 2.20E-05 9.8% (6/61)
Mitotic Roles of Polo-Like Kinase 3.47E-05 9.1% (6/66)
Death Receptor Signaling 2.23E-04 6.5% (6/92)
Activati  f IRF by Cyt solic Pattern Recognition Receptors 2.81E-04 8.1% (5/62)
Summary of Analysis - ALL1
 Top upstream regulators P-value Predicted activation
IFNL1 7.36E-34 Activated
IFNA 5.08E-31 Activated
IRF7 1.11E-28 Activated
PRL 2.15E-27 Activated
MAPK1 3.81E-24 Inhibited
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Top Canonical Pathways p-value Overlap
Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I 5.46E-03  4.3 % 1/23
Glycolysis I 5.93E-03  4.0 % 1/25
Gluconeogenesis I 5.93E-03  4.0 % 1/25
Pyrimidine Ribonucleotides Interconversion 7.59E-03  3.1 % 1/32
Pyrimidine Ribonucleotides De Novo Biosynthesis 8.06E-03  2.9 % 1/34
Top Upstream Regulators p-value of overlap
NEDD9 3.42E-08
salirasib 1.06E-07
paroxetine 9.37E-06
COMMD1 1.02E-05
HIF1A 4.11E-05
Summary of Analysis - ALL2
Supplementary Figure 4B. Ingenuity Pathway Analyses results. changes in MSCs induced by 
ALL2.
(A-D) The probesets, which were differentially expressed (Limma; adj. p < 0.05) in MSCs (n=6) after 
co-culture with primary leukemic samples (n=4) compared to MSC monocultures were analyzed using 
Ingenuity Pathway Analysis. Top 5 most significant canonical pathways and upstream regulators are 
shown per BCP-ALL sample (ALL1-ALL4). In the interferon/STAT1 pathway, significantly altered genes 
are depicted in red.
 Top canonical pathways P-value Overlap
Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I 5.46E-03 4.3% (1/23)
Glycolysis I 5.93E-03 4.0% (1/25)
Glyconeogenesis I 5.93E-03 4.0% (1/25)
Pyrimidine Ribonucleotides Interconversion 7.59E-03 3.1% (1/32)
Pyrimidi nucleotides De Nov  Biosynthesis 8.06E-03 2.9% (1/34)
 Top upstream regulators P-value
NEDD9 3.42E-03
salirasib 1.06E-03
paroxetine I 9.37E-03
COMMD1 1.02E-03
HIF1A 4.11E-03
Summary of Analysis - ALL2
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Top Canonical Pathways p-value Overlap
Antigen Presentation Pathway 3.64E-11 43.2 % 16/37
Interferon Signaling 2.85E-10 41.7 % 15/36
Glycolysis I 3.54E-08 44.0 % 11/25
Cell Cycle Control of Chromosomal Replication 9.34E-08 40.7 % 11/27
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 2.99E-07 28.6 % 14/49
Top Upstream Regulators p-value of overlap Predicted Activation
NKX2-3 8.83E-55 Inhibited
IFNA2 7.68E-54 Activated
TP53 1.11E-49 Inhibited
IFNL1 5.76E-45 Activated
MAPK1 8.03E-44 Inhibited
Summary of Analysis - ALL3
Supplementary Figure 4C. Ingenuity Pathway Analyses results. changes in MSCs induced by 
ALL3.
(A-D) The probesets, which were differentially expressed (Limma; adj. p < 0.05) in MSCs (n=6) after 
co-culture with primary leukemic samples (n=4) compared to MSC monocultures were analyzed using 
Ingenuity Pathway Analysis. Top 5 most significant canonical pathways and upstream regulators are 
shown per BCP-ALL sample (ALL1-ALL4). In the interferon/STAT1 pathway, significantly altered genes 
are depicted in red.
 Top canonical pathways P-value Overlap
Antigen Presentation Pathway 3.64E-11 43.2%% (16/37)
Interferon Signaling I 2.85E-10 41.7% (15/36)
Glycolysis I 3.54E-08 44.0% (11/25)
Cell Cycle Control of Chromosomal Replication 9.34E-08 40.7% (11/27)
Cell C l : 2/M DNA Damage Checkpoint regulation 2.99E-07 28.6% (14/49)
Summary of Analysis - ALL3
 Top upstream regulators P-value Predicted activation
NKX2-3 8.83E-55 Inhibited
IFNA 7.98E-54 Activated
TP53 1.11E-49 Inhibited
IFNL1 5.76E-45 Activated
MAPK1 8.03E-44 Inhibited
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Top Canonical Pathways p-value Overlap
Interferon Signaling 1.84E-08  8.3 % 3/36
Extrinsic Prothrombin Activation Pathway 3.04E-03  6.2 % 1/16
Coagulation System 6.64E-03  2.9 % 1/35
Activation of IRF by Cytosolic Pattern Recognition Receptors 1.17E-02  1.6 % 1/62
Top Upstream Regulators p-value of overlap
CNOT7 8.62E-09
IFNAR2 2.54E-08
stallimycin 2.91E-08
STAT2 3.11E-08
bromodeoxyuridine 4.49E-08
Summary of Analysis - ALL4
Supplementary Figure 4D. Ingenuity Pathway Analyses results. changes in MSCs induced by 
ALL4.
(A-D) The probesets, which were differentially expressed (Limma; adj. p < 0.05) in MSCs (n=6) after 
co-culture with primary leukemic samples (n=4) compared to MSC monocultures were analyzed using 
Ingenuity Pathway Analysis. Top 5 most significant canonical pathways and upstream regulators are 
shown per BCP-ALL sample (ALL1-ALL4). In the interferon/STAT1 pathway, significantly altered genes 
are depicted in red.
 Top canonical pathways P-value Overlap
Interferon Signaling 1.84E-08 8.3% (3/36)
Extrinsic Prothrombin Activation Pathway 3.04E-03 6.2% (1.16)
Coagulation System 6.64E-03 2.9% (1/35)
Activation of IRF by Cytosolic Pattern Recognition Receptors 1.17E-02 1.6% (1/62)
 Top upstrea  regulators P-value
CNOT7 8.62E-09
IFNAR2 2.54E-08
stallimycin 2.91E-08
STAT2 3.11E-08
bromodeoxyuridine 4.49E-08
Summary of Analysis - ALL4
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Top Canonical Pathways p-value Overlap
Hematopoiesis from Pluripotent Stem Cells 3.59E-05 10.6 % 5/47
Primary Immunodeficiency Signaling 3.98E-05 10.4 % 5/48
B Cell Development 2.29E-03  9.1 % 3/33
Atherosclerosis Signaling 3.56E-03  3.9 % 5/127
PI3K Signaling in B Lymphocytes 3.69E-03  3.9 % 5/128
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Supplementary Figure 5. Gene expression profiling of leukemic-MSCs and control-MSCs.
Gene expression profiling of 86 primary MSCS isolated from 35 newly diagnosed BCP-ALL cases 
(leukemic-MSCs), 29 patients after 79 days of (induction) therapy (remission-MSCs), 6 relapse patients 
(relapse-MSCs), and 16 MSCs healthy controls (control-MSCs).
 Top canonical pathways P-value Overlap
Hematopoiesis from Pluripotent Stem Cells 3.59E-05 10.6% (5/47)
Primary Immunodeficiency Signaling 3.98E-05 10.4% (5/48)
B Cell Development 2.29E-03 9.1% (3/33)
Atherosclerosis Signaling 3.56E-03 3.9% (5/127)
PI3K Signaling in B Lymphocytes 3.69E-03 3.9% (5/128)
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Chapter 7
Carcinogenesis is a multi-dynamic process, depending on numerous variables. During 
the last decades, insights increased in the biology of cancer cells. In 2000 Hanahah 
and Weinberg proposed six hallmarks of cancer cells: sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis.1 In 2011 two additional hallmark 
were added: reprogramming of energy metabolism, and evading immune destruction.2 
Genomic instability and inflammation underlie these hallmarks. In addition, the tumor 
microenvironment provides another dimension of complexity.1,2 These hallmarks of cancer 
cells are key elements for therapeutic intervention. 
Normal cells evolve to malignant lesions by acquiring a series of mutations over time. 
Mutations occur as random events in cells, both in normal and cancer cells. However, 
only lesions that provide a growth advantage will drive the formation of cancer. A typical 
tumor contains two to eight of these driver mutations. The remaining mutations that are 
detected within these tumor samples are passengers, which do not confer a selective 
growth advantage.3 It is important to distinguish driving lesions from passenger mutations, 
as targeting passenger mutations most likely will not be effective in the elimination of 
cancer cells. Across all different cancer types, numerous driving mutations have been 
identified. Strikingly, the number of cellular signaling pathways that are affected by these 
mutations is more limited and can even be reduced to three core cellular processes: cell 
fate determination, cell survival, and genome maintenance.3 It is our scientific challenge to 
determine which mutations are good targets for therapeutic intervention.
Pediatric cancer
Pediatric cancers differ from adult tumors, especially by their very low mutational rate. This 
low mutational burden might be explained by the origin of pediatric cancers: these cells 
have not yet been able to renew themselves as often as in adults.3-6 In addition, leukemias 
may require fewer rounds of clonal expansion compared to solid tumors.7,8 Pediatric 
leukemias are often characterized by chromosomal translocations and therefore less likely 
arise from small point mutational events.9 These chromosomal rearrangements result in 
the formation of fusion genes, which result in activation of proto-oncogenes (e.g. ABL1). 
However, to induce an overt leukemia additional cooperating lesions are required.10,11
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy.12 During the 
last decades, outcome of patients improved enormously: in the early 1960 cure rate was 
approximately 10% whereas nowadays approximately 90% of the patients survives the 
disease.13 This remarkable increase in survival was achieved by improved risk stratification, 
stem cell transplantations and therapy intensification.14 However, still one out of the ten 
children diagnosed with ALL in the Netherlands dies due to the consequences of leukemia. 
Strikingly, the improvement in outcome of ALL cases was achieved without addition of 
new chemotherapeutic agents, with the exception of the ABL-kinase inhibitor Imatinib for 
BCR‑ABL1-positive ALL. The traditional chemotherapeutic agents are already used for 
decades and are not specific for leukemia. Consequently, survivors of childhood ALL are 
at risk to develop long-term side effects due to aspecificity of these chemotherapeutic 
agents.15 To further improve outcome and reduce side effects new treatment options are 
warranted. Ideally, unraveling the molecular pathobiology underlying ALL enables specific 
targeting of oncogenic lesions by precision medicines and thereby improves outcome and 
reduces side effects.
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The treatment of cancer
During the past decades an incredible progress in the field of genomics was made. This 
resulted in increased knowledge of the pathobiology of diseases and identification of 
(new) genomic aberrations.16 In addition, targeted therapies, including kinase inhibitors 
and therapeutic antibodies, are transforming the field of oncology.17 Pharmaceutical 
companies rapidly developed a scale of anti-cancer drugs, which specifically target 
signaling pathways involved in the survival and expansion of cancer cells. Matching the 
appropriate targeted therapy to molecular tumor profiles showed successful treatment 
responses. Among the earliest targeted therapies are imatinib (leukemia), herceptin (breast 
cancer), and cetuximab (colorectal cancer).18-20
Current targeted treatment strategies are predominantly focused on the inactivation of 
oncogenes that have kinase activity. Unfortunately it remains a challenge to restore the 
function of tumor suppressors genes, to interfere with transcription factors, or to target 
the tumor microenvironment. These three important determinants of cancer should also be 
addressed in the hunt for new druggable targets.
Pathobiology of B-cell precursor acute lymphoblastic leukemia and targeted 
therapies
Pediatric ALL is a heterogeneous disease, caused by the malignant transformation of either 
T-cell (T-ALL,~15% of the cases) or B-cell (~85% of the cases) progenitors. The focus of 
this thesis was on B cell precursor ALL (BCP-ALL). Based on genomic aberrations BCP-ALL 
can be subdivided in subtypes with different long-term clinical outcome, including the 
favorable prognostic subtypes ETV6‑RUNX1, high hyperdiploid, TCF3-rearranged, and 
the poor prognostic subtypes BCR‑ABL1, and KMT2A-rearranged BCP-ALL. However, 
approximately 25% of the BCP-ALL patients has a genetically unclassified disease and 
are defined as ‘B-other’. The past decade, unraveling the genetic landscape of B-other ALL 
has been the main focus of many research projects. These genetically unclassified cases 
can be subdivided in BCR‑ABL1-like and non-BCR‑ABL1-like B-other BCP-ALL.21,22 Whole 
genome sequencing and RNAseq analyses revealed presence of activating tyrosine kinase 
lesions in a subgroup of BCR‑ABL1-like patients, including chromosomal translocations 
involving ABL class kinases (ABL1, ABL2, PDGFRB, CFS1R) or JAK class kinases (JAK2, 
CRLF2, EPOR), as shown in literature and Chapter 2 of this thesis.15,23,24 Furthermore, 
point mutations in tyrosine kinases (e.g. JAK2) and cytokine receptors (e.g. CRLF2, IL7R) 
were observed in another subgroup of BCR‑ABL1-like cases.15,23,24 These observations 
indicate that BCR‑ABL1-like cases are characterized by genetic aberrations, resulting in 
activation of tyrosine kinases. The success story of imatinib in BCR‑ABL1-positive BCP-ALL 
cases25 provides a strong rationale for its implementation in the treatment of ABL class 
rearranged BCP-ALL. Indeed, case reports have shown that refractory/relapsed patients 
harboring ABL class fusion genes respond successfully to imatinib.26-28 Therefore, in the 
current DCOG-ALL11 study newly diagnosed ABL class rearranged ALL cases with a poor 
response to induction therapy receive imatinib on top of the treatment protocol.
The COG-study group in the USA initiated a trial to add the JAK1/2 inhibitor ruxolitinib 
to the treatment protocol of pediatric BCP-ALL patients harboring JAK2 lesions (JAK2 
translocations and JAK2 point mutations) or CRLF2 rearrangements. Although JAK2 point 
mutations and JAK2 translocations represent biologically distinct entities, both may be 
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targetable by JAK inhibitors. However, results presented in Chapter 3 of this thesis imply 
that further optimization and evaluation of JAK inhibitor treatment is necessary prior to 
its clinical integration in pediatric BCP-ALL. We showed that JAK inhibitors have a high 
efficacy in JAK2 mutated and JAK2 translocated cells. Despite these promising findings, at 
least three limitations of momelotinib and ruxolitinib were identified. The two JAK inhibitors 
induced accumulation of phosphorylated JAK2Y1007, which eventually resulted in a profound 
re-activation of JAK2 signaling upon release of the inhibitors. As these type I inhibitors 
bind JAK2 in its active conformation, reactivation of JAK2 may be overcome by type II 
inhibitors, which bind JAK2 in its inactive conformation.29,30 Preclinical and clinical data 
of these novel inhibitors (e.g. CHZ868) are therefore warranted.30 In addition, JAK2 point 
mutations are likely secondary aberrations, since we observed that that these mutations 
occur at subclonal levels of in our pediatric BCP-ALL cohort (Chapter 3). Consequently, 
the effect of JAK inhibition may be compromised in JAK2 mutated cells by alternative 
pathway activation. Heterogeneity of the leukemic cell population suggests that mutations 
in alternative survival pathways (e.g. KRAS mutations) may provide a way for these cells to 
escape JAK inhibitor treatment.31 In fact, this is what we observed in NSG mice injected with 
primary JAK2-mutated BCP-ALL cells: a KRAS-mutated subclone grew out at the expense 
of the major JAK2-mutated clone (Chapter 3). The third limitation of JAK inhibitor therapy 
that we observed is micro-environmental-induced resistance. Microenvironment-induced 
resistance of leukemic cells has also been reported before for conventional drugs, e.g. 
prednisolone and asparaginase, and for imatinib in BCR‑ABL1-positive cells.32-36 These 
findings highlight that the micro-environmental protection should be taken into account for 
the evaluation of therapeutic agents. While we specifically analyzed the potential of JAK 
inhibitor treatment in this thesis, these limitations exemplify the major challenges for the 
clinical implementation of precision medicines in general.
Regardless of imatinib targeting the driving lesion, approximately 30% of the 
BCR‑ABL1-positive BCP-ALL cases develop resistance and relapse.25,37 A variety of 
mechanisms can underlie this resistance, e.g. activation of alternate survival pathways, 
down-regulation of drug influx transporters, or mutations at the inhibitor-binding domains 
(e.g. ABLT315I).38-42 Mutations at the inhibitor-binding domain can be overcome with 
inhibitors that bind the kinases via different domains. However, in time resistance against 
these new inhibitors will also develop.41,43,44 Current knowledge implies that imatinib itself 
selects for pre-existing subclones, which gradually outgrowth the drug sensitive cells.45 
Similar observations have been reported in solid tumors.46-51 These observations indicate 
the importance to screen for resistance-mutations in time and expose the cancer cells to 
alternative tyrosine kinase inhibitors that still target these cancer cells (e.g. dasatinib).
Non-tyrosine kinase activating lesions
Although a subgroup of BCR‑ABL1-like B-other patients is characterized by 
kinase activating lesions, the pathobiology of the remaining BCR‑ABL1-like and 
non-BCR‑ABL1-like B-other cases remains poorly understood. Only very recently, 
chromosomal translocations involving DUX4, ZNF384, and MEF2D were identified in 
non BCR‑ABL1-like B-other cases.52-54 The pro-apoptotic gene DUX4 is located within 
the D4Z4 macrosatellite repeat array on chromosome 4 and 10 and encodes a double 
homeobox transcription factor. DUX4 is normally expressed in germline and testis cells, 
but epigenetically silenced in somatic cells.55,56 Loss of function of the differentiation factor 
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ERG is an important secondary event in DUX4-rearranged cases.54 Interestingly, DUX4-
rearrangements and ERG deletions are associated with a favorable prognosis.53,54,57,58 
Therefore, DUX4-rearrangement can be used to a identify a favorable prognostic group 
within the B-other subtype. Despite this favorable prognosis, a targeted treatment for these 
cases is warranted to reduce side effects of therapy. As specific targeting of transcription 
factors remains a challenge, it is important to identify dysregulated signaling pathways 
downstream of DUX4. We show in Chapter 4 that high expression of STAP1 is a hallmark 
of DUX4-rearranged BCP-ALL cases. However, STAP1 is not a likely target for precision 
medicines in these cases, since silencing of STAP1 did not induce death of leukemic 
cells.  Therefore, the search to downstream factors and affected signaling pathways in 
DUX4-rearranged cells needs to be continued.
Cooperating lesions in B-cell development genes and risk stratification
BCP-ALL is often characterized by chromosomal rearrangements. These chromosomal 
rearrangements induce a pre-leukemic state, but additional events are required to 
develop leukemia.10,11,59,60 Deletion of IKZF1 is an example of a cooperating lesion 
in BCR‑ABL1-positive leukemia. Loss of IKZF1 circumvents the necessity to acquire 
additional pro-oncogenic hits, resulting in an accelerated onset of leukemia, as shown 
in a BCR‑ABL1-positive mouse model.61 The leukemia that developed in these mice was 
characterized by a polyclonal nature and few additional chromosomal abnormalities. 
In contrast, BCR‑ABL1-positive mice without loss of IKZF1 developed a monoclonal 
leukemia, in which leukemic cells harbored more chromosomal abnormalities.61 Besides 
IKZF1, deregulation of other B-cell development regulators (e.g. EBF1, PAX5, ERG, ETV6), 
cell cycle and proliferations (CDKN2A/B, RB1), and apoptosis (BTG1) is often observed 
in BCP-ALL.6,62,63 Lineage-specific transcription and fragility of highly transcribed loci are 
a major cause for enrichment of these lesions in BCP-ALL cells.63
Current research is focused on the implementation of copy number aberrations (CNAs) 
in B-cell development genes in risk factor stratification.64,65 IKZF1 was shown to predict 
a poor clinical outcome,22,66,67 and therefore implemented as risk factor in the ongoing 
Dutch Childhood Oncology Group (DCOG) ALL11 protocol. Associations between CNAs 
and an unfavorable prognosis suggest that lesions in these differentiation factors and 
cell cycle regulators might cause cellular drug resistance. Indeed, IKZF1 deletions were 
reported to mediate resistance towards glucocorticoids.68-70 However, the relationship 
between remaining CNAs and cellular drug resistance is yet unknown. In  Chapter 5 
we show that, with the exception of an IKZF1 deletion, none of the remaining CNAs 
associated as single marker both with an unfavorable clinical prognosis and cellular drug 
resistance. The biological and clinical importance of CNAs in these eight genes appeared 
to be highly context dependent and differed between the diverse oncogenic drivers of 
pediatric BCP-ALL. For example, the relation between cellular drug resistance and IKZF1 
deletions differed per cytogenetic subtype: in high hyperdiploid cases loss of IKZF1 
was associated with >1500 fold resistance to prednisolone, whereas in BCR‑ABL1-like 
and non-BCR‑ABL1-like B-other cells deletion of IKZF1 was associated with thiopurine 
resistance. In contrast to the prognostic value in the above mentioned groups, loss of 
IKZF1 does not reverse the favorable outcome of ETV6‑RUNX1, DUX4-rearranged, and 
ERG-deleted cases, indicating that these genomic lesions negate the effect of IKZF1 
deletions.53,54,57,58,71 Context-dependency is also shown by deletions of the BTG1 gene: loss 
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of BTG1 only does not affect cellular drug resistance or the prognosis of BCP-ALL cases, 
while presence of BTG1 deletions in IKZF1-deleted cases strongly enhanced the risk for 
a relapse and glucocorticoid resistance.69 Taken together, these observations imply that 
the genetic context (e.g. oncogenic driver, cell type, differentiation stage) contributes to 
which intracellular pathways are activated and thereby affect carcinogenesis and/or the 
response to chemotherapeutic agents. This theory is supported by diverse consequences of 
genetic aberrations in different cancer types. For example, a deletion of ERG is an important 
secondary event for leukemogenesis in DUX4-rearranged ALL, whereas ERG expression 
is essential for leukemogenesis in AML1‑ETO rearranged acute myeloid leukemia.54,72,73 
Moreover, the importance of the genetic background for the response to anti-cancer 
therapy is illustrated by findings in solid tumors: BRAFV600E mutations are reported both 
in melanoma and colorectal cancer patients, but BRAF inhibitors (e.g. Vemurafenib) only 
induce a tumor response in melanoma patients.74,75 Absence of a response in colorectal 
patient is caused by feedback activation of EGFR upon BRAF inhibition, which is not 
induced in melanoma patients.76
In conclusion, the genetic context determines which intracellular pathways are activated 
and thereby affects carcinogenesis and cellular drug response. Consequently, efficient 
targeting of a genetic aberration in a specific cancer might not be effective in another 
cancer type. These findings indicate the importance to evaluate the efficacy of potential 
treatment strategies the correct cellular and genetic context in preclinical studies, which 
will facilitate more efficient clinical studies.
Cooperating lesions and opportunities for therapeutic intervention
During the last decade IKZF1 was one of the main focusses for research. Deletions of the 
gene were reported to confer resistance to prednisolone and tyrosine kinase inhibitors.37,77,78 
Though imatinib directly targets the BCR-ABL1 fusion protein, deletion of IKZF1 causes an 
aberrant stem cell phenotype and deregulates cellular adhesion, which enables BCP-ALL 
cells to evade cytotoxicity of imatinib and other tyrosine kinase inhibitors.78 Combination 
therapy directed against both the BCR‑ABL1 oncogene and the consequences of IKZF1 
deletions might be an attractive treatment strategy for these cases and is currently being 
explored.78 
In addition, IKZF1 was recently shown to be a regulator of energy and glucose metabolism.77 
During normal B-cell development, IKZF1 prevents malignant transformation by limiting 
the supply of glucose and energy. Deletion of the gene hinders this tumor suppressive 
function and consequently ATP and glucose levels increase. Besides enabling malignant 
transformation, these increased glucose levels cause glucocorticoid resistance.77 
Interestingly, we previously observed an association between increased glucose 
consumption and glucocorticoid resistance in primary BCP-ALL cells.79 Inhibition of 
glycolysis by 2-deoxyglucose (2-DG) restored prednisolone efficacy in primary pediatric 
BCP-ALL cells.79,80 Therefore, this role of IKZF1 as energy regulator might potentially offer 
an alternative treatment strategy for IKZF1-deleted prednisolone resistant BCP-ALL cells. 
This hypothesis should be further explored in in vitro assays. 
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The bone marrow microenvironment
Oncology research is often focused on the cancer cell as a single entity. However, 
the tumor microenvironment has a profound effect in the initiation and progression of 
cancer.81 This tumor niche consists of cancer cells and a supporting framework, including 
mesenchymal stromal cells (MSCs), fibroblasts, endothelial cells, pericytes and a variety 
of immune-regulatory cells.82,83 Leukemic cells reside in the bone marrow, where they 
hijack the normal hematopoietic stem cell niches to create a leukemic niche.84 In this thesis, 
the importance of the bone marrow niche for BCP-ALL cell survival was demonstrated 
by microenvironment-induced resistance to JAK inhibitors (Chapter 3). Unraveling the 
mechanism of protection may provide novel options for therapeutic intervention.
Tumor cells can take advantages of niche specific signaling, manipulate their 
microenvironment to promote survival, or cancer might even be the consequence of a 
disrupted microenvironment.85-87 In myeloid malignancies, dysfunction of the bone 
marrow has been reported to contribute to the development of the disease and vice 
versa leukemogenesis can induce abnormal bone marrow niches.88-92 Conflicting results 
have been reported concerning the genetic background of mesenchymal stromal cells 
(MSCs) in pediatric BCP-ALL.93-95 Therefore, we studied in Chapter 6 of this thesis whether 
MSCs obtained from pediatric BCP-ALL patients (leukemic-MSCs) are different compared 
to MSCs obtained from healthy pediatric controls (control-MSCs). Our results indicate 
that leukemic-MSCs are intrinsically not different compared to control-MSCs. Instead, 
BCP-ALL cells induce gene expression changes in MSCs, which coincide with an increased 
survival of BCP-ALL cells. Each BCP-ALL sample induced a characteristic gene expression 
change, which was consistent between different MSCs. This change in expression was 
only transient, as elimination of leukemic cells reversed gene expression changes. The 
interferon/STAT1 pathway was the most commonly induced pathway, suggesting a central 
role of STAT1 in the interaction between MSCs and BCP-ALL cells. However, knockdown 
of STAT1 in our MSCs did not reduce the survival benefit of BCP-ALL cells upon co-culture 
with MSCs. Residual expression levels of STAT1 or rescue via alternative pathways may 
have occurred and therefore the role of the interferon/STAT1 pathway in BCP-ALL remains 
elusive.96 Taken together, our finding indicate that MSCs are not actively involved in the 
initiation of pediatric BCP-ALL or a relapse. Rather BCP-ALL cells manipulate MSCs to 
support leukemogenesis. Targeting the direct interaction between BCP-ALL cells and MSCs 
or downstream factors of these processes might offer alternative treatment approaches.
In order to support BCP-ALL cell survival and vice versa induce changes in the gene 
expression profile of MSCs, MSCs and BCP-ALL cells need to interact. Interaction can 
occur through soluble factors (e.g. chemokines and cytokines) and cellular projections 
(e.g. tunneling nanotubes).97 Tunneling nanotubes (TNTs) can transfer various cargo, e.g. 
mitochondria and autophagosomes, which will affect with ongoing cellular processes.97-99 
Previously we showed that TNT signaling induces secretion of pro-survival cytokines. Like 
gene expression profiles, these cytokine secretion patterns are leukemia-specific, again 
suggesting that BCP-ALL cells, but not MSCs, are responsible for the active modulation of 
the tumor microenvironment.100 Combining results from this study and Chapter 6 indicate 
that there are at least three different approaches to interfere with the ALL-MSC interaction: 
1) TNT signaling, 2) ALL-induced signaling pathways in MSCs, and 3) cytokine signaling. 
Results presented in this thesis show the variety of effects induced in MSCs by leukemic 
samples. Interference with a common mechanism of the ALL-MSC interaction, like TNT 
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inhibition, would be an attractive treatment approach. Unfortunately, no specific TNT 
inhibitors are available yet. Since our results show that MSCs are not actively involved in 
leukemogenesis, therapeutic interference should preferentially target leukemic cells and/
or factors that are released upon co-culture of BCP-ALL cells and MSCs. 
Immunotherapy
Targeted treatment strategies will be of great importance to improve the prognosis and 
reduce sight effect in pediatric BCP-ALL patients. In this thesis, we show promising results for 
the implementation of JAK inhibitor therapy in the treatment of BCP-ALL, but also identified 
important limitations (accumulation of phosphorylated JAK2, tumor heterogeneity, micro-
environmental induced resistance) of these type of inhibitors. These limitations should be 
taken into account during treatment and provide directions for future research.
Besides targeted therapies, immunotherapy includes a promising new treatment approach 
against leukemia. High remission rates were achieved in relapsed and refractory BCP-ALL 
patients by bispecific antibodies, immunotoxins, and chimeric antigen receptor T cell 
therapy.101-107 CD19 and CD22 are the main targets for these treatment strategies. Both 
proteins are expressed exclusively on B-cell lineage cells.101 Blinatumomab is a bispecific 
antibody that simultaneously binds to CD19-positive cells and to endogenous cytotoxic 
T cells. This binding enables recognition and elimination of CD19-positive cells by these 
cytotoxic T cells.101-103 Immunotoxins use the rapid internalization of CD22 upon antibody 
binding to mediate intracellular delivery of cytotoxic agents.104,108 Inotuzumab ozogamicin 
is an anti-CD22 monoclonal antibody that is conjugated to the cytotoxic antibiotic 
agent calicheamicin.109 The intracellular release of calicheamicin induces cells death 
in CD22-positive cells.109 Chimeric antigen receptor T cell therapy involves the ex vivo 
modification of cytotoxic T cells. Expression of chimeric antigen receptors against CD19 
or CD22 directs these T cells towards the leukemic cells.105-107 Unfortunately, severe side 
effect are reported (e.g. severe cytokine release syndrome) and in time leukemic cells can 
also develop resistance against these immunotherapeutic approaches.103,105,106 Leukemic 
cells can evade these therapies via different mechanisms, e.g. loss of CD19 expression, 
increased regulatory T-cells, or immunosuppressive cytokines.110 Cells that acquired 
resistance due to loss of CD19 might be targeted by CD22-directed approaches.107 In 
addition, blockade of T cell activation through high expression levels of inhibitory ligands 
on tumor cells (i.e. PD-L1) was proposed to be one of the main contributors of resistance.111 
Combined treatment with blinatumomab and antibodies that block the binding of PD-L1 
on tumor cells to the PD-1 inhibitory T cell receptor (e.g. nivolumab) might increase the 
cytotoxicity of T cells. Indeed, promising results were obtained by combination therapy 
in a pediatric patient with refractory BCP-ALL.112 The potency of this combination therapy 
will be studied in more detail in a phase I study for relapsed or refractory CD19+ BCP-ALL 
(NCT02879695).
Taken together, targeted therapies and immunotherapy have a high potential in the 
treatment of leukemia. However, the ability of leukemic cells to acquire resistance against 
different types of therapies suggests that future treatment approaches may need to combine 
different strategies.
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Concluding remarks
The aim of this thesis was to gain insight in pathobiology of high risk BCP-ALL cases. 
In this journey we explored the potential of new targets for therapeutic intervention (i.e. 
JAK2 and STAP1), the association between CNAs in B-cell development genes, long-term 
prognosis and cellular drug resistance, and the involvement the bone marrow niche 
in leukemogenesis. Our results show the efficacy of new precision medicines, i.e. JAK 
inhibitors, in BCP-ALL therapy, but we also identified important limitations that should be 
overcome. Moreover, we show that the genetic context matters and that the effect of anti-
cancer drugs should be studied in the proper genetic context. Lastly, we show that MSCs 
are not actively involved in BCP-ALL leukemogenesis. Instead leukemic cells actively 
modulate signaling pathways in MSCs to support BCP-ALL cell survival. Targeting this 
interaction between BCP-ALL cells and MSCs might be an attractive alternative treatment 
strategy and will therefore be further explored in our future studies.
170
Chapter 7
REFERENCES
1. Hanahan D, Weinberg RA. The hallmarks of 
cancer. Cell 2000;100:57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: 
the next generation. Cell 2011;144:646-74.
3. Vogelstein B, Papadopoulos N, Velculescu VE, 
Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome 
landscapes. Science 2013;339:1546-58.
4. Zhang J, Ding L, Holmfeldt L, et al. The genetic 
basis of early T-cell precursor acute lymphoblastic 
leukaemia. Nature 2012;481:157-63.
5. Lilljebjorn H, Rissler M, Lassen C, et al. Whole-
exome sequencing of pediatric acute lymphoblastic 
leukemia. Leukemia 2012;26:1602-7.
6. Mullighan CG, Goorha S, Radtke I, et al. Genome-
wide analysis of genetic alterations in acute 
lymphoblastic leukaemia. Nature 2007;446:758-64.
7. Nowell PC. The clonal evolution of tumor cell 
populations. Science 1976;194:23-8.
8. Laurenti E, Dick JE. Molecular and functional 
characterization of early human hematopoiesis. 
Annals of the New York Academy of Sciences 
2012;1266:68-71.
9. Dupain C, Harttrampf AC, Urbinati G, Geoerger B, 
Massaad-Massade L. Relevance of Fusion Genes 
in Pediatric Cancers: Toward Precision Medicine. 
Mol Ther Nucleic Acids 2017;6:315-26.
10. Mori H, Colman SM, Xiao Z, et al. Chromosome 
translocations and covert leukemic clones are 
generated during normal fetal development. 
Proceedings of the National Academy of Sciences 
of the United States of America 2002;99:8242-7.
11. Cazzaniga G, van Delft FW, Lo Nigro L, et al. 
Developmental origins and impact of BCR-ABL1 
fusion and IKZF1 deletions in monozygotic twins 
with Ph+ acute lymphoblastic leukemia. Blood 
2011;118:5559-64.
12. de Ridder-Sluiter H, Kollen WJW. Jaarverslag 
SKION 2015. . 2016.
13. Pui CH, Evans WE. A 50-year journey to cure 
childhood acute lymphoblastic leukemia. Semin 
Hematol 2013;50:185-96.
14. Pieters R, de Groot-Kruseman H, Van der Velden 
V, et al. Successful Therapy Reduction and 
Intensification for Childhood Acute Lymphoblastic 
Leukemia Based on Minimal Residual Disease 
Monitoring: Study ALL10 From the Dutch 
Childhood Oncology Group. J Clin Oncol 
2016;34:2591-601.
15. Robison LL, Hudson MM. Survivors of childhood 
and adolescent cancer: life-long risks and 
responsibilities. Nature reviews Cancer 
2014;14:61-70.
16. Heard E, Tishkoff S, Todd JA, et al. Ten years of 
genetics and genomics: what have we achieved 
and where are we heading? Nature reviews 
Genetics 2010;11:723-33.
17. Dietel M, Johrens K, Laffert MV, et al. A 2015 
update on predictive molecular pathology and its 
role in targeted cancer therapy: a review focussing 
on clinical relevance. Cancer gene therapy 
2015;22:417-30.
18. Zardavas D, Tryfonidis K, Goulioti T, Piccart M. 
Targeted adjuvant therapy in breast cancer. Expert 
review of anticancer therapy 2016;16:1263-75.
19. Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT. 
Molecular Diagnostics for Precision Medicine 
in Colorectal Cancer: Current Status and Future 
Perspective. BioMed research international 
2016;2016:9850690.
20. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy 
and safety of a specific inhibitor of the BCR-ABL 
tyrosine kinase in chronic myeloid leukemia. N 
Engl J Med 2001;344:1031-7.
21. Den Boer ML, van Slegtenhorst M, De Menezes RX, 
et al. A subtype of childhood acute lymphoblastic 
leukaemia with poor treatment outcome: a genome-wide 
classification study. Lancet Oncol 2009;10:125-34.
22. Mullighan CG, Su X, Zhang J, et al. Deletion of 
IKZF1 and prognosis in acute lymphoblastic 
leukemia. N Engl J Med 2009;360:470-80.
23. Roberts KG, Morin RD, Zhang J, et al. Genetic 
alterations activating kinase and cytokine 
receptor signaling in high-risk acute lymphoblastic 
leukemia. Cancer Cell 2012;22:153-66.
24. Reshmi SC, Harvey RC, Roberts KG, et al. 
Targetable kinase gene fusions in high-risk B-ALL: 
a study from the Children's Oncology Group. 
Blood 2017;129:3352-61.
25. Schultz KR, Bowman WP, Aledo A, et al. 
Improved early event-free survival with imatinib 
in Philadelphia chromosome-positive acute 
lymphoblastic leukemia: a children's oncology 
group study. J Clin Oncol 2009;27:5175-81.
26. Lengline E, Beldjord K, Dombret H, Soulier J, 
Boissel N, Clappier E. Successful tyrosine kinase 
inhibitor therapy in a refractory B-cell precursor 
acute lymphoblastic leukemia with EBF1-PDGFRB 
fusion. Haematologica 2013;98:e146-8.
27. Schwab C, Ryan SL, Chilton L, et al. EBF1-
PDGFRB fusion in pediatric B-cell precursor acute 
lymphoblastic leukemia (BCP-ALL): genetic profile 
and clinical implications. Blood 2016;127:2214-8.
28. Weston BW, Hayden MA, Roberts KG, et al. 
Tyrosine kinase inhibitor therapy induces remission 
in a patient with refractory EBF1-PDGFRB-positive 
acute lymphoblastic leukemia. J Clin Oncol 
2013;31:e413-6.
29. Meyer SC, Levine RL. Molecular pathways: 
molecular basis for sensitivity and resistance to JAK 
kinase inhibitors. Clin Cancer Res 2014;20:2051-9.
30. Wu SC, Li LS, Kopp N, et al. Activity of the 
Type II JAK2 Inhibitor CHZ868 in B Cell 
Acute Lymphoblastic Leukemia. Cancer Cell 
2015;28:29-41.
31. Tannock IF, Hickman JA. Limits to Personalized Cancer 
Medicine. N Engl J Med 2016;375:1289-94.
32. Polak R, de Rooij B, Pieters R, den Boer ML. 
B-cell precursor acute lymphoblastic leukemia 
cells use tunneling nanotubes to orchestrate their 
microenvironment. Blood 2015;126:2404-14.
33. Iwamoto S, Mihara K, Downing JR, Pui CH, 
Campana D. Mesenchymal cells regulate the 
response of acute lymphoblastic leukemia cells to 
asparaginase. The Journal of clinical investigation 
2007;117:1049-57.
34. Vianello F, Villanova F, Tisato V, et al. Bone marrow 
mesenchymal stromal cells non-selectively protect 
chronic myeloid leukemia cells from imatinib-
induced apoptosis via the CXCR4/CXCL12 axis. 
Haematologica 2010;95:1081-9.
171
General Discussion
 7
35. Ehsanipour EA, Sheng X, Behan JW, et al. 
Adipocytes cause leukemia cell resistance to 
L-asparaginase via release of glutamine. Cancer 
research 2013;73:2998-3006.
36. Feldhahn N, Arutyunyan A, Stoddart S, et al. 
Environment-mediated drug resistance in Bcr/
Abl-positive acute lymphoblastic leukemia. 
Oncoimmunology 2012;1:618-29.
37. van der Veer A, Zaliova M, Mottadelli F, et al. 
IKZF1 status as a prognostic feature in BCR-ABL1-
positive childhood ALL. Blood 2014;123:1691-8.
38. Ottmann OG, Wassmann B. Treatment of 
Philadelphia chromosome-positive acute 
lymphoblastic leukemia. Hematology Am Soc 
Hematol Educ Program 2005:118-22.
39. Mian AA, Oancea C, Zhao Z, Ottmann 
OG, Ruthardt M. Oligomerization inhibition, 
combined with allosteric inhibition, abrogates the 
transformation potential of T315I-positive BCR/
ABL. Leukemia 2009;23:2242-7.
40. Ramchandren R, Schiffer CA. Dasatinib in the 
treatment of imatinib refractory chronic myeloid 
leukemia. Biologics 2009;3:205-14.
41. Weisberg E, Manley PW, Cowan-Jacob SW, 
Hochhaus A, Griffin JD. Second generation 
inhibitors of BCR-ABL for the treatment of imatinib-
resistant chronic myeloid leukaemia. Nature 
reviews Cancer 2007;7:345-56.
42. Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich 
KP. Targeting cancer with kinase inhibitors. The 
Journal of clinical investigation 2015;125:1780-9.
43. Wei G, Rafiyath S, Liu D. First-line treatment for 
chronic myeloid leukemia: dasatinib, nilotinib, or 
imatinib. J Hematol Oncol 2010;3:47.
44. Sirvent A, Benistant C, Roche S. Cytoplasmic 
signalling by the c-Abl tyrosine kinase in normal 
and cancer cells. Biol Cell 2008;100:617-31.
45. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-
ABL kinase domain mutations confer polyclonal 
resistance to the tyrosine kinase inhibitor imatinib 
(STI571) in chronic phase and blast crisis chronic 
myeloid leukemia. Cancer Cell 2002;2:117-25.
46. Manzano JL, Layos L, Buges C, et al. Resistant 
mechanisms to BRAF inhibitors in melanoma. 
Annals of translational medicine 2016;4:237.
47. Khattak M, Fisher R, Turajlic S, Larkin J. Targeted 
therapy and immunotherapy in advanced 
melanoma: an evolving paradigm. Therapeutic 
advances in medical oncology 2013;5:105-18.
48. Hammond WA, Swaika A, Mody K. Pharmacologic 
resistance in colorectal cancer: a review. Therapeutic 
advances in medical oncology 2016;8:57-84.
49. Morgillo F, Della Corte CM, Fasano M, Ciardiello F. 
Mechanisms of resistance to EGFR-targeted drugs: 
lung cancer. ESMO open 2016;1:e000060.
50. Liegl B, Kepten I, Le C, et al. Heterogeneity of 
kinase inhibitor resistance mechanisms in GIST. The 
Journal of pathology 2008;216:64-74.
51. Barouch-Bentov R, Sauer K. Mechanisms of 
drug resistance in kinases. Expert opinion on 
investigational drugs 2011;20:153-208.
52. Lilljebjorn H, Henningsson R, Hyrenius-Wittsten 
A, et al. Identification of ETV6-RUNX1-like and 
DUX4-rearranged subtypes in paediatric B-cell 
precursor acute lymphoblastic leukaemia. Nature 
communications 2016;7:11790.
53. Yasuda T, Tsuzuki S, Kawazu M, et al. Recurrent 
DUX4 fusions in B cell acute lymphoblastic 
leukemia of adolescents and young adults. Nat 
Genet 2016;48:569-74.
54. Zhang J, McCastlain K, Yoshihara H, et 
al. Deregulation of DUX4 and ERG in 
acute lymphoblastic leukemia. Nat Genet 
2016;48:1481-9.
55. van Geel M, Dickson MC, Beck AF, et al. Genomic 
analysis of human chromosome 10q and 4q 
telomeres suggests a common origin. Genomics 
2002;79:210-7.
56. Kowaljow V, Marcowycz A, Ansseau E, et al. 
The DUX4 gene at the FSHD1A locus encodes a 
pro-apoptotic protein. Neuromuscular disorders : 
NMD 2007;17:611-23.
57. Harvey RC, Mullighan CG, Wang X, et al. 
Identification of novel cluster groups in pediatric 
high-risk B-precursor acute lymphoblastic 
leukemia with gene expression profiling: 
correlation with genome-wide DNA copy number 
alterations, clinical characteristics, and outcome. 
Blood 2010;116:4874-84.
58. Clappier E, Auclerc MF, Rapion J, et al. An 
intragenic ERG deletion is a marker of an 
oncogenic subtype of B-cell precursor acute 
lymphoblastic leukemia with a favorable outcome 
despite frequent IKZF1 deletions. Leukemia 
2014;28:70-7.
59. Morrow M, Horton S, Kioussis D, Brady HJ, 
Williams O. TEL-AML1 promotes development 
of specific hematopoietic lineages consistent with 
preleukemic activity. Blood 2004;103:3890-6.
60. Wiemels JL, Cazzaniga G, Daniotti M, et al. 
Prenatal origin of acute lymphoblastic leukaemia 
in children. Lancet 1999;354:1499-503.
61. Virely C, Moulin S, Cobaleda C, et al. 
Haploinsufficiency of the IKZF1 (IKAROS) tumor 
suppressor gene cooperates with BCR-ABL in a 
transgenic model of acute lymphoblastic leukemia. 
Leukemia 2010;24:1200-4.
62. Rosenbauer F, Tenen DG. Transcription factors in 
myeloid development: balancing differentiation 
with transformation. Nat Rev Immunol 
2007;7:105-17.
63. Boulianne B, Robinson ME, May PC, et al. Lineage-
Specific Genes Are Prominent DNA Damage 
Hotspots during Leukemic Transformation of B Cell 
Precursors. Cell reports 2017;18:1687-98.
64. Moorman AV, Enshaei A, Schwab C, et al. A novel 
integrated cytogenetic and genomic classification 
refines risk stratification in pediatric acute 
lymphoblastic leukemia. Blood 2014;124:1434-44.
65. Gupta SK, Bakhshi S, Kumar L, Kamal VK, Kumar R. 
Gene copy number alteration profile and its clinical 
correlation in B-cell acute lymphoblastic leukemia. 
Leukemia & lymphoma 2017;58:333-42.
66. van der Veer A, Waanders E, Pieters R, et al. 
Independent prognostic value of BCR-ABL1-like 
signature and IKZF1 deletion, but not high CRLF2 
expression, in children with B-cell precursor ALL. 
Blood 2013;122:2622-9.
67. Kuiper RP, Waanders E, van der Velden VH, et 
al. IKZF1 deletions predict relapse in uniformly 
treated pediatric precursor B-ALL. Leukemia 
2010;24:1258-64.
172
Chapter 7
68. Marke R, Havinga J, Cloos J, et al. Tumor 
suppressor IKZF1 mediates glucocorticoid 
resistance in B-cell precursor acute lymphoblastic 
leukemia. Leukemia 2016;30:1599-603.
69. Scheijen B, Boer JM, Marke R, et al. Tumor 
suppressors BTG1 and IKZF1 cooperate during 
mouse leukemia development and increase 
relapse risk in B-cell precursor acute lymphoblastic 
leukemia patients. Haematologica 2017;102:541-
51.
70. Imamura T, Yano M, Asai D, et al. IKZF1 
deletion is enriched in pediatric B-cell precursor 
acute lymphoblastic leukemia patients showing 
prednisolone resistance. Leukemia 2016;30:1801-
3.
71. Enshaei A, Schwab CJ, Konn ZJ, et al. Long-term 
follow-up of ETV6-RUNX1 ALL reveals that NCI 
risk, rather than secondary genetic abnormalities, 
is the key risk factor. Leukemia 2013;27:2256-9.
72. Mandoli A, Singh AA, Prange KHM, et al. The 
Hematopoietic Transcription Factors RUNX1 and 
ERG Prevent AML1-ETO Oncogene Overexpression 
and Onset of the Apoptosis Program in t(8;21) 
AMLs. Cell reports 2016;17:2087-100.
73. Martens JH, Mandoli A, Simmer F, et al. ERG and 
FLI1 binding sites demarcate targets for aberrant 
epigenetic regulation by AML1-ETO in acute 
myeloid leukemia. Blood 2012;120:4038-48.
74. Barras D. BRAF Mutation in Colorectal Cancer: An 
Update. Biomarkers in cancer 2015;7:9-12.
75. Mao M, Tian F, Mariadason JM, et al. Resistance to 
BRAF inhibition in BRAF-mutant colon cancer can 
be overcome with PI3K inhibition or demethylating 
agents. Clin Cancer Res 2013;19:657-67.
76. Prahallad A, Sun C, Huang S, et al. 
Unresponsiveness of colon cancer to BRAF(V600E) 
inhibition through feedback activation of EGFR. 
Nature 2012;483:100-3.
77. Chan LN, Chen Z, Braas D, et al. Metabolic 
gatekeeper function of B-lymphoid transcription 
factors. Nature 2017;542:479-83.
78. Churchman ML, Mullighan CG. Ikaros: Exploiting 
and targeting the hematopoietic stem cell niche 
in B-progenitor acute lymphoblastic leukemia. 
Experimental hematology 2017;46:1-8.
79. Hulleman E, Kazemier KM, Holleman A, et al. 
Inhibition of glycolysis modulates prednisolone 
resistance in acute lymphoblastic leukemia cells. 
Blood 2009;113:2014-21.
80. Aries IM, Hansen BR, Koch T, et al. The 
synergism of MCL1 and glycolysis on pediatric 
acute lymphoblastic leukemia cell survival 
and prednisolone resistance. Haematologica 
2013;98:1905-11.
81. Nombela-Arrieta C, Pivarnik G, Winkel B, et al. 
Quantitative imaging of haematopoietic stem and 
progenitor cell localization and hypoxic status in 
the bone marrow microenvironment. Nature cell 
biology 2013;15:533-43.
82. Hong IS, Lee HY, Kang KS. Mesenchymal stem 
cells and cancer: friends or enemies? Mutat Res 
2014;768:98-106.
83. D'Souza N, Burns JS, Grisendi G, et al. MSC and 
Tumors: Homing, Differentiation, and Secretion 
Influence Therapeutic Potential. Adv Biochem Eng 
Biotechnol 2013;130:209-66.
84. Colmone A, Amorim M, Pontier AL, Wang S, 
Jablonski E, Sipkins DA. Leukemic cells create 
bone marrow niches that disrupt the behavior of 
normal hematopoietic progenitor cells. Science 
2008;322:1861-5.
85. Raaijmakers MH. Niche contributions to 
oncogenesis: emerging concepts and implications 
for the hematopoietic system. Haematologica 
2011;96:1041-8.
86. Schepers K, Campbell TB, Passegue E. Normal and 
leukemic stem cell niches: insights and therapeutic 
opportunities. Cell stem cell 2015;16:254-67.
87. Sneddon JB, Werb Z. Location, location, 
location: the cancer stem cell niche. Cell stem cell 
2007;1:607-11.
88. Walkley CR, Shea JM, Sims NA, Purton LE, 
Orkin SH. Rb regulates interactions between 
hematopoietic stem cells and their bone marrow 
microenvironment. Cell 2007;129:1081-95.
89. Walkley CR, Olsen GH, Dworkin S, et al. A 
microenvironment-induced myeloproliferative 
syndrome caused by retinoic acid receptor 
gamma deficiency. Cell 2007;129:1097-110.
90. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone 
progenitor dysfunction induces myelodysplasia and 
secondary leukaemia. Nature 2010;464:852-7.
91. Schepers K, Pietras EM, Reynaud D, et al. 
Myeloproliferative neoplasia remodels the 
endosteal bone marrow niche into a self-reinforcing 
leukemic niche. Cell stem cell 2013;13:285-99.
92. Krause DS, Fulzele K, Catic A, et al. Differential 
regulation of myeloid leukemias by the 
bone marrow microenvironment. Nat Med 
2013;19:1513-7.
93. Conforti A, Biagini S, Del Bufalo F, et al. Biological, 
functional and genetic characterization of bone 
marrow-derived mesenchymal stromal cells from 
pediatric patients affected by acute lymphoblastic 
leukemia. PLoS One 2013;8:e76989.
94. Menendez P, Catalina P, Rodriguez R, et al. Bone 
marrow mesenchymal stem cells from infants with 
MLL-AF4+ acute leukemia harbor and express 
the MLL-AF4 fusion gene. Journal of Experimental 
Medicine 2009;206:3131-41.
95. Shalapour S, Eckert C, Seeger K, et al. Leukemia-
associated genetic aberrations in mesenchymal 
stem cells of children with acute lymphoblastic 
leukemia. Journal of Molecular Medicine 
2010;88:249-65.
96. Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk 
A, Wesoly J, Bluyssen HA. The unique role of STAT2 
in constitutive and IFN-induced transcription and 
antiviral responses. Cytokine & growth factor 
reviews 2016;29:71-81.
97. Abounit S, Zurzolo C. Wiring through tunneling 
nanotubes--from electrical signals to organelle 
transfer. Journal of cell science 2012;125:1089-98.
98. de Rooij B, Polak R, Stalpers F, Pieters R, Boer MLD. 
Tunneling nanotubes facilitate autophagosome 
transfer in the leukemic niche. Leukemia 
2017;31:1651-4.
99. Saenz-de-Santa-Maria I, Bernardo-Castineira C, 
Enciso E, et al. Control of long-distance cell-to-cell 
communication and autophagosome transfer in 
squamous cell carcinoma via tunneling nanotubes. 
Oncotarget 2017;8:20939-60.
173
General Discussion
 7
100. Polak R, de Rooij B, Pieters R, den Boer ML. 
B-cell precursor acute lymphoblastic leukemia 
cells use tunneling nanotubes to orchestrate their 
microenvironment. Blood 2015.
101. von Stackelberg A, Locatelli F, Zugmaier G, et 
al. Phase I/Phase II Study of Blinatumomab in 
Pediatric Patients With Relapsed/Refractory 
Acute Lymphoblastic Leukemia. J Clin Oncol 
2016;34:4381-9.
102. Kantarjian H, Stein A, Gokbuget N, et al. 
Blinatumomab versus Chemotherapy for 
Advanced Acute Lymphoblastic Leukemia. N Engl 
J Med 2017;376:836-47.
103. Topp MS, Kufer P, Gokbuget N, et al. Targeted 
therapy with the T-cell-engaging antibody 
blinatumomab of chemotherapy-refractory 
minimal residual disease in B-lineage acute 
lymphoblastic leukemia patients results in high 
response rate and prolonged leukemia-free 
survival. J Clin Oncol 2011;29:2493-8.
104. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. 
Inotuzumab Ozogamicin versus Standard Therapy 
for Acute Lymphoblastic Leukemia. N Engl J Med 
2016;375:740-53.
105. Maude SL, Frey N, Shaw PA, et al. Chimeric 
antigen receptor T cells for sustained remissions in 
leukemia. N Engl J Med 2014;371:1507-17.
106. Grupp SA, Kalos M, Barrett D, et al. 
Chimeric antigen receptor-modified T cells 
for acute lymphoid leukemia. N Engl J Med 
2013;368:1509-18.
107. Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted 
CAR T cells induce remission in B-ALL that is naive 
or resistant to CD19-targeted CAR immunotherapy. 
Nat Med 2018;24:20-8.
108. Daver N, O'Brien S. Novel therapeutic strategies 
in adult acute lymphoblastic leukemia--a focus 
on emerging monoclonal antibodies. Current 
hematologic malignancy reports 2013;8:123-31.
109. DiJoseph JF, Armellino DC, Boghaert ER, et al. 
Antibody-targeted chemotherapy with CMC-
544: a CD22-targeted immunoconjugate of 
calicheamicin for the treatment of B-lymphoid 
malignancies. Blood 2004;103:1807-14.
110. Park JA, Cheung NV. Limitations and opportunities 
for immune checkpoint inhibitors in pediatric 
malignancies. Cancer Treat Rev 2017;58:22-33.
111. Krupka C, Kufer P, Kischel R, et al. Blockade of the 
PD-1/PD-L1 axis augments lysis of AML cells by 
the CD33/CD3 BiTE antibody construct AMG 
330: reversing a T-cell-induced immune escape 
mechanism. Leukemia 2016;30:484-91.
112. Feucht J, Kayser S, Gorodezki D, et al. T-cell 
responses against CD19+ pediatric acute 
lymphoblastic leukemia mediated by bispecific 
T-cell engager (BiTE) are regulated contrarily 
by PD-L1 and CD80/CD86 on leukemic blasts. 
Oncotarget 2016;7:76902-19.

8Chapter
SUMMARY
Summary
To improve the prognosis of children with B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL), new targeted approaches are needed. Therefore, it is essential to unravel the 
underlying pathobiology. For BCR‑ABL1-like and non-BCR‑ABL1-like B-other patients the 
driving oncogenic lesions and mechanisms of therapy failure are poorly understood. 
In the past decade, the genetic landscape of BCR‑ABL1-like and non-BCR‑ABL1-like 
B-other ALL has been intensively studied. Whole genome sequencing and RNA 
sequencing in USA patient cohorts identified activating tyrosine kinase lesions in a 
subgroup of BCR‑ABL1-like patients.1-3 The frequency of genetic lesions in ALL is linked 
to the genetic background (ancestry) of patients.4-6 In Chapter 2, we therefore examined 
the prevalence of tyrosine kinase fusions in a Caucasian cohort of Dutch and German 
children with BCR‑ABL1-like and non-BCR‑ABL1-like ALL, using RT-PCR and targeted-
locus-amplification. Tyrosine kinase fusions were solely detected in BCR‑ABL1-like cases. 
These tyrosine kinase positive BCR‑ABL1-like patients often harbored deletions of IKZF1 
and showed an unfavorable treatment outcome. Tyrosine kinase fusions involved either 
ABL class (ABL1, ABL2, PDGFRB, CFS1R) or JAK class (JAK2, CRLF2) kinases. The success 
of the ABL tyrosine kinase inhibitor imatinib in the treatment of BCR‑ABL1-positive cases,7 
provides a strong rationale for the introduction of tyrosine kinase inhibitor treatment in 
patients carrying these new type of ABL fusion genes. Currently the first BCR‑ABL1-like 
patients harboring ABL class tyrosine kinase fusions are being treated with imatinib.8-10
To gain insight in the clinical potential of JAK inhibitors in pediatric BCP-ALL, we determined 
the occurrence of JAK2 aberrations, i.e. mutations and translocations, in different subtypes 
of childhood BCP-ALL. Results of this study are described in Chapter 3. JAK2 translocations 
were a hallmark of BCR‑ABL1-like ALL (6.5%). In contrast, JAK2 point mutations were 
detected in three subtypes of BCP-ALL, i.e. BCR‑ABL1-like (7.6%), B-other (11.9%) and 
high hyperdiploid (1.6%). Although JAK2 point mutations and JAK2 translocations 
represent genetically distinct entities, both may be targetable by JAK inhibitors. Therefore 
we examined the efficacy of the JAK inhibitors momelotinib and ruxolitinib in these cells. 
Momelotinib and ruxolitinib were cytotoxic in both JAK2 translocated and JAK2 mutated 
cells, although efficacy in JAK2 mutated cells highly depended on cytokine receptor 
activation by TSLP. Despite these promising findings, we identified certain limitations of 
both JAK inhibitors. The inhibitors induced accumulation of phosphorylated JAK2Y1007, 
which resulted in a profound re-activation of JAK2 signaling upon release of the inhibitors. 
In addition, we showed that the effect of JAK inhibition may be compromised by mutations 
in alternative survival pathways and microenvironment-induced resistance. Therefore, 
our results indicate that further optimization and evaluation of JAK inhibitor treatment is 
necessary prior to its clinical integration in pediatric BCP-ALL.
In Chapter 4 we studied the signaling molecule STAP1, which may serve as new therapeutic 
target for DUX4-rearranged BCP-ALL. Only very recently, chromosomal translocations 
involving DUX4 were identified in non-BCR‑ABL1-like B-other cases.11-13 Loss of function of 
the transcription factor ERG is proposed to be a direct consequence of DUX4 deregulation.13 
Precision medicines mainly target kinase pathways and cell surface proteins, whereas 
transcription factors remain difficult to target. Therefore, it is important to identify signaling 
pathways that are affected by these transcription factors. We identified STAP1 to be highly 
expressed in BCR‑ABL1-like and non-BCR‑ABL1-like B-other cases that often harbored 
ERG deletions. High expression of STAP1 associated with high expression levels of genes 
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that are involved in the precursor B-cell receptor (pre-BCR) signaling pathway, which 
is an attractive pathway for therapeutic intervention. However, upregulation of pre-BCR 
signaling could not be confirmed in cases with high expression of STAP1. In addition, 
knockdown of STAP1 did not induce cell death nor block the proliferation rate of these 
cells. These results indicate that STAP1 is not a likely candidate for precision medicines. 
Therefore, the search for downstream factors and affected signaling pathways in DUX4-
rearranged cells needs to be continued.
Besides chromosomal rearrangements, additional genetic aberrations such as mutations 
and copy-number alterations (CNAs) have been observed in BCP-ALL. Especially CNAs in 
genes that are involved in B-cell development and cell cycle progression are often detected 
in children with BCP-ALL.5,6 In Chapter 5 we showed that CNAs in B-cell development-
associated genes occur in 71% of BCP-ALL cases and are not equally distributed across 
cytogenetic subtypes: the frequency was above 75% in BCR‑ABL1-positive, BCR‑ABL1-
like, non-BCR‑ABL1-like B-other, and ETV6‑RUNX1-positive patients, but below 40% 
in KMT2A-rearranged, high hyperdiploid and TCF3‑PBX1-positive cases. A deletion in 
IKZF1 was the only risk factor that associated with both adverse clinical outcome and 
cellular drug resistance. However, associations with cellular drug resistance depended 
on the genetic context: extreme high prednisolone resistance (~1500-fold, p<0.01) was 
found in IKZF1-deleted high hyperdiploid cells, whereas thiopurine resistance (~1.7-fold, 
p<0.05) was predominantly detected in BCR‑ABL1-like and B-other IKZF1-deleted cells. 
These results indicate that distinct combinations of genetic aberrations may have different 
effects on cellular drug resistance and therefore emphasize that the genetic context should 
be taken into account for functional studies that focus on cellular drug resistance.
In Chapter 6 we gained insight in the interaction between leukemic cells and mesenchymal 
stromal cells (MSCs). MSCs are key components of the process of hematopoiesis through 
both cytokine secretion and direct cell-to-cell communication.6,14,15 Furthermore, MSCs 
protect BCP-ALL cells against chemotherapeutic agents, including JAK inhibitors as 
demonstrated in Chapter 3.16-20 Unraveling the role of the bone marrow microenvironment 
in leukemia may provide novel options for therapeutic intervention. Therefore, it was studied 
whether MSCs derived from leukemia patients at initial diagnosis (leukemic-MSCs) are 
different from MSCs isolated from healthy donors (control-MSCs). A significant increase in 
survival of BCP-ALL cells was observed if these cells were co-cultured with MSCs compared 
to the survival of BCP-ALL cells in mono-culture. Both control-MSCs and leukemic-MSCs 
provided a similar survival benefit and hence, the source of MSCs was not causing the 
increase in survival of leukemic cells. Strikingly, the gene expression profiles of MSCs did 
significantly change upon co-culture with primary BCP-ALL cells. Each BCP-ALL sample 
induced a specific change in gene expression profiles of MSCs, which was consistent 
between different MSCs. These changes were transient and were restored upon removal 
of leukeic cells. Taken together our results indicate that leukemic-MSCs are not intrinsically 
different from control-MSCs. Instead, BCP-ALL cells alter the transcriptome of MSCs, which 
coincides with an increased survival of BCP-ALL cells. Therefore our findings suggest that 
the bone marrow microenvironment by itself is not leukemogenic, but is actively being 
hijacked by leukemic cells to support the pathogenesis of BCP-ALL. Further knowledge 
about this interaction between BCP-ALL cells and MSCs may provide clues to target 
leukemic cells more specifically.
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Leukemia is a multi-dynamic process, depending on numerous variables. Full understanding 
of the pathobiology of BCP-ALL is essential for the identification of new therapies. In this 
thesis, potential targets for therapeutic intervention were studied. In addition, our results 
show an important role for the bone marrow microenvironment in therapy resistance. 
The interaction between leukemic cells and the niche should be a central topic for future 
research.
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Chapter 8
Nederlandse samenvatting voor niet ingewijden
Een cel moet een aantal eigenschappen verwerven om kanker te veroorzaken. Zo moet 
een kankercel oneindig kunnen delen, ongeremd kunnen groeien en celdood voorkomen. 
Bovendien speelt de interactie van deze cel met de omgeving een belangrijke rol: een 
kankercel moet voorkomen dat hij wordt opgeruimd door het immuunsysteem, of niet meer 
kan delen als gevolg van omgevingsfactoren. Normale cellen kunnen in kankercellen 
veranderen door het verwerven van mutaties. Dit is een dynamisch proces dat veel tijd 
in beslag neemt. Zowel in gezonde cellen als kankercellen ontstaan spontaan mutaties. 
Echter alleen mutaties die een groei- en overlevingsvoordeel met zich meebrengen, 
dragen bij aan het ontstaan van  kanker. Deze mutaties worden ook wel driver mutaties 
genoemd. Een tumor bevat normaal gesproken twee tot acht van deze driver mutaties. 
De andere mutaties zijn later ontstaan (passenger mutaties) of zijn zelfs helemaal niet 
betrokken bij het ontstaan van de ziekte. Bij de behandeling van kanker is het belangrijk 
om op deze driver mutaties te focussen, omdat deze belangrijk zijn voor de overleving 
van de kankercellen. 
Leukemie
Leukemie is een verzamelnaam voor een vorm van kanker die wordt veroorzaakt door een 
ongeremde groei van witte bloedcellen. Bloedcellen ontwikkelen zich in het beenmerg 
uit één voorloper cel: de bloedstamcel of ook wel de hematopoietische stamcel (HSC) 
genoemd. Deze HSC kan zich ontwikkelen tot drie typen bloedcelen: witte bloedcellen, 
rode bloedcellen en bloedplaatjes. De verschillende typen bloedcellen hebben ieder 
een specifieke functie. Zo zijn de witte bloedcellen belangrijk voor de afweer van ons 
lichaam tegen virussen, zijn rode bloedcellen verantwoordelijk voor zuurstoftransport 
en zorgen bloedplaatjes voor stolling. Ontwikkeling en rijping van bloedcellen, ook 
wel hematopoïese genoemd, vindt in het beenmerg plaats. De HSC heeft de bijzondere 
eigenschap dat deze, naast de ontwikkeling in specifieke bloedcellen, zichzelf ook 
kan vernieuwen. Op deze manier is er een ‘eindeloze’ voorraad van bloedcellen. Hoe 
ontwikkelder en volgroeider een bloedcel raakt, hoe beperkter de levensduur en de 
mogelijkheid tot celdeling. Volgroeide, rijpe bloedcellen verlaten het beenmerg en gaan 
de bloedbaan in. Op deze manier wordt de hoeveelheid bloedcellen in ons lichaam 
continue gereguleerd, vernieuwd en aangevuld. Echter een fout in de rijping van witte 
bloedcellen kan tot een blokkade in de ontwikkeling leiden, waardoor deze cel het 
beenmerg niet kan verlaten. Gecombineerd met ongeremde celdeling kan deze bloedcel 
leukemie veroorzaken: de leukemiecel verdringt en overgroeit gezonde bloedcellen. Dit 
heeft tot gevolg dat patiënten met leukemie een verminderde weerstand hebben (tekort 
aan gezonde witte bloedcellen), bloedarmoede hebben (tekort aan rode bloedcellen) en 
er gemakkelijk blauwe plekken en bloedingen ontstaan (tekort aan bloedplaatjes).
Er zijn verschillende vormen van leukemie. Zo kan leukemie acuut of chronisch zijn. Een 
acute leukemie ontwikkelt zich relatief snel uit niet gerijpte, voorloper, witte bloedcellen. 
Bij een chronische leukemie is de bloedcel beter ontwikkeld, maar kan deze niet geheel 
normaal functioneren. Dit heeft tot gevolg dat de leukemie zich wat langzamer ontwikkelt. 
Een verdere onderverdeling van leukemie vindt plaats aan de hand van het type witte 
bloedcel dat de leukemie veroorzaakt, namelijk een myelöide cel of lymfocyt. Deze cellen 
behoren tot de twee verschillende immuunsystemen. Myeloïde cellen zijn onderdeel van 
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het aangeboren immuunsysteem, de algemene afweer van ons lichaam. Lymfocyten 
zijn onderdeel van het verworven immuunsysteem. Dit immuunsysteem ontwikkelt zich 
gedurende ons leven en heeft  een geheugen: nadat je eenmalig in aanraking bent 
geweest met ziekteverwekkers, kan je immuunsysteem de infectie bij een nieuwe infectie 
sneller onderdrukken.
Acute lymfatische leukemie
Acute lymfatische leukemie (ALL) is de meest voorkomende vorm van kanker bij kinderen. 
Jaarlijks worden er in Nederland zo’n 125 kinderen gediagnostiseerd met de ziekte. ALL kan 
worden onderverdeeld in voorloper B-cel of T-cel ALL; de verschillende typen lymfocyten. 
In 85% van de gevallen wordt ALL veroorzaakt door een fout in de ontwikkeling van de 
B-cellen, ook wel B-cel precursor ALL (BCP-ALL) genoemd. In deze thesis is gefocust op 
dit type leukemie.
De overlevingskans van kinderen met ALL is de afgelopen jaren enorm toegenomen: in de 
jaren 60 overleefde ongeveer 10% van de kinderen de ziekte, maar hedendaags is de 
overlevingskans ongeveer 90%.1 Alhoewel dit een enorme stijging is, betekent dit helaas 
nog steeds dat 1 op de 10 kinderen met leukemie overlijdt aan de gevolgen van de 
ziekte. Daarnaast hebben overlevenden van kinderkanker vaak te maken bijwerkingen en 
nare (late) effecten als gevolg van de behandeling van hun ziekte. Om de prognose van 
deze kinderen te verbeteren en gevolgen van de behandeling te verminderen zijn nieuwe 
therapeutische opties nodig.
Pathobiologie van B-cell Precursor Acute Lymfatische Leukemie
De ontwikkeling (differentiatie) van B cellen heeft als doel om een volwassen (mature) 
B-cel met unieke B-cel receptor te creëren, waarmee ziekteverwekkers worden herkend. 
Dit ontwikkelingsproces verloopt gefaseerd, waarbij de cel vanuit het diepe beenmerg 
richting de bloedvaten migreert. Regulatie van dit differentiatieproces vindt plaats door 
factoren in de cel (intracellulair), maar ook door andere factoren in het beenmerg 
(extracellulair). Intracellulaire regulatie vindt plaats door transcriptiefactoren, die 
ervoor zorgen dat de juiste processen in de cel actief zijn.2 Voorbeelden van deze 
transcriptiefactoren zijn ERG, IKZF1, EBF1 en PAX5. Naast transcriptiefactoren wordt de 
ontwikkeling van B-cellen gecontroleerd door andere niet-hematopoietische cellen uit het 
beenmerg, o.a. mesenchymale stroma cellen (MSCs). MSCs scheiden groeifactoren uit en 
activeren signaleringscascades in B-cellen door direct cel-cel contact.3-5
BCP-ALL is een heterogene ziekte die door een spectrum van genetische afwijkingen kan 
worden veroorzaakt. Een veelvoorkomend mechanisme dat betrokken is bij het ontstaan 
van leukemie zijn chromosomale translocaties. Bij een translocatie worden DNA segmenten 
van twee chromosomen ‘uitgewisseld’, wat leidt tot (twee) nieuwe chromosomen. Zo kan 
een chromosomale translocatie tot gevolg hebben dat het BCR gen op chromosoom 22 
doormidden wordt gebroken en fuseert met een deel van het ABL1 gen op chromosoom 9. 
Dit BCR‑ABL1 fusiegen verstoort de normale signaleringsprocessen in de cel en activeert 
groei- en overlevingsprocessen. Andere voorbeelden van fusiegenen in BCP-ALL zijn 
ETV6‑RUNX1, TCF3‑PBX1 en KMT2A-AF4. Naast fusiegenen wordt de leukemiecel bij 
een ander groot deel (~30%) van de kinderen gekarakteriseerd door een afwijkend aantal 
chromosomen. Indien er meer dan 50 chromosomen aanwezig zijn in de leukemiecel 
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spreekt men over hoog hyperdiploïde leukemie. Met de onderverdeling in fusiegenen 
en chromosoom aantallen, blijft ongeveer 25% van de leukemiepatiënten over met een 
genetisch ongekarakteriseerde ziekte. Opmerkelijk is dat het genexpressie profiel van de 
leukemiecellen van een deel van deze patiënten sterk lijkt op het genexpressieprofiel van 
BCR‑ABL1-positieve cellen. Echter is het BCR‑ABL1 fusiegen niet aanwezig in deze cellen. 
Deze vorm van leukemie wordt daarom BCR‑ABL1-like leukemie genoemd. De overige 
patiënten worden gekarakteriseerd als hebbende een ‘overige’ vorm van leukemie, ook 
wel ‘B-other’ leukemie genoemd.
De verschillende subtypen van leukemie zijn ieder geassocieerd met een specifieke 
prognose. Zo hebben kinderen met de ETV6‑RUNX1 translocatie of hoog hyperdiploïde 
leukemie een relatief goede prognose. TCF3‑PBX1 en ‘B-other’ leukemie zijn geassocieerd 
met een intermediaire prognose en kinderen met KMT2A-herschikte, BCR‑ABL1, of 
BCR‑ABL1-like hebben een relatief slechte prognose. Behalve het feit dat deze genetische 
afwijkingen voorspellend zijn voor de prognose, kunnen ze ook een doel (target) 
vormen voor doelgerichte therapie. Patiënten met BCR‑ABL1-positieve leukemie worden 
behandeld met een specifiek middel, imatinib, dat de signalering van het BCR‑ABL1 
oncogen remt. In Nederland is BCR‑ABL1-positieve leukemie het enige subtype van 
BCP-ALL dat met een doelgerichte therapie (=precisiemedicijn) wordt behandeld.
De behandeling van kinderleukemie
De enorme stijging in de overleving van kinderen met leukemie, die de afgelopen 
decennia heeft plaatsgevonden, is niet veroorzaakt door de introductie van nieuwe 
geneesmiddelen. De middelen die worden gebruikt voor de behandeling van leukemie 
zijn namelijk al jaren in de kliniek en alles behalve specifiek voor de leukemiecel, met 
de uitzondering van imatinib. De toename in overleving is met name te danken aan een 
verbeterde risico-indeling van leukemiepatiënten met daarbij horende behandeling, en 
stamcel transplantaties bij kinderen met een slechte prognose. 
De afgelopen jaren is het inzicht in genetische afwijkingen die bijdragen aan het ontstaan 
van kanker toegenomen. Bovendien vormen precisiemedicijnen een doorbraak in de 
behandeling van kanker. Precisiemedicijnen zijn gericht tegen een specifieke genetische 
afwijking in de kankercel. Voor een succesvolle behandeling is het daarom van groot 
belang om het juiste moleculaire tumorprofiel te koppelen aan het juiste precisiemedicijn. 
Het aantal bekende DNA afwijkingen groeit snel, maar er valt nog veel inzicht te winnen in 
klinisch relevante combinaties van DNA afwijkingen en precisiemedicijnen. Het vergroten 
van de kennis van genetische afwijkingen die betrokken het ontstaan van kinderleukemie 
zal hier aan bijdragen. Daarnaast bevordert het bestuderen van potentiële targets en 
precisiemedicijnen in preklinische modellen succesvolle implementatie in de kliniek. Om 
hieraan bij te dragen, is in deze thesis gefocust op de pathobiologie van pediatrische 
BCP-ALL, met name de genetisch ongeclassificeerde BCR‑ABL1-like en B-other BCP-ALL. 
De biologie van BCR-ABL1-like leukemie
Het afgelopen decennium is het genetische landschap van BCR‑ABL1-like leukemie 
intensief bestudeerd. De gelijkenis in de genexpressieprofielen met BCR‑ABL1-positieve 
leukemie impliceert dat een vergelijkbaar mechanisme verantwoordelijk is voor het 
ontstaan de leukemie. Recente studies en hoofdstuk 2 van deze thesis laten zien dat dat een 
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deel van deze patiënten gekenmerkt wordt door zeldzame chromosomale translocaties.6-8 
Deze translocaties kunnen worden onderverdeeld in ABL klasse translocaties en JAK klasse 
translocaties. Aangezien imatinib naast ABL1 ook andere ABL familieleden remt, wordt de 
effectiviteit van imatinib in de behandeling van deze patiënten momenteel onderzocht. 
Daarnaast wordt geïmpliceerd om de JAK klasse fusiegenen met specifieke JAK remmers 
te behandelen, zoals bijvoorbeeld ruxolitinib of momelotinib. In hoofdstuk 3 van deze 
thesis hebben we ons verdiept in de therapeutische potentie van deze JAK remmers. 
Naast de JAK translocaties, wordt een deel van de kinderen met BCP-ALL namelijk ook 
gekenmerkt door puntmutaties in het JAK2 gen. Deze puntmutaties zijn niet beperkt tot het 
BCR‑ABL1-like subtype, maar worden ook in B-other en hoog hyperdiploïde leukemie 
patiënten gevonden. Alhoewel de biologie van de JAK2 translocaties en JAK2 mutaties 
anders is, kunnen beiden mogelijk worden geremd door JAK remmers. Onze resultaten 
laten zien dat deze JAK remmers inderdaad effectief zijn in het doden van cellen met 
een JAK2 translocatie of JAK2 puntmutatie. Helaas laten onze resultaten ook een aantal 
limitaties zien:
1. De huidige remmers (ruxolitinib en momelotinib) binden de mutant JAK2 en JAK2 
fusiegenen in een actieve conformatie. Opheffing van deze binding (bijvoorbeeld 
als gevolg van instabiliteit/afbraak van de remmer) resulteert in hypersignalering. 
Om re-activatie van de JAK2 signalering te voorkomen, dient er een JAK remmer te 
worden ontwikkeld die de JAK2 mutanten en fusiegenen in een inactieve toestand 
kan binden.
2. Leukemiecellen met JAK2 puntmutaties kunnen ontsnappen aan het effect van 
JAK remmers d.m.v. alternatieve signaleringspathways. Naast JAK2 puntmutaties, 
zijn er namelijk ook andere puntmutaties in de leukemiecellen aanwezig (bijv. 
KRAS). In een muismodel observeerden we een heterogeen uitgroeipatroon van 
deze mutaties, waarin de JAK2 mutaties zelfs kon verdwijnen. Deze observaties 
suggereren dat JAK2 mutaties, geen drivers maar passenger mutaties zijn.
3. De beenmerg micro-omgeving speelt een belangrijke rol in de bescherming van 
leukemiecellen tegen JAK remmers. MSCs blijken niet alleen belangrijk voor de 
ontwikkeling van bloedcellen; ze kunnen leukemiecellen ook beschermen tegen 
JAK remmers.
Deze resultaten laten zien dat JAK remmers veel potentie bieden, maar verdere 
optimalisatie nodig is voor hun implementatie in de kliniek. 
De biologie van ‘B-other’ leukemie
Recente publicaties hebben het inzicht in de onderliggende mechanismen van B-other 
leukemie vergroot. Een deel van deze B-other patiënten blijkt namelijk een genetische 
translocatie van het DUX4 gen te bevatten.9-11 Helaas is er momenteel nog geen doelgerichte 
therapie tegen DUX4 beschikbaar. Om toch een precisiemedicijn te kunnen geven aan 
deze patiënten is het van belang om volledig inzicht te verkrijgen in de signaleringscascade 
van DUX4 in leukemiecellen. Op deze manier kan therapie eventueel worden gericht op 
een belangrijke factor voor DUX4 signalering. In hoofdstuk 4 van de thesis ontdekten we 
dat een deel van de B-other en BCR‑ABL1-like patiënten een verhoogde expressie van 
het STAP1 gen hebben, wat een specifiek kenmerk bleek van leukemiepatiënten met een 
DUX4-translocatie. Onderzoek naar de therapeutische potentie van STAP1 bleek helaas 
niet veelbelovend. Verlaging van STAP1 expressie levels resulteerde niet in celdood, noch 
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maakte het cellen gevoeliger voor chemotherapeutische middelen. Dit betekent dat de 
zoektocht naar targets voor therapie in deze DUX4-rearranged patiënten vervolgd dient 
te worden.
Coöperatieve genetische afwijkingen
Chromosomale translocaties alleen zijn niet voldoende om leukemie te veroorzaken; 
ze hebben een meewerkende, coöperatieve, genetische aberratie nodig. De frequentie 
waarmee de ETV6‑RUNX1 translocatie wordt gedetecteerd in navelstrengbloed ligt 
bijvoorbeeld 100 keer hoger dan de incidentie van deze vorm van leukemie.12 Daarnaast 
laat een studie in een eeneiige tweelingen zien dat de BCR‑ABL1 translocatie ook 
afhankelijk is van een additionele aberratie. In de navelstrengbloedsamples werd bij 
beide kinderen de BCR‑ABL1 translocatie geïdentificeerd. Echter alleen het kind waar 
ook een deletie van het IKZF1 gen aanwezig was, ontwikkelde een leukemie.13 Deze 
voorbeelden suggereren dat naast een initiële hit, coöperatieve genetische afwijkingen 
nodig zijn voor het ontstaan van leukemie. De afgelopen jaren is er veel onderzoek gedaan 
naar additionele afwijkingen bij kinderleukemie en het belang van deze afwijkingen voor 
risicostratificatie.14,15
Opvallend worden in BCP-ALL patiënten vaak deleties gedetecteerd in genen die van 
belang zijn voor de regulatie van de B cel ontwikkeling (IKZF1, EBF1, PAX5, ETV6), 
celdeling (CDKN2A/B, RB1) of celdood (BTG1). In hoofdstuk 5 detecteerden we in 71% 
van de kinderen met leukemie een deletie in een van deze genen. Echter verschilde de 
verdeling van deze deleties per subtype. Zo ligt de frequentie van één of meer deleties 
in BCR‑ABL1, BCR‑ABL1-like, B-other en ETV6‑RUNX1 patiënten boven de 75%. In 
KMT2A-herschikte, hoog hyperdiploid en TCF3‑PBX1 leukemie ligt deze frequentie 
beneden de 40%. Verder onderzoek naar de relaties van deleties van deze genen met 
chemotherapieresistentie en een slechte prognose, toonde alleen een associatie aan met 
IKZF1 deleties. Deze associatie was afhankelijk van het BCP-ALL subtype, oftewel de 
genetische context van de leukemiecel. Zo bleken hoog hyperdiploïde cellen met een 
IKZF1 deletie extreem resistent tegen prednisolon, terwijl BCR‑ABL1-like en B-other cellen 
resistent bleken tegen thiopurines. Deze resultaten laten zien dat het van groot belang is 
om studies naar chemotherapieresistentie en prognose te verrichten in de juiste genetische 
context.
De beenmergmicro-omgeving
MSCs zijn een belangrijke factor voor de ontwikkeling van bloedcellen, zowel door 
secretie van groeifactoren als direct cel-cel contact.3-5 In hoofdstuk 3 van deze thesis 
hebben we gezien dat MSCs leukemiecellen beschermen tegen het effect van JAK 
remmers. Vergelijkbare observaties zijn gerapporteerd voor andere middelen die worden 
gebruikt in de behandeling van leukemie.16-20 Deze observaties laten het belang van 
MSCs voor de overleving van de leukemiecel zien. Daarom stond in hoofdstuk 6 van 
deze thesis de vraag centraal of MSCs van kinderen met leukemie (leukemie-MSCs) 
verschillen van MSCs van gezonde kinderen (controle-MSCs). Om dit te onderzoeken zijn 
ondersteunende eigenschappen voor leukemieceloverleving van deze MSCs vergeleken. 
De overleving van leukemiecellen is namelijk verhoogd als deze in de aanwezigheid 
van MSCs worden gekweekt. Onze resultaten laten zien dat zowel leukemie-MSCs 
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als controle-MSCs de overleving van BCP-ALL cellen verhogen en er werd geen 
verschil gedetecteerd in ondersteuning tussen leukemie-MSCs en controle-MSCs. Een 
opmerkelijke bevinding was echter dat het genexpressieprofiel van MSCs verandert als 
deze samen met leukemiecellen worden gekweekt. Elk leukemie sample induceerde een 
karakteristieke verandering in het genexpressie profiel van MSCs, die consistent was 
tussen verschillende MSCs. Deze veranderingen in het genexpressie profiel van de MSCs 
bleken niet permanent, maar verdwenen in afwezigheid van de leukemiecellen. Er werden 
namelijk kleine verschillen geobserveerd tussen de genexpressieprofielen van leukemie-
MSCs en controle-MSC, maar deze verschillen waren verdwenen in MSCs die tijdens 
de behandeling van leukemie werden geïsoleerd. Samengenomen laten deze resultaten 
zien dat leukemie-MSCs intrinsiek niet verschillen van controle-MSCs. Echter manipuleren 
leukemiecellen het genexpressieprofiel van MSCs, wat samenvalt met een verhoogde 
overleving van deze BCP-ALL cellen. Daarmee is de interactie tussen leukemiecellen en 
MSCs mogelijk een belangrijk target voor de behandeling van leukemie. Deze interactie 
dient dan ook verder bestudeerd te worden in toekomstig onderzoek.
Leukemie is een dynamisch proces dat afhankelijk is van verscheidene variabelen. 
Volledig inzicht in de pathobiologie van BCP-ALL is essentieel voor de identificatie 
voor nieuwe therapeutische targets. In deze thesis, zijn een aantal potentiële targets 
bestudeerd. Daarnaast laten onze resultaten een belangrijke rol zien van de beenmerg 
micro-omgeving in therapieresistentie. Deze interactie tussen BCP-ALL cellen en MSCs 
staat centraal in ons vervolg onderzoek. 
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contact en uiteindelijk bleek dat we beiden een baan in Rotterdam hadden gevonden! 
Wat was het fijn dat er iemand die ik zo goed kende ook naar die vreemde stad ging. 
Ik ben je heel erg dankbaar voor al je steun en nuchterheid. Ook al zijn de wekelijkse 
etentjes er niet meer, we voelen elkaar nog steeds goed aan. Ik ben je heel erg dankbaar 
voor je vriendschap en het is een eer dat je mijn paranimf wilt zijn.
Elise, ik ben heel blij dat we contact hebben gehouden na de stage bij pathologie. Of 
we nu in Rotterdam, het mooie Gouda, of Utrecht afspreken, het is altijd goed. Heel veel 
succes met je avontuur in Canada!
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Loes, we leerden elkaar eigenlijk pas goed kennen toen jij besloot Maastricht te verlaten. 
Het heeft onze vriendschap er niet minder sterk op gemaakt. Waar je ook woonde, je bent 
altijd erg belangrijk voor me geweest. Bedankt voor de bijzondere band die hebben en 
heel veel succes en geluk voor de toekomst.
Natuurlijk wil ik ook m’n vriendinnen uit Oirlo en omgeving bedanken. We kennen elkaar 
allemaal al erg lang en dat maakt het ook zo vertrouwd. Anne, Ilse, Lilian, Lonneke, 
Marieke, Sanne, Sandra en Sandra. Bedankt voor de gezelligheid, alle leuke uitjes, maar 
ook jullie luisterende oor en interesse in mijn promotie. Jolanda, Linda en Mariëlle, na de 
middelbare school zijn we allemaal in een ander deel van Nederland terecht gekomen, 
maar gelukkig zijn we elkaar nooit uit het oog verloren. De uitstapjes zijn altijd een groot 
succes en ik hoop dat we samen nog veel gaan ondernemen in de toekomst!
De familie Steeghs en Peters: alle ooms en tantes en neven en nichten die met me hebben 
meegeleefd de afgelopen jaren en altijd geïnteresseerd waren: heel erg bedankt voor 
jullie steun! Jullie interesse voor m’n onderzoek was altijd groot en dat was erg fijn. Mijn 
peetoom en peettante: Pieter, jij bent erg intensief bij alles betrokken geweest. Iedere 
verhuizing heb je meegemaakt en altijd stond je weer klaar om me te helpen. Daarnaast 
hebben we in Rotterdam ook kunnen genieten van heel wat etentjes. Bedankt voor alles! 
Ria, jij ook bedankt voor al je interesse, betrokkenheid en steun.
Elvire, Walter, Anne-Hilde en Wouter: bedankt voor de warme ontvangst die jullie me 
in jullie gezin hebben gegeven. Daarnaast heeft jullie interesse en steun veel voor me 
betekend de afgelopen tijd.
Lieve mam en pap, de afgelopen jaren zijn voor jullie niet makkelijk geweest. Ook mijn 
keuzes waren daarbij niet altijd de meest voor de hand liggende en makkelijkste voor 
jullie. Toch hebben jullie altijd iedere keuze gerespecteerd en gesteund. Ik ben jullie erg 
dankbaar voor jullie positiviteit en hoop dat de komende jaren veel moois voor jullie in 
petto hebben. Anne-Mieke, jij bent er altijd voor me geweest. We zijn het lang niet altijd 
eens, maar je bent wel altijd bereid om me te helpen. Of het nu is om nieuwe woonruimte 
te zoeken, afleiding tijdens een leuke vakantie, winkelen, een goed telefoongesprek, of 
gezelligheid, ik kan altijd op je rekenen. Ik ben erg blij dat je m’n zus bent! Silke, voor 
jou is er de afgelopen tijd veel veranderd. Ik ben blij dat je zo je draai hebt gevonden, 
zowel op het werk als in jullie eigen huis. Het is fijn dat we elkaar zo makkelijk snappen. 
Peter-Jan, jij was nog zo jong toen ik ging studeren, maar inmiddels ben je zo volwassen 
geworden! Ik ben trots op m’n kleine broertje! Jij hebt je draai helemaal gevonden in 
Nijmegen. Geniet nog lekker van deze mooie periode! Ruud en Rob, jullie ook bedankt 
voor alle steun en heel veel succes en geluk voor  de toekomst!
Lieve Vincent, bedankt voor al je liefde en toeverlaat. Het is zeker niet altijd makkelijk 
voor je geweest. Toch hielden je goede adviezen en geduld nooit op, en bleef je me 
onvoorwaardelijk steunen. Je creativiteit heeft zelfs een belangrijke rol gespeeld bij het 
ontwerp van de cover. En zeker niet minder belangrijk: alle mooie momenten die we 
samen hebben beleefd zijn een bron van inspiratie geweest voor de afronding van dit 
proefschrift.  Bedankt voor alles en ik kijk uit naar onze toekomst samen.
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Dankwoord
